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Abstract  
 
Study of the interplay between hepatitis B and hepatitis delta viruses 
and evaluation of investigational anti-HDV immuno-modulators in 
superinfection cell culture models 
 
HDV/HBV superinfection is the most aggressive form of chronic viral hepatitis and is 
estimated to affect 15-20 million patients worldwide. HDV is not susceptible to 
available direct anti-HBV drugs and sustained response to IFNα therapy occurs in less 
than 1/4 of patients. Despite the faster progression of liver disease, most HDV/ HBV 
infected patients present a suppression of HBV replication. The details of the 
interactions between HDV, HBV and the host cell innate immune response remain 
largely unexplored and research efforts have been limited by the lack of infection 
models. 
The aims of this thesis work were: i) to study HDV infection and the interplay with the 
host innate immune response; ii) to identify novel therapeutic strategies for the 
inhibition of HDV; iii) to further explore HDV/ HBV interference. 
The experimental strategy was based on infection of dHepaRG cells, which are known 
to be permissive to both HBV and HDV full replicative cycles and to present 
physiological innate immune responses.  
We observed that: i) HDV infection is associated with a strong, yet transient 
replication, a potent induction of the expression of ISGs; ii) IFN-α treatment of HDV-
infected cells does not induce a further increase of ISG expression and has a modest 
antiviral activity. Conversely, some PRR agonists, in particular those inducing the NF-
kB pathway, induce a strong decline in HDV replication; iii) despite the low number of 
coinfected cells, HDV as well as its encoded proteins exert a repressive effect on HBV 
replication. 
Our work opens an array of perspectives on the pathogenesis of hepatitis delta and 
the identification of novel immune modulatory therapeutic strategies. 
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Résumé 
 
Étude des interactions entre les virus des hépatites B et delta et 
évaluation de nouveaux immuno-modulateurs anti-HDV dans des  
modèles cellulaires de surinfection  
 
La surinfection par HDV/ HBV est la forme la plus grave d’hépatite virale chronique et 
affecte entre 15-20 millions de patients au niveau mondial. HDV n’est pas susceptible 
aux traitements anti-HBV et le taux de réponse à l’IFNα est <25%. Malgré une 
progression plus rapide de la maladie hépatique, la majorité des patients présente une 
suppression de la réplication du HBV. Les détails des interactions entre HDV, HBV et 
le système immunitaire inné des cellules infectées restent inconnus.  
Les objectifs de ces travaux de thèse ont été: i) l’étude de l’infection par HDV et son 
interaction avec la réponse innée cellulaire; ii) l’identification de nouvelles stratégies 
thérapeutiques anti-HDV; iii) l’exploration de l’interaction entre HDV et HBV. 
L’approche expérimentale a été basée sur l’infection de cellules dHepaRG, capables 
d´entretenir des cycles réplicatifs complets de HBV et HDV et ayant une réponse 
immunitaire innée physiologique. 
Nous avons observé que: i) l’infection par HDV est associée à un réplication forte dans 
un nombre limité de cellules, et à une induction de l’expression des ISGs; ii) le 
traitement des cellules infectées par HDV avec de l’IFNα ne conduit pas à une 
induction accrue des ISGs et a une faible activité antivirale. Quelques agonistes de 
PRR, notamment activant la voie NF-kB, induisent une forte diminution de la 
réplication de HDV; iii) malgré le faible nombre de cellules infectées, HDV et ses 
protéines induisent une diminution de la réplication de HBV.  
Ces travaux ouvrent des perspectives importantes concernant la caractérisation de la 
pathogénèse de l’hépatite delta et l’identification de nouvelles stratégies 
thérapeutiques immuno modulatrices. 
  
Mots clé: virus de l’hépatite D; virus de l’hépatite B; interférence virale; réponse IFN; 
immuno-modulateurs. 
 
 
- 10 - 
 
  
 
- 11 - 
 
Résumé substantiel 
Étude des interactions entre les virus des hépatites B et delta et  
évaluation de nouveaux immuno-modulateurs anti-HDV dans des  
modèles cellulaires de surinfection 
 
 
Travaux de thèse réalisés par Dulce Alfaiate au sein du Centre de Recherche en 
Cancérologie de Lyon (CRCL), UMR INSERM 1052, CNRS 5286, Centre Léon Bérard, 
dirigé par A. Puisieux  
151 Cours Albert Thomas 69003, Lyon, France 
Direction de thèse : Paul Dény et David Durantel 
 
Introduction:  
L’infection par les virus de l’hépatite B (HBV) et de l’hépatite delta (HDV) représente 
la forme la plus agressive d’hépatite virale chronique. Le nombre estimé de patients 
affectés au niveau mondial est de 15-20 millions. Le virus de l’hépatite delta est un 
satellite du HBV. Deux modes d’acquisition sont décrits : soit une infection simultanée 
par les deux virus (coinfection) qui conduit à une guérison dans la majorité des cas ; 
soit une infection delta d’un patient porteur du HBV (surinfection), qui est associé à 
une progression vers la chronicité et le développement de complications associées à 
une hépatite D chronique (dont la cirrhose et le carcinome hepato-cellulaire). De 
façon intéressante, chez les patients infectés par HDV, malgré la progression plus 
agressive de la maladie hépatique, il y a souvent une répression de la réplication du 
HBV. Ceci a été vérifié par l’étude de biopsies hépatiques de patients, mais aussi dans 
des modèles expérimentaux in vivo et in vitro. Des mécanismes de régulation de la 
transcription du génome HBV par les protéines du HDV ont été proposés, mais les 
détails de cette interaction ne sont pas connus.  
Il est connu que l’infection par HBV n’induit pas une réponse immunitaire innée de 
type interféron dans les cellules infectées (de plus en plus d’évidences suggèrent 
même une inhibition active de cette réponse). En ce que concerne HDV, une 
modulation de la réponse interféron a également été proposée, mais les études 
précédentes n’ont pas été conclusives.  
Il est important de noter que la réplication d’HDV n’est pas affectée par les inhibiteurs 
spécifiques d’HBV actuellement disponibles. De plus, le traitement prolongé avec 
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l’interféron (IFN) alfa pégylé entraîne une réponse soutenue dans moins d’un quart 
des cas et est associé à un nombre significatif de rechutes tardives, soulignant 
l’urgence de trouver de nouvelles options thérapeutiques contre HDV.  
Pour cela, il est fondamental d’étudier la réplication des deux virus et leurs 
interactions avec la réponse immunitaire de l’hôte dans des cellules infectées. Cette 
étude a été limitée au cours du temps par un manque de modèles d’infection 
adéquats. Les cellules HepaRG sont sensibles à l’infection par ces deux virus 
hépatotropes et, jouant d’une réponse immunitaire innée fonctionnelle, représentent 
un modèle stable et alternatif aux hépatocytes primaires humains (PHH). 
 
Objectifs du projet de recherche : 
Cette thèse a eu comme objectifs : 1) l’établissement et caractérisation d’un modèle 
in vitro de surinfection par HBV/ HDV ; 2) la caractérisation et étude des mécanismes 
d’interaction entre les deux virus ; 3) l’évaluation de la réponse immunitaire innée 
dans les hepatocytes infectés par HDV et 4) l’utilisation du modèle établi pour 
l’évaluation de nouvelles stratégies thérapeutiques contre HDV. 
  
Matériel et méthodes:  
Des cellules HepaRG différenciées ont d’abord été infectées par HDV à différentes 
multiplicités d’infection (MOI), et les paramètres de la réplication virale ainsi que la 
réponse immunitaire cellulaire ont été suivies au cours du temps.  
Pour l’évaluation d’un contexte de surinfection (plus physiologique), les cellules ont 
été infectées (ou non) par HBV puis surinfectées (ou non) par HDV. Les marqueurs de 
la réplication de chaque virus et de la réponse immunitaire cellulaire ont été suivis 
dans chaque condition par qPCR, RT-qPCR, Northern blot, ELISA, Western blot et 
immunofluorescence.  
Les cellules infectées ont aussi été utilisées pour l’évaluation de l’effet anti-HDV de 
molécules immuno-modulatrices, notamment des agonistes de senseurs de 
l’immunité innée (‘Pattern Recognition Receptors’; PRRs). Leur effet sur la réplication 
de HDV a été évalué par qRT-PCR et Northern Blot.  
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Résultats :  
Les cellules HepaRG supportent une forte mono-infection transitoire par HDV en 
l’absence d’HBV. Comme attendu, si la réplication d’HDV était similaire en présence 
ou en absence d’infection par HBV, la sécrétion de virions HDV n’a été observée qu’en 
co-infection. Ce résultat confirme la coexistence des deux virus dans une même 
cellule, malgré le faible pourcentage de cellules infectées. La surinfection par HDV 
était associée à une diminution des paramètres de réplication d’HBV, sauf de 
l’ADNccc, confirmant un certain degré d’interférence virale dans ce modèle.  
L’infection par HDV était associée à une forte induction de l’expression des gènes de 
la réponse interféron (‘Interferon Stimulated Genes’; ISGs), aussi bien en mono qu’en 
surinfection. Cette induction est associée à l’augmentation du MOI de HDV et suit la 
cinétique d’accumulation de l’ARN du HDV dans les cellules. 
Nous avons identifié 4 agonistes de PRRs présentant un effet antiviral significatif sur 
la réplication de HDV: Pam3, Imiquimod, Poly (d :A ; dT) et Poly (I :C)).  
 
Conclusions et perpectives:  
Nous avons mis en place un modèle cellulaire original de surinfection HBV/HDV qui 
conduit à une meilleure caractérisation moléculaire des interactions entre HBV et 
HDV. Nous confirmons dans ce modèle le rôle suppresseur du HDV sur la réplication 
du HBV et nous avons aussi pu démontrer que l’infection par HDV est associée à une 
forte induction de la réponse interféron dans les cellules infectées. Par ailleurs, et de 
façon originale, nous avons identifié des molécules immuno modulatrices avec un 
effet répressif sur la réplication de HDV. 
Ce modèle est donc pertinent pour étudier et identifier de nouvelles cibles 
thérapeutiques, évaluer de nouveaux antiviraux à action directe, et définir les 
molécules immuno-modulatrices spécifiques. Ça permettra dans un futur proche 
d’approfondir l’étude des mécanismes d’interaction entre HDV et HBV, bien que de 
mieux caractériser la réponse immunitaire à l’infection par HDV et le mécanisme 
d’action des immuno-modulateurs identifiés.  
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TA – tetracycline transactivator 
TDP – tyrosyl-DNA-
phosphodiesterase 
TGF - transforming growth factor 
TLR – toll like receptor 
TP – terminal protein 
TR – tetracycline repressor 
TRAIL - tumour necrosis factor 
related apoptosis inducing ligand 
Vge – viral genome equivalent 
VVI – virus-virus interaction 
WHO – World Health Organization 
WHV – woodchuck hepatitis virus 
YFV – yellow fever virus
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1. Overview 
Currently, 250 million people are infected by Hepatitis B Virus (HBV). Among them, 
15-20 million are estimated to be co-infected the Hepatitis Delta Virus (HDV). Chronic 
hepatitis delta (CHD) is considered to be the most severe form of chronic viral hepatitis 
and still poses major challenges to both clinicians and researchers. 
In order to approach this problem, a thorough knowledge of the characteristics of 
both diseases and viruses is warranted. Moreover, lessons learnt from other cases of 
viral interactions and a wider perspective of the host response to viral infection need 
to be applied in the interpretation of this very particular clinical and virological entity. 
 
2. Hepatitis B 
2.1. Introduction 
2.1.1. Discovery of Hepatitis B virus 
The history of Hepatitis B virus identification goes hand in hand with the major 
milestones in the timeline of hepatitis research, as represented in  
Figure 1. Descriptions of epidemic jaundice, although very likely associated not only 
with hepatitis but also with other diseases such as malaria and leptospirosis, date from 
ancient times, and it was Hippocrates who first used the expression “icterus”. The 
hypothesis of a transmissible cause for jaundice was first issued in the 19th century 
(associated to disease outbreaks following mass vaccination procedures). The first 
suggestion that some forms of jaundice could be due to viral infection was made 10 
years after the discovery of the first virus and consequent foundation of virology by 
Beijerink in 1898. The development of the liver biopsy technique and the discovery of 
the inflammatory nature of the disease led to the introduction of the term “viral 
hepatitis”, by the time of the 2nd World War. Two types of hepatitis were then 
described, based on different transmission pathways and clinical courses: epidemic 
hepatitis or hepatitis A (acute, fecal-oral transmission) and serum hepatitis or 
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hepatitis B (related mainly to vaccination and parenteral procedures, with a longer 
incubation period and evolution to chronicity) (Thomas et al., 2015; Trepo, 2014). 
Two major discoveries in the history of HBV followed: in 1965 Baruch Blumberg 
identified the Australia Antigen (now known as HBsAg) and five years later David Dane 
described the HBV virion (Dane’s particle) (Blumberg et al., 1965; Dane et al., 1970). 
These discoveries soon led to the full characterization of the virus and the 
development of screening and immunization strategies with a huge public health 
impact. Indirectly, they also led to the identification of a second form of serum 
hepatitis (non-A, non-B) that opened the research field of Hepatitis C. 
 
 
 
Figure 1. Timeline of major advancements in HBV research and treatment. Adapted from 
(Thomas et al., 2015) 
 
2.1.2. Clinical and virological relevance 
From a clinical standpoint, and despite the existence of an effective vaccine, hepatitis 
B still is a particularly challenging entity. Firstly, vaccination is still costly and not 
universally accessible, being particularly limited in some of the regions with highest 
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incidence of the disease. Secondly, the current pool of chronically infected patients 
remains very significant and, although effective antivirals exist, no single treatment 
ensures a cure and a life-long therapy is warranted. Finally, HBV infection is the major 
cause of hepatocellular carcinoma (HCC) and death (an estimated 786,000 people die 
each year as a result of HBV infection) (Locarnini et al., 2015). 
In terms of virological characteristics, HBV (and hepadnaviruses in general) display 
some particular and challenging features, including: i) similarities with retroviruses (as 
the presence of a reverse transcription step); ii) the establishment of a permanent 
viral form in the infected cells (circular-covalently-closed DNA or cccDNA) with 
fascinating properties; and iii) a unique capability of silencing the host cell immune 
response. 
 
2.2. The virus 
2.2.1. Viral classification  
HBV is a partially double-stranded DNA virus belonging to group VII of the Baltimore 
classification (double-stranded DNA viruses that replicate through a RNA 
intermediate). Following the International Committee on the Taxonomy of Virus 
(ICTV) classification, HBV belongs to the Hepadnaviridae family (standing for 
hepatotropic DNA virus). The members of this family have in common their 
hepatotropism, genetic organization, viral morphology and replication mechanism 
(that includes a retro-transcription step). The family is divided into two genera, 
depending on the species specificity of the viruses: the genus orthohepadnavirus 
includes HBV and other mammalian viruses (as woodchuck hepatitis virus [WHV], 
ground squirrel hepatitis virus, woolly monkey hepatitis virus and bat hepatitis virus), 
while the genus avihepadnavirus includes avian virus, as the duck hepatitis B virus 
(DHBV) and heron HBV (Schaefer, 2007). 
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2.2.2. Viral structure 
Virions and subviral particles  
Two major types of particles have historically been characterized in the serum of HBV 
infected patients, as represented in Figure 2: 
 
 
 
Figure 2. HBV virion and empty subviral particles. A. HBV virion (Dane particle). B. Spherical 
SVP. C. Filamentous SVP. Reproduced from (Urban et al., 2014) 
 
1. Complete virions, also named Dane particles, are the infectious particles and 
can be present in the serum of patients in titers as high as 1010 genome-
copies/mL. They are spherical, 42nm in diameter, have an inner icosahedral 
symmetry, and a buoyant density of 1,24-1,27 g/mL in CsCl (Dane et al., 1970; 
Hruska and Robinson, 1977). HBV virions consist of (from the surface to the 
interior): a) a lipoprotein membrane with the three forms of HBsAg (S-HBsAg, 
M-HBsAg and L-HBsAg) with a ratio of 4:1:1; b) a nucleocapsid featuring 120 
dimers of the core/capsid protein (HBcAg or HBc; triangulation number T=4; a 
smaller proportion of “empty” virions has 90 dimers and T=3); c) the capsid 
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contains one single copy of HBV DNA in its relaxed-circular form (rcDNA), 
covalently linked to the viral polymerase (Howley, 2013);  
 
2. Subviral non-infectious particles (SVP) are constituted only by envelope 
proteins embedded in the bilayer membrane. They have approximately 22nm 
and with a buoyant density of 1,18-1,19 g/mL and circulate in 1000-10000 fold 
excess relative to virions in patients’ sera (Urban et al., 2014). Two types are 
known: spherical particles, with an octahedral symmetry; and asymmetrical, 
rod-like (or filamentous) particles with variable length and width. Whereas 
filamentous SVP have a ratio of surface proteins similar to virions, spheres do 
not have L-HBsAg and have a 4:1 ratio of S-HBsAg: M-HBsAg. Their precise role 
in HBV infection is still debated, although they may favor viral infection 
through a saturation of the humoral response to HBV and hence play a role in 
immune subversion mechanisms. 
 
Besides these HBsAg containing particles, identified from patients’ sera, two other 
sub-viral forms have been described: 
 
1. Non-enveloped nucleocapsids, found to be secreted in vitro by HBV 
replicating hepatoma cell lines and suggested to play a role in virus spreading 
(Cooper and Shaul, 2006; Watanabe et al., 2007). Their existence and potential 
role in vivo is still to be demonstrated; 
 
2. More recently, enveloped empty capsids have also been described in patients’ 
sera, but their proper relevance and function is yet to be determined 
(Luckenbaugh et al., 2015). 
 
Viral DNAs 
HBV genome is found both in the viral particle and inside mature capsids in the 
cytoplasm of infected cells. It is a partially double-stranded circular DNA molecule of 
around 3,2kb, also called rcDNA. The complete strand, from which transcription will 
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occur, is of negative polarity and is covalently linked to the viral polymerase at its 5’ 
extremity. The positive, incomplete, strand contains a gap and a 3’ extremity of 
variable length (Summers et al., 1975) and is associated with an RNA oligomer derived 
from pregenomic RNA (pgRNA), that serves as a template for negative strand 
completion. The circularity of the molecule is guaranteed by a 200 nucleotide-long 
region in the positive strand that overlaps the 5’ and 3’ extremities of the negative 
strand. It comprises direct repeat (DR) 1 and 2 sequences, necessary for viral 
replication (Howley, 2013). Being very compact, the HBV genome is also highly 
complex. It contains 4 open reading frames (ORF), 4 promoters, 2 enhancer elements 
and a single polyadenylation signal to regulate the expression of all viral RNAs. All 
nucleotides have coding functions for at least one protein (as a result of the presence 
of overlapping ORFs) and transcription regulation regions overlap with coding 
information (Nassal, 2015). A schematic representation of HBV genome organization 
is shown in Figure 3. 
 
 
 
Figure 3. HBV genome organization, including key regulatory elements, open reading frames 
and RNA transcripts. Reproduced from (Liang, 2009). 
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The overlapping ORFs (all in the same direction and encompassing the whole HBV 
genome), which code for the 7 viral proteins, are: 
 
 Polymerase ORF – it’s the largest ORF, accounting for 80% of the viral genome, 
and codes for the viral polymerase; 
 PreS1/ PreS2/ S ORF – contained within the Polymerase ORF, contains three 
in-phase starting codons and codes for the three forms of the envelope protein 
(S-, M- and L-HBsAg, which stand for small, medium and large HBV surface 
antigen, respectively);  
 PreCore/ Core ORF – contains two in-phase initiation codons and codes for the 
secreted HBeAg and the HBcAg (core antigen); 
 X ORF – codes for the X protein. 
 
Transcription is regulated by 4 promoters (Core, PreS, S and X), 2 enhancer elements 
(Enh1 and Enh2) and cis-acting negative regulatory elements. These elements are only 
functional in the nucleus, after the conversion of rcDNA to cccDNA (Moolla et al., 
2002). The organization and functions of the regulatory regions will be discussed in 
further detail in the Transcriptional regulation of the cccDNA section. 
 
CccDNA is the form of HBV DNA responsible for virus persistence in infected cells. 
Although isolated reports have suggested its existence in other cells, it has only been 
conclusively demonstrated in the nucleus of infected hepatocytes (Howley, 2013). It 
is an episomal, plasmid-like, replicative intermediate that resides in the nucleus of the 
infected cells. In physiological conditions, cccDNA molecules are organized into a 
chromatin-like structure, forming a viral minichromosome, associated with histones 
and other host and viral proteins (Levrero et al., 2009). The organization into 
nucleosomal structure has been described for several other DNA viruses that cause 
human disease and is commonly associated with the establishment of latent 
infections. Examples are polyomaviruses, the simian virus 40, adenoviruses, herpes 
viruses (namely herpes simplex type 1 [HSV1], the gammaherpesvirus Kaposi  
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associated herpes virus [KSHV] and Epstein Barr virus [EBV]) and papillomaviruses 
(Lieberman, 2006). 
HBV cccDNA serves as the only template for transcription of the viral RNAs and 
constitutes a stable pool in infected cells (mean copy number/ cell = 1,8 [0,008-54] in 
HBeAg positive patients and 0,09 [0,01-15] in HBeAg negative patients) (Volz et al., 
2007). The regulation of the cccDNA pool has been a subject of debate and research 
throughout time. It is known that cccDNA persists in quiescent hepatocytes, with no 
effect on their viability. However, cccDNA half-life and its persistence through mitosis 
are still controversial (Howley, 2013). Furthermore, in chronic infection, the 
eradication of cccDNA is a rare event, although its clearance (at least partial) exists 
notably in the acute infection setting. Several mechanisms have been proposed to 
explain the clearance: i) the “curing” or non-cytolytic elimination model postulates 
that cccDNA may be directly eliminated by the action of cytokines, with no need for 
hepatocyte death or regeneration; ii) the alternative “killing” model proposes that 
cccDNA may only be eliminated by hepatocyte death. A third model proposes that in 
the absence of cccDNA neo-formation (as happens patients under nucleot(s)ide 
analogues [NA] therapy), the existing pool may be progressively eliminated by a 
combination of hepatocyte death and mitotic loss (Levrero et al., 2009; Nassal, 2015). 
 
RNA transcripts 
HBV replication occurs, as is characteristic of hepadnaviruses, through RNA 
intermediates. Transcription is carried out by the cellular RNA-polymerase II, using 
cccDNA as a template. Five transcripts (2 genomic and 3 sub-genomic, all possessing 
a 5’ cap and a shared polyA tail) can be identified in infected cells: 
 
1) Pregenomic RNA (pgRNA; 3,5 kb) – serves as a template for translation of 
polymerase and core proteins and is the template for de novo synthesis of viral 
DNA genome by reverse transcription; 
2) PreCore mRNA (3,5 kb) is the template for translation of the precore protein, 
that is ultimately secreted as HBeAg; 
3) PreS1 mRNA (2,4 kb) codes for the L-HBsAg; 
Thesis Dulce Alfaiate 
33 
 
4) PreS2/S mRNA (2,1 kb) and 5), that codes for S- and M-HBsAg; 
5) X mRNA (0,7 kb) that codes for the X protein (Moolla et al., 2002). 
 
These RNAs are detected as 3 major bands on Northern blot (3,5 kb; 2,4 kb and 2,1 
kb). The X transcript is only occasionally detected in infected tissues (Howley, 2013). 
These major transcripts and the encoded protein products are represented in Figure 
4.  
 
 
 
Figure 4. Major HBV RNA transcripts and their respective protein products. X mRNA (not 
represented) is only occasionally identified in infected cells. Reproduced from (Liang, 2009). 
 
Viral proteins 
HBV genome codes for 7 proteins: HBV polymerase, Core protein (HBcAg), PreCore 
(later cleaved to originate HBeAg), large, medium and small envelope proteins (L-, M- 
and S-HBsAg respectively) and X protein (Seeger and Mason, 2015). The role of an 
eighth protein, resulting from alternative splicing of pgRNA, hence called hepatitis B 
spliced protein (HBSP), identified in patients’ liver biopsies is still debated (Soussan et 
al., 2003). 
 
Envelope proteins (HBsAg) 
As previously mentioned, three forms of envelope proteins (clinically detected as 
circulating or intracellular HBsAg) are translated from the PreS1/PreS2/S ORF, from 3 
different ATG codons. They are synthetized in the endoplasmic reticulum (ER) and, 
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after oligomerization, are secreted as the envelope of HBV virions and subviral 
proteins. Their characteristics are summarized below and represented in Figure 5.  
 
 
 
Figure 5. HBV envelope proteins. A. The three forms of HBsAg share the same C-terminus (S). 
As translation initiates in different in-frame sites, besides S (the only domain of S-HBsAg), M-
HBsAg contains PreS2 and L-HBsAg further contains the 108 aa of PreS1. B. Schematic 
representation of membrane inserted HBsAg, showing the four putative transmembrane 
domains (1-4) and the two conformations of L-HBsAg, i-PreS1 and e-PreS1 (see text for details). 
Circled N and circled O represent glycosylation modifications. Reproduced from (Prange, 
2012). 
 
 S-HBsAg (226 amino acids [aa]; 24-27 kDa, depending on the glycosylation 
status) – is the most abundant envelope protein and contains the major 
antigenic determinants that led to the identification of the Australia antigen. 
It is considered to have 4 putative hydrophobic transmembrane domains (I-
IV). The first and last two domains (I-II and III-IV) are separated by cytosolic 
loops (facing the interior of the viral particle), whereas between domains II and 
III lies an antigenic loop (called “a” determinant) that is exposed in the outside 
of the viral particle and is the target of neutralizing antibodies. The antigenic 
loop is an infectivity determinant (Abou-Jaoudé and Sureau, 2007) and its 
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amino acid sequence was used to classify HBV into 4 serotypes, as discussed 
below; 
 M-HBsAg (281 aa; 31 kDa) – differs from S-HBsAg by an additional 55 amino 
acids at its N-terminus (PreS2 domain) and is always glycosylated.  It represents 
10-15% of the total HBsAg contained in infected cells. Its function is still not 
clear as it does not seem to be necessary for either assembly or infectivity 
(Fernholz et al., 1991); 
 
 L-HBsAg (389 aa; 42 kDa) – contains, in addition to M-HBsAg, the PreS1 domain 
(108 aa), that becomes myristoylated and is essential for both viral assembly 
and infectivity (Gripon et al., 1995). It is a minor form in the infected cells (1-
2%), but is much enriched in virions. It is not present in the spherical SVPs. L-
HBsAg has 2 conformations in virions: half of the PreS1 (i-PreS1) N-terminal 
domains is located in the cytosol (viral interior) and mediate the interaction 
with the nucleocapsid; for the other half (e-PreS1), the N-terminus is exposed 
on the outside of virions and mediates the interaction with the viral receptor. 
The major infectivity determinants are located in the 75 N-terminal aa (Seeger 
and Mason, 2015; Urban et al., 2014). 
 
Core protein (HBcAg) 
The Core protein (HBcAg) is composed by 183aa, has a molecular weight of 21 kDa 
and corresponds to the structural unit of the viral nucleocapsid, as depicted in Figure 
6. It has two main domains: the N-terminal domain (NTD), involved in capsid 
dimerization and envelopment, and the C-terminal “protamine” domain (CTD), 
involved in pgRNA encapsidation and DNA replication. The level of phosphorylation of 
the CTD is associated with capsid maturation, as DNA synthesis is accompanied by 
core dephosphorylation and conformational re-organization of the CTD. The kinases 
and phosphatases involved in this process are not definitely identified. Such changes 
expose binding sites for the envelope proteins leading to assembly of the mature (but 
not immature) nucleocapsids into virions (Mabit and Schaller, 2000; Perlman et al., 
2005). Furthermore, the CTD possesses a nuclear localization signal (NLS) that 
mediates nuclear transport of the entering and part of the newly synthetized capsids 
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(a phenomenon called recycling) (Yeh et al., 1990). HBcAg is highly immunogenic. 
Although in HBV-infected patients HBcAg can only be detected in the liver, circulating 
anti-HBc antibodies are a relevant clinical marker of current and past infection. 
 
 
 
Figure 6. HBV core structure. Central section (A) and an interior view (B) of the T = 4 capsid, 
obtained by cryo-electron microscopy. C. Representation of HBcAg, PreCore and HBeAg 
domain organization. Adapted by Isorce N from (Steven et al., 2005) 
 
PreCore protein and HBeAg 
The translation of the PreCore mRNA leads to the synthesis of a precursor protein of 
25 kDa that has, in addition to the domains previously described for the Core protein, 
an N-terminal extension of 29 aa (Yeh et al., 1990). This protein is signaled to the ER 
and enters the secretory pathway, where, after sequential cleavage, it is secreted as 
the 17 kDa HBeAg, a soluble protein (Standring et al., 1988). Although most of their 
primary amino acid sequence is identical, HBcAg and HBeAg display different antigenic 
properties (Salfeld et al., 1989). Represenatation of their organization is shown in 
Figure 6. HBeAg identification in the serum of infected patients is used as a surrogate 
marker of active replication, although it has no obvious role in HBV replication within 
hepatocytes. HBeAg to anti-HBeAg seroconversion may be associated with the end of 
active viral replication and the beginning of clinical resolution. However, in a particular 
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subset of patients, HBeAg loss is associated with the selection of mutants bearing 
either PreCore stop codon mutations or BCP (i.e. basal core promoter) mutations that 
abrogate its synthesis. These patients albeit having no circulating HBeAg, may have a 
continuous disease activity (Volz et al., 2007) 
 
Polymerase 
The polymerase (830 aa; 90 kDa) is the only enzyme encoded by the HBV genome and 
the target of currently available direct-acting antiviral (DAA) drugs. Significant body of 
evidence regarding its structure and function has been obtained in DHBV infection 
models. Up until now, no direct structural data are available for HBV polymerase. 
Sequence analysis identifies three functional domains (depicted in Figure 7): terminal 
protein (TP), the reverse transcriptase (RT) and RNAse-H. A spacer (with no clear 
function, except keeping away the two other domains) links TP and RT (Nassal, 2008).  
 
 
 
Figure 7. HBV polymerase domain organization. The four functional domains are represented 
from N- to C-terminus: TP, terminal protein, RT, reverse transcriptase, and RNase H. Position 
Y65 is necessary for priming of reverse transcription while RT position 204 (part of the YMDD 
conserved motif) is frequently mutated in cases of nucleos(t)ide analogue resistance. 
Reproduced from (Howley, 2013). 
 
The TP domain is essential for the interaction with the “epsilon” (Ԑ) packaging signal 
of pgRNA and confers template specificity to the polymerase activity. Reverse 
transcription is primed from the Y65 residue of the TP, resulting in the formation of a 
covalent link between the polymerase and the nascent minus-strand DNA (Nassal, 
2008; Weber et al., 1994) It has recently been suggested that the TP domain could 
contribute to the nuclear import of HBV genome, after the identification of a NLS 
(Lupberger et al., 2013). 
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The RT domain is associated with two enzymatic functions throughout HBV replicative 
cycle: the retro-transcription of pgRNA into the minus-strand DNA and the DNA-
dependent DNA synthesis of the HBV DNA positive strand from the minus-strand DNA 
template. RT activity is dependent on a conserved YMDD motif, where the first RT-
inhibitor resistance mutation was identified (rtM204V) (Gish et al., 2012). The retro-
transcriptase has no 3’-5’ exonuclease activity, which makes it error-prone, 
contributing to HBV variability (1.4-3.2 x 10-5 substitutions per site per year) (Okamoto 
et al., 1987). 
 
The RNAse-H domain is responsible for the pgRNA degradation following the synthesis 
of the minus-strand of HBV DNA, as well as for the generation of the short RNA primer 
that is required for DNA positive strand synthesis  (Wei and Peterson, 1996). RNase-H 
inhibitors were shown to block HBV replication and it is tempting to consider them as 
potential therapeutic options in the future (Tavis and Lomonosova, 2015). 
 
X protein (HBx) 
X is the smallest of HBV proteins (154 aa; 17 kDa) and the most enigmatic. It is known 
to be required for HBV replication in vivo and to act as a trans-activator of a number 
of cellular promoters. The exact mechanism of its activity is still elusive, as it varies 
greatly depending on the model system used (Bouchard and Schneider, 2004). 
Its essential role in the establishment of HBV infection has been demonstrated both 
in vitro and in vivo, in the woodchuck model (Lucifora et al., 2011; Zoulim et al., 1994). 
It has been suggested that this effect is mediated by a role in the epigenetic activation 
of cccDNA (Belloni et al., 2009). Regulation of the nucleocapsid phosphorylation status 
by X has also been postulated to be important for the promotion of HBV replication 
(Melegari et al., 2005). Furthermore, X has been shown to trans-activate all HBV 
promoters (Moolla et al., 2002), particularly from extrachromosomal DNA templates, 
and not from integrated DNA (van Breugel et al., 2012). 
The interaction of HBx with the host cell signaling pathways and its role in the 
pathogenesis of HBV infection have been a matter of debate throughout the years. 
Although it does not directly bind DNA, it can interact with transcription factors and 
hence regulate expression of host genes (Lara-Pezzi et al., 1998). Its interaction with 
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histone modification enzymes suggests a role in epigenetic regulation of gene 
expression (Tian et al., 2013). Finally, roles in cell cycle regulation, apoptosis, DNA-
damage response and in the modulation of innate immune response have also been 
proposed (Wei et al., 2010a, 2010b). Through its multiple interactions with cell 
signaling pathways, HBx has been proposed to be involved in the development of HBV-
associated HCC, although this is still debated (Fallot et al., 2012) 
 
2.2.3. Viral life cycle 
The complete HBV life cycle has been described to occur only in differentiated 
hepatocytes from a narrow range of species. For HDV, as explored in the 
corresponding chapter, hepatotropism and species specificity seem to be related only 
to the viral receptor (as, after entry or genome delivery, the virus can effectively 
replicate in a wide range of mammal cells, including murine). Conversely, for HBV, 
genome delivery is not sufficient and there seem to be other host factors essential for 
viral replication. Host and liver-specific transcription factors may notably be involved 
in RNA transcription from cccDNA (see Transcriptional regulation of the cccDNA 
below), although their role in earlier phases of HBV life cycle, previous to cccDNA 
establishment (as nucleocapsid migration and conversion of rcDNA to cccDNA) cannot 
be excluded (Seeger and Mason, 2015). Unlike HDV, HBV does not establish an 
infection in murine cells expressing human sodium taurocholate cotransporter 
peptide (hNTCP), the putative HBV/ HDV receptor, and, although it replicates in 
transgenic mouse models, no cccDNA can be detected (Guidotti et al., 1995; Yan et 
al., 2013). If such a restriction is due to the lack of specific factors or the presence of 
inhibitory elements has not been fully explored. 
Given the very narrow range of susceptible and permissive hosts to HBV infection, a 
limited number of models is available for the study of HBV life cycle. In vitro studies 
have relied on transfection of hepatoma cell lines (not susceptible to natural infection 
due to the lack of viral receptor), primary hepatocytes (mainly human and tupaia) and, 
alternatively, on the HepaRG model (that, upon differentiation, allows a full replicative 
cycle, including the entry steps) (Gripon et al., 2002; Zeisel et al., 2015). An important 
body of evidence was collected in vivo using other hepadnaviruses, namely DHBV and 
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WHV. A discussion of the models currently available for the study of HBV and HDV 
infection is made in the HDV chapter. 
Viral entry  
Mechanisms of viral attachment and receptor-mediated entry are thought to be 
shared by HBV and HDV and are described in further detail in the HDV chapter. 
The steps of HBV internalization after binding to the receptor are not completely clear. 
A pH-independent endocytosis mechanism has been proposed as likely, and both 
caveolin, on the one hand, and clathrin on the other have been suggested to be 
involved (Huang et al., 2012; Macovei et al., 2013). 
 
Nuclear import and cccDNA formation 
After release of the nucleocapsid in the hepatocyte cytoplasm, it is transported to the 
nucleus using the microtubular system and crosses the nuclear pore upon interaction 
of the core NLS with importins α and β. This model, depicted in Figure 8, postulates 
that the capsid disintegrates within the nuclear pore and releases rcDNA into the 
nucleus. Only mature, hypophosphorylated capsids would disintegrate, guarantying 
that only rcDNA, and not pgRNA, are imported into the nucleus (Kann et al., 2007). 
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Figure 8. Nuclear trafficking of hepadnaviral nucleocapsids. Capsids are drawn as grey 
icosahedra. The nucleic acid found within the capsids is depicted as a dotted line (RNA) or a 
full line (DNA). Immat-Capsid, immature capsid; Mat-Capsid, mature capsid. Reproduced from 
(Kann et al., 2007). 
 
Available evidence supports a model where cccDNA is synthetized from rcDNA (from 
both incoming virions and recycled capsids). For the formation of cccDNA, the rcDNA 
must undergo several steps, still not fully under understood (Levrero et al., 2009; 
Nassal, 2015), including (as represented in Figure 9): 
 
 
 
Figure 9. HBV cccDNA in the viral life-cycle. Reproduced from (Levrero et al., 2009). 
 
1. Removal of the HBV polymerase, covalently linked to the 5’ extremity of the 
negative strand of rcDNA. A recent study suggests that this step may be 
mediated by the host cell DNA repair machinery and Tyrosyl-DNA-
phosphodiesterase 2 (TDP2) was shown to be one of the (but possible not the 
only) enzyme involved in this cleavage (Königer et al., 2014). The existence of 
an intermediate protein-free rcDNA (PF-rcDNA) has been suggested in vitro 
(Levrero et al., 2009);  
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2. Removal of the RNA primer covalently linked to the 5’ end of the positive 
strand of rcDNA; 
3. Removal of one copy of the terminal redundancy of the minus strand; 
4. Completion of the plus strand to originate a full length double-stranded DNA. 
This step is not fully understood as it could be mediated by either HBV RT or a 
cell polymerase. The evidence that RT inhibitors do not preclude cccDNA 
synthesis, suggests that need for cellular factors (Seeger and Mason, 2015); 
5. Ligation of the ends of both strands, also likely to be mediated by a cell 
enzyme. 
 
Unlike retroviruses, HBV replication is independent from the integration of viral DNA 
into the host genome. However, integrated HBV DNA has been demonstrated in 
patients (it is thought to be present in 10-100% of hepatocytes from chronic carriers 
by the time they develop HCC).  Integration seems to originate from a double-stranded 
linear DNA form – DSL DNA - that arises during rcDNA synthesis. The involvement of 
randomly integrated HBV in HCC development has been proposed but is not 
established (Seeger and Mason, 2015). 
 
pgRNA transcription, encapsidation and retro-transcription 
HBV RNAs are transcribed from cccDNA by the cellular DNA-dependent RNA 
polymerase II and hence all contain a 5’ cap and a common polyA tail. They are next 
translated as cellular RNAs by the ER-associated ribosomes. 
The binding of the polymerase to the Ԑ loop on the 5’ end of the pgRNA from which it 
was translated, triggers the co-packaging of both molecules into nucleocapsids, 
through the interaction between the pgRNA molecule and the CTD of the core protein 
(Bartenschlager et al., 1990; Nassal, 2015). The polymerase conformational change 
induced by the interaction with the core protein would favor the initiation of retro-
transcription. Retro-transcription of pgRNA first gives rise to the negative strand of 
rcDNA, followed by RNAse digestion of the template (with the exception of a small 
oligomer at the 5’ extremity of pgRNA that will serve as a primer for the synthesis of 
the positive strand), as represented in Figure 10. The complete negative strand is then 
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used as a template for the synthesis of the positive strand. The reason why the positive 
strand is less than one genome long is unknown, but may be related to the depletion 
of nucleotides inside the capsid (Beck and Nassal, 2007). DSL DNA results from a 
defective retro-transcription process.  
 
 
Figure 10. Essential steps of rcDNA synthesis. A. pgRNA organization and its interaction with 
the polymerase. Binding of the polymerase (P) to 5´ Ԑ, but not 3´ Ԑ, initiates pgRNA 
encapsidation and replication. B. Transfer of the RNA primer to DR2 is necessary for proprer 
DNA synthesis. C. Elongation. After reaching the 5’ end of the (-)-DNA template, the small 
terminal redundancy (r) enables exchange against the sequence-identical 3’ r sequence such 
that (+)-strand synthesis can go on to generate rcDNA. Reproduced from (Beck and Nassal, 
2007; Nassal, 2015). 
 
Retro-transcription is closely linked to capsid maturation. Capsids containing pgRNA 
are hyperphosphorylated (immature) while the retro-transcription process is 
associated with a progressive dephosphorylation of the core protein (mature capsids). 
This process has two direct consequences: on the one hand, the conformational 
changes induced by dephosphorylation allow only the mature capsid to interact with 
HBsAg, guarantying a correct viral secretion; on the other, phosphorylated immature 
capsids are stable and do not disintegrate upon interaction with nuclear pores, 
ensuring that only rcDNA is delivered to the nucleus for cccDNA synthesis, upon re-
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circulation (Bruss, 2007; Kann et al., 2007). The regulation of the fate of mature 
capsids (viral assembly versus re-circulation) depends on the amount of L-HBsAg being 
synthesized (Summers et al., 1990). 
 
Assembly and secretion 
Viral envelope proteins, synthesized in the ER, face two major possibilities: they can 
either be used for nucleocapsid assembly (a process that is dependent on the 
presence of L-HBsAg) or be secreted as subviral particles. The cell secretion pathways 
involved seem to be different. For SVP secretion, envelope proteins are thought to be 
directed to the ER-Golgi intermediate compartment (ERGID) and from then to the 
Golgi secretory pathway. Secretion of virions was shown to occur through the 
multivesicular body (MVB) pathway (Huovila et al., 1992; Watanabe et al., 2007), as 
depicted in Figure 11. 
 
 
Figure 11. Hypothetical model of HBV particle morphogenesis, showing the release of SVP 
(through the Golgi - 1), virions (via MVB - 2) and naked capsids (3). Reproduced from (Prange, 
2012). 
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Transcriptional regulation of the cccDNA 
HBV DNA contains, as stated above, several regulatory sequences, including four 
promoters and 2 enhancers, as represented above in Figure 3, page 30. 
 
Enhancer I (Enh I), a 270-bp major element of transcriptional regulation, is situated 
between ORFs PreS1/PreS2/S and X, partially overlapping the X promoter region. It 
particularly induces the activation of Core and X and more modestly that of PreS and 
S promoters. It has binding sites not only for ubiquitary transcription factors, as AP-1 
and NF-κB, but also to liver-specific transcription factors, as HNF1, HNF3 and HNF4 
(Moolla et al., 2002). An interferon stimulated response element (ISRE) has been 
described in the EnhI sequence and may underly a mechanism for interferon-induced 
regulation of HBV transcription, through the binding of STAT1 and STAT2 (Belloni et 
al., 2012; Tur-Kaspa et al., 1990). STAT3 has also been shown to fixate to EnhI and 
increase its activity. 
 
Enhancer II (Enh II) is 105-bp long and is located upstream of the Core promoter and 
mostly induces PreS, S and X activity and to a lesser extent Core promoter activity. 
HNF3, HNF4 and Sp1 have be shown to also bind this region (Moolla et al., 2002). 
Interestingly the Core and X promoters seem to be stronger than the S1 and S2 
promoters, likely reflecting their proximity to the enhancer elements. 
 
Besides direct regulation of the enhancer and promoter regions, cccDNA transcription 
if further regulated through epigenetic modifications of both the DNA molecule and 
the attached histones. As previously mentioned, cccDNA is subject to 
chromatinization. It was seen to display the characteristic “beads-on-a-string” 
arrangement on electronic microscopy and to be organized into nucleosomes, 
although with a reduced spacing when compared to host cell chromatin (Bock et al., 
2001; Newbold et al., 1995). The Core protein is a structural component of the HBV 
nucleosome. Histone proteins H3 and H2B were the most prominent species 
identified, but lower levels of histone proteins H4, H2A, and H1 were also detectable 
by immunoblotting. A number of cellular transcription factors (CREB, ATF YY1 STAT1 
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and STAT2) and chromatin modifying enzymes (PCAF, p300/CBP, HDAC1, SIRT1 and 
EZH2) have been shown, by Chromatin Immunoprecipitation (ChIP), to bind to the 
cccDNA in human hepatoma cells containing replicating HBV (Belloni et al., 2009; 
Pollicino et al., 2006). For some of the transcription factors known to interact in vitro 
with HBV enhancer elements, the association with the cccDNA minichromosome 
remains to be proven (Levrero et al., 2009). The amino-terminal tails of the four core 
histones on the nucleosome surface are subjected to a variety of enzyme-catalyzed, 
post-translational modifications, including lysine acetylation, lysine and arginine 
methylation, serine phosphorylation, ubiquitination and SUMOylation, associated 
with specific patterns of gene expression. Briefly, and as represented in Figure 12, 
histone acetylation is associated with transcription initiation, whereas reduced 
acetylation of histones H3 and H4 N-terminal leads to the recruitment of histone 
methyl-transferase and DNA methyl-transferase enzymes that results in repression of 
gene expression and heterochromatinization.  
 
 
Figure 12. Proteins involved in cccDNA transcriptional regulation. CccDNA is organized as a 
minichromosome in the nucleus of the infected cells and is subject to epigenetic regulation. 
High transcriptional activity is associated a relaxed structure, histone acetylation and with the 
recruitment of proteins such as transcription factors (TFs), histones acetyltransferases (HAT), 
HBc and HBx. Conversely, during periods of low transcriptional activity, the chromatin is 
condensed, histones and DNA are methylated and there is recruitment of histone deacetylases 
(HDAC), histone methyltransferases (HMTs) and DNA methyltransferases (DNMTs). Adapted 
from (Zoulim et al., 2013). 
 
The transcriptional activity of cccDNA has been show to vary throughout the course 
of the disease and to be modulated by immune factors, as interferon administration, 
and by the binding of X protein (Belloni et al., 2009, 2012; Levrero et al., 2009). Besides 
post-translational histone modifications, methylation of the CpG islands on HBV DNA 
also contributes to the regulation of HBV gene expression. At least six CpG islands have 
been identified in the HBV genome and their methylation status has been associated 
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with transcriptional repression, both in vitro and in vivo (Zhang et al., 2013). The most 
common chromatin modifications are summarized in Table I. 
 
Table I. cccDNA epigenetic modifications. Type, site and function of known chromatin marks. 
Numbers within brackets identify the amino acid residues involved in specific modifications. 
Adapted from (Levrero et al., 2009) 
 
 
 
2.3. The disease 
2.3.1. Epidemiology 
2.3.1.1. Prevalence and geographic distribution  
HBV infection, both in its acute and chronic forms, is estimated to be responsible for 
780000 deaths per year worldwide (being ranked 15th in the Global Burden of Disease 
Study) (Locarnini et al., 2015). It is estimated that 248 million people are chronically 
infected with HBV (translating into a global prevalence of 3,61%) (Schweitzer et al., 
2015). Depending on HBsAg prevalence, endemicity is categorized as low (<2%), low-
intermediate (2-4,9%), high-intermediate (5-7,9%) and high (≥8%), with a distribution 
that can be observed in  
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Figure 13. 
 
 
Figure 13. HBsAg global prevalence (1957-2013). Reproduced from (Schweitzer et al., 2015). 
 
2.3.1.2. Molecular epidemiology and genotypes 
The first classification of HBV was based on the antigenicity of the extracellular loop 
of HBsAg (antigenic loop) and it has been largely used for epidemiological studies. 
Briefly, it considers the major “a” determinant (residues 124-147) and two pairs of 
mutually exclusive determinants, d/y and r/w, to define 4 major serotypes (Dény and 
Zoulim, 2010; Norder et al., 1992). 
Extensive sequence analysis has led to the definition of viral genotypes. HBV is 
considered to be divided into 8 genotypes (A-H), based on a nucleotide sequence 
dissimilarity of more than 7,5%. Two other Asian genotypes (I and J) have been 
proposed, but not yet approved by the ICTV. Genotypes can further be divided into 
sub-genotypes (dissimilarity greater than 4%) and recombinants have also been 
described (Dény and Zoulim, 2010; Locarnini et al., 2013). Geographical distribution of 
the genotypes is represented Figure 14. 
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Figure 14. Geographical distribution of the HBV genotypes and sub-genotypes. Genotype I 
and J are not shown as they have not been ratified by the ICTV; genotype I is found in Southern 
China and Vietnam whilst genotype J was identified from a Japanese World War II person who 
lived in Borneo. Reproduced from (Locarnini et al., 2015) 
 
Correlations between genotypes, clinical progression and treatment response have 
been established, although data are not clear enough to attribute to each genotype a 
severity predictive value. Genotype D has been particularly associated with mutations 
in the PreCore region that abolish the secretion of HBeAg (Dény and Zoulim, 2010; 
Howley, 2013). Finally, it should be noted that no correlation exists between the 
serotyping and genotyping classifications. 
 
2.3.2. Transmission pathways 
Two major patterns of HBV transmission are recognized: vertical and horizontal (Dény 
and Zoulim, 2010): 
 
 Vertical transmission (mother to infant) is particularly important in the 
perpetuation of infection in highly endemic areas. It occurs during the 
peripartum or in the initial months after birth. No significant transplacental 
transmission has been demonstrated. Acute HBV infection in the third 
trimester, high viral load and HBeAg positivity are associated with the highest 
risk of transmission; 
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 Horizontal transmission, important in low endemicity areas, occurs mainly by 
parenteral exposure to infected blood (namely through intravenous drug use, 
occupational exposure, tattooing, blood transfusion or other medical 
procedures) or intimate contacts with exchange of bodily fluids (as sexual 
contacts) (Kidd-Ljunggren et al., 2006). 
 
However, in about 40% of the adults with acute HBV infection, no specific route of 
transmission can be identified, reflecting the high infectivity of the virus.  
 
2.3.3. Clinical features and natural history 
After contamination, the incubation period ranges from 1 to 6 months.  
 
Acute hepatitis B (lasting 1-2 weeks) is asymptomatic in 60-80% of the cases. Less 
than one third of the patients will display hyperbilirubinemia-related signs and 
symptoms. Fulminant hepatitis (acute liver failure) occurs in less than 1% of the cases 
(this proportion is increased in the setting of HDV coinfection as described below). 
Following acute infection, more than 90% of the children and 5% of the adults will 
progress to chronicity (Lai and Yuen, 2007). 
 
Chronic hepatitis B (CHB) is defined by the persistence of HBsAg for more than 6 
months. It can be schematically divided into 5 phases of variable duration and not 
necessarily sequential (European Association For The Study Of The Liver, 2012; 
Locarnini et al., 2015): 
 
1. ‘‘Immune tolerant’’ phase is most common and more prolonged in patients 
infected perinatally or in early childhood. It is characterized by high viral 
replication (as evidenced by HBeAg positivity and high HBV viremia) in the 
absence of liver damage (normal alanine aminotransferase [ALT] levels, 
minimal liver histological activity). The concept of immune tolerance has been 
challenged, as evidence suggests that immune mediated liver damage, albeit 
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low level, exists during this phase (Bertoletti and Kennedy, 2015). The 
pathology of this phase is particularly difficult to analyze, given that, in the 
absence of markers of liver damage, liver biopsies are seldom performed; 
 
2. “Immune reactive” phase corresponds to the maturation of a specific anti-HBV 
immune response, clinically translated by a decrease in viremia and an 
increase of ALT levels, as a consequence of hepatic necro-inflammatory 
activity. This phase culminates with HBe seroconversion; 
 
3. “Inactive carrier state”. It’s a low replicative phase following HBeAg to anti-
HBe antibody seroconversion. It is characterized by very low or undetectable 
serum HBV DNA levels (below 2000 IU/ml), and normal serum 
aminotransferases, accounting for minimal hepatic necro-inflammatory 
activity. It is associated with a favourable clinical course. HBsAg loss and 
seroconversion to anti-HBs antibody may occur spontaneously in 1–3% of 
cases per year. However, viral infection is not resolved and progression to CHB 
(and its associated complications), may still occur; 
 
4.  “HBeAg negative chronic hepatitis B” represents a later immune reactive 
phase in the natural history of CHB. It is characterized by a pattern of 
fluctuating HBV DNA and aminotransferases levels and active hepatitis. HBeAg 
remains undetectable, due to a selection of pre-core and basal core promoter 
mutants; 
 
A fifth stage or “HBsAg negative phase” can be considered, although these patients 
can be included in the broader definition of occult HBV infection. Occult HBV infection 
refers to the presence of HBV DNA in the liver (with or without HBV DNA detectable 
in serum) in the absence of HBsAg, as determined by the currently available assays 
(Kwak and Kim, 2014). In some patients this presentation may result from HBs escape 
mutants not detected by serologic assays, being associated with high HBV DNA titers. 
However, occult hepatitis B is most commonly a result of low HBV replicative activity, 
that may be associated with cccDNA epigenetic silencing (Levrero et al., 2009). 
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Untreated CHB patients will progress to develop fibrosis, cirrhosis and HCC, at variable 
rates, depending on disease activity. In the inactive carrier state, progression is slow, 
<1% per year, while in the immune reactive and HBeAg negative hepatitis phases, 
progression to cirrhosis can be as high as 2-10% per year. Overall, in CHB patients a 
cumulative risk of cirrhosis development ranges from 8 to 20%.  
Cirrhotic patients present an increased risk of liver decompensation, HCC and death 
(European Association For The Study Of The Liver, 2012; Locarnini et al., 2015): 
 
 The 5-year cumulative incidence of hepatic decompensation is approximately 
20% for untreated patients with compensated cirrhosis. The overall 5-year 
mortality of HBV cirrhotic patients is 15%. Untreated patients with 
decompensated cirrhosis, however, have a 5-year mortality as high as 65-86%  
 In cirrhotic patients, the 5-year cumulative risk of HCC varies depending of the 
region, being as high as 17% in East Asia and 10% in Western Europe and USA. 
The main risks factors for progression for HCC are HBeAg positivity (3,6 times 
higher incidence than HBeAg negative patients) and HBV DNA levels 
(identified as the main determinant of progression in the Taiwanese REVEAL- 
HBV study); 
 Overall, the outcome of CHB is determined by both viral (HBV DNA levels, 
genotype, and particular mutation patterns) and host factors (age, gender, 
genetic background, immune status) (Liang, 2009). 
 
2.3.4. Diagnosis 
The diagnosis of HBV infection, both acute and chronic, is based on a combination of 
clinical signs and symptoms with biochemical, serologic, virologic and histological 
parameters. Most commonly used serologic and virologic markers and their 
significance are represented in Table II, whereas their evolution through the phases in 
infection is summarized in Figure 15. 
Primary diagnosis of HBV infection relies on a combination of HBsAg and anti-HBc 
antibodies. If both are negative, infection by a wild type virus can be excluded, while, 
if at least one is positive, further evaluation is warranted. 
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Table II. Serologic and virologic markers used in the diagnosis of HBV infection. Adapted from 
(Liang, 2009). 
 
 
 
 
Figure 15. Natural course of chronic hepatitis B infection – evolution of serologic and virologic 
markers throughout the course of the disease. CH: chronic hepatitis. Reproduced from (Dény 
and Zoulim, 2010). 
 
In a patient with signs, symptoms or laboratory features of acute hepatitis and positive 
HBsAg, the diagnosis of acute hepatitis B is confirmed by a high level anti-HBc IgM in 
serum (low levels of circulating IgM anti-HBc can be detected during periods of 
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reactivation of chronic infection). Serologic evaluation may be complemented by 
serum HBV DNA quantification by qPCR. Evaluation of a possible HDV coinfection is 
indicated at this point, as well as exclusion of other forms of acute viral hepatitis. 
CHB is usually asymptomatic and often found during screening procedures, by 
detection of HBsAg. HBeAg, anti-HBe antibodies and viremia will vary, depending on 
the phase of the disease as mentioned above. Although HBe serologic status may be 
informative regarding the phase of the disease, decisions to treat are based in three 
factors that must be determined in all CHB patients: ALT levels, serum HBV DNA levels 
and the severity of liver disease. As for acute infection, exclusion of other forms of 
viral hepatitis is warranted, in particular HDV co- or superinfection (that will greatly 
influence treatment decisions), as is screening for Human Immunodeficiency Virus 
(HIV) infection (European Association For The Study Of The Liver, 2012).  
Liver disease severity can be accessed by both invasive (liver biopsy) and non-invasive 
(FibroTest, FibroScan®) methodologies. Basic indicators of liver function include 
bilirubin, albumin, prothrombin time and platelet counts and will be abnormal in the 
presence of cirrhosis. The use of biochemical fibrosis scores and non-invasive methods 
for liver stiffness evaluation, as means of avoiding liver biopsy, has attracted much 
interest, although further evaluation and validation of their use in HBV infected 
patients are needed (Branchi et al., 2014). Liver biopsy is still useful in cases where 
diagnosis or treatment indications are not clear. However it is usually not required in 
patients with clinical evidence of cirrhosis or in those in whom treatment is indicated 
irrespective of the grade of activity or the stage of fibrosis (European Association For 
The Study Of The Liver, 2012). 
 
2.3.5. Pathogenesis 
Progression to HCC 
The association between HBV infection and HCC has been known since the early days 
that followed HBV discovery (Blumberg et al., 1975). HBV infected patients were 
estimated to have a 233 fold increased risk of HCC, when compared to healthy 
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individuals (Beasley et al., 1981). Posterior data supported this link and led to the 
classification of HBV as an oncogenic virus. 
The process conducting to the development of HCC in CHB patients is multifactorial 
and both immune response (associated with hepatocyte death and regeneration) and 
viral factors are involved. The latter would include: i) the transactivator role of HBx, 
and its involvement on the epigenetic regulation of cell transcription ; ii) the induction 
of oxidative stress in the infected cells, associated with the accumulation of envelope 
proteins (notably in the presence of PreS2 mutations, that lead to the synthesis of a 
truncated M-HBsAg); iii) the random integration of viral DNA in the host cell genome, 
that was shown to occur in transcriptionally active regions, in the proximity of cell 
genes (Fallot et al., 2012; El-Serag, 2012). These factors can help explaining the few 
cases of HCC that occur in HBV infected patients in the absence of cirrhosis. However, 
in the majority of the patients, HCC does develop after decades of infection and is 
associated with liver fibrosis, underscoring the importance of liver inflammation and 
regeneration in the pathogenic process. NF-kB activation, oxidative stress, cytokine 
production and hepatocyte killing by cytotoxic T lymphocytes (CTL) (Howley, 2013) are 
involved. Importantly, it is worth noting that nucleos(t)ide analogue-based therapies, 
which are associated with long-lasting viro-supression (i.e. no detectable viremia, but 
almost no effect of intrahepatic cccDNA and transcription) in CHB patients, do not 
abrogate the risk of developing HCC. Indeed, in large Asiatic cohorts of patients it was 
shown that the incidence was reduced and delayed but did not return to baseline 
(Hosaka et al., 2013). 
 
Immune response to HBV infection 
HBV infection is associated with a modulation of both innate and adaptive immune 
responses. Throughout the years, research has focused mainly on the role of the 
adaptive immune response in the control of HBV and no induction of innate immune 
responses was thought to occur in response to the infection. Recent data now 
challenge the concept that HBV is a stealth virus. 
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Modulation of the innate immune response modulation by HBV 
The control of HBV infection mostly lays in the induction of a cellular and adaptive 
response. However, the importance of the innate immune response to HBV infection 
was first suggested by an in vivo study in the chimpanzee model, showing that acute 
infection was cleared by a non-cytolytic mechanism before the establishment of an 
adaptive response (Guidotti et al., 1999). A subsequent study from the same group 
further indicated that, in HBV infected chimpanzees, in contrast to HCV and HIV 
infected animals, no activation of an innate immune response could be detected 
(Wieland et al., 2004). Furthermore, only low levels of interferon (IFN) were shown to 
be present in the serum of patients with acute HBV infection (Dunn et al., 2009). 
Overall, these observations led to the definition of HBV as being a “stealth virus”, not 
recognized by the innate immune system (Wieland and Chisari, 2005).  
Over the years, it has, however, become clear that, more than not being recognized, 
HBV could in fact inhibit the host antiviral immune response at several levels: 
 
 Data obtained in vitro by the use of a baculovirus containing HBV genome have 
suggested that HBV replication may indeed induce an interferon response, 
implying that inhibitory mechanism must be in place in the case of natural 
infection (Luangsay et al., 2015a; Lucifora et al., 2010); 
 Recent data from the humanized mouse model, suggests a low, yet detectable, 
basal rate if ISG expression by HBV (Lütgehetmann et al., 2011);  
 Early data suggested that HBc was able to suppress IFNβ expression in infected 
cells, as well as inhibit the expression of ISGs. These data have recently been 
approached in our laboratory, further suggesting the active inhibitory role of 
HBV core protein (Fernández et al., 2003; Gruffaz et al., 2013; Twu et al., 1988); 
 Inhibition of Jak-STAT signaling has been proposed as a mechanism of 
interferon resistance (Christen et al., 2007). Such modulation has been 
proposed to be mediated by the viral polymerase (Wu et al., 2007); 
 The viral polymerase has further been suggested to inhibit IFNβ expression in 
response to TLR3 stimulation (Wang and Ryu, 2010); 
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 A similar mechanism of inhibition has been proposed to be mediated by HBx, 
inhibiting IFN production in response to RLR stimulation (Wei et al., 2010a). 
 
The concept of “invisibility” of HBV is hence slowly being replaced by a model of early 
recognition and active inhibition of the innate immune response by the virus. 
 
2.4. Prevention 
The history of the HBV vaccine goes hand in hand with the history of HBV discovery 
itself. After the identification of HBsAg containing SVPs, purification and inactivation 
of carriers’ plasma led to the development of a first vaccine. The first clinical trials 
were completed by 1981, demonstrating safety, effective induction of an humoral 
response (in nearly 100% of the patients) and protection against HBV infection in 
comparison to non-vaccinated controls (Szmuness et al., 1981). Three years after, the 
first wide-range vaccination program was started in Taiwan (an area of high HBV 
endemicity, associated with vertical transmission), It was based on universal screening 
of pregnant women for HBV infection and vaccination of neonates born to HBsAg 
mothers (Chen et al., 1987).  
Given the growing difficulties in fulfilling the high plasma requirements for the 
production of the inactivated vaccine, an alternative strategy led to the development 
of a recombinant vaccine (produced in yeast) that was licensed in 1986 and that is 
currently used (Hilleman, 2000).   
Global HBV vaccination coverage with 3 doses of hepatitis B vaccine is estimated at 
81% of the children worldwide and a total of 183 countries had already introduced a 
nationwide hepatitis B vaccination program for infants by the end of 2013 
(http://www.who.int/mediacentre/factsheets/fs378/en/), representing an amazing 
evolution in the fifty years since the identification of the virus. The Taiwanese 
experience offers an invaluable proof of the impact of vaccination with 91% decrease 
in HBsAg carriage in people aged <25 years old, 80% decrease in the incidence of HCC 
in patients younger than 30 years old, and 90% decrease in the infant mortality from 
fulminant hepatitis (Locarnini et al., 2015). 
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Prevention of vertical transmission is based on the combination of passive (hepatitis 
B immunoglobulin - HBIg) and active immunization (HBV vaccination) of the neonate 
at the time of birth (European Association For The Study Of The Liver, 2012). Such a 
strategy has led to a significant decrease in vertical transmission rates with an impact 
in the number of infections and complications (as stated above). However, a 
proportion of newborns from highly viremic (serum HBV DNA >106–107 IU/ml), mostly 
HBeAg positive mothers, still present a >10% risk of vertical HBV transmission despite 
HBIg and vaccination (that can increase to more than 30% with maternal viremia > 109 
IU/ml) (Chen et al., 2012; Wen et al., 2013). It has been shown that the initiation of 
antiviral therapy in the third trimester in highly viremic women leads to a further 
decrease in vertical transmission in comparison to immunization alone (Han et al., 
2011a). Current treatment guidelines hence postulate initiation of antiviral therapy in 
the third trimester for women with viral load> 106 IU/ml (European Association For 
The Study Of The Liver, 2012). 
 
Besides the strategies for transmission prevention just discussed, prevention of HBV 
reactivation or disease exacerbation is warranted in the setting of predictable immune 
suppression (as the initiation of immune modulatory therapies, anti-cancer 
chemotherapy and transplantation) and is achieved by the instauration of pre-
emptive therapy with DAAs. Furthermore, for HBV infected patients subjected to liver 
transplantion, prevention of graft infection may be achieved by a combination of 
antiviral treatment and passive immunization (with HBIg) (European Association For 
The Study Of The Liver, 2012). 
 
2.5. Treatment 
2.5.1. Current available therapeutic strategies 
Whereas no specific therapy is indicated for acute hepatitis B, current CHB treatment 
is based on the utilization of 7 available drugs, including two formulations of IFNα 
(conventional and pegylated) and 5 nucleos(t)ide polymerase inhibitors (lamivudine, 
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telbivudine, adefovir dipivoxil, tenofovir disoproxil fumarate and entecavir). Data on 
the efficacy of antiviral drugs are compiled in Table III. 
 
Table III. Outcomes of the most commonly used HBV therapies, evaluated at 48 weeks of 
treatment. Adapted from (Zoulim and Durantel, 2015). 
 
 
 
IFN has long been known to have an effect on HBV infection (Greenberg et al., 1976) 
and has been approved for the treatment of CHB in the early nineties. It is currently 
recommended for HBeAg positive patients with low viral loads and persistent liver 
necro-inflammatory activity (as evidenced by elevated aminotransferases).  
The definitive mechanism of inhibitory effect of IFN  on HBV infection is not 
established and a number of possibilities have been suggested. Replication inhibition 
has been reported to be mediated by (non-exhaustive list): 
 blockage of RNA-containing core particle formation (Wieland et al., 2000); 
 accelerated decay of replication-competent core particles (Xu et al., 2010); 
 degradation of the pgRNA (Li et al., 2010); 
 MxA mediated inhibition of nuclear export of HBV mRNAs (Gordien et al., 
2001); 
 inhibition of HBV transcriptional activity, associated with repression of 
enhancer 1 activity (Rang et al., 1999; Tur-Kaspa et al., 1990; Uprichard et al., 
2003); 
 epigenetic regulation of cccDNA transcriptional activity (Belloni et al., 2012; Liu 
et al., 2013); 
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 non-hepatotoxic degradation of cccDNA (Lucifora et al., 2014); 
 
Besides a direct effect on hepatocytes, IFNα was shown to activate natural killer (NK) 
and NK-T cells in HBV infected patients (Micco et al., 2013), while an induction of 
specific TCD8 + cells was noted in another study (Chen et al., 2010). 
 
DAAs directly inhibit HBV polymerase by mimicking natural nucleotides and are 
incorporated into newly synthesized HBV DNA leading to chain termination (Koumbi, 
2015). They contribute to a very slow (i.e. decades) decrease of the amounts of 
cccDNA, hypothesized to be associated with the impairment in mature nucleocapsid 
recirculation, with no impact on the establishment of the initial pool of cccDNA (that 
will not be degraded) (Werle-Lapostolle et al., 2004). These molecules can be classified 
into 3 groups, according to their structure (Zoulim and Durantel, 2015): 
 
 L-nucleosides as lamivudine (3TC) and telbivudine; 
 Acyclic phosphonates, including adefovir dipivoxil (ADF) and tenofovir 
disoproxil fumarate (TDF); 
 Cyclopentanes, represented by entacavir (ETV). 
 
Contrary to interferon therapy, that is limited in time (recommended duration of 1 
year), no current stopping strategy has been possible for NAs and relapses (associated 
with clinical exacerbations) follow therapeutic interruption, meaning that NAs 
treatment with must be kept lifelong. The problem of cumulative resistance 
mutations, first evidenced with 3TC, seems to have been circumvented with the 
development of ETV and TDF, as shown on Figure 16. 
Currently, and based on their potency and favorable resistance profile, entecavir and 
tenofovir are the main choices (European Association For The Study Of The Liver, 
2012).  
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Figure 16. Cumulative annual incidence of resistance among patients who are nucleos(t)ide 
analogue naïve. Reproduced from (Gish et al., 2012). 
 
2.5.2. Investigational drugs in preclinical/ clinical development 
Despite the existence of an effective and safe vaccine and several therapeutic options 
that manage to control viral replication, a main challenge remains: no current therapy 
leads to viral eradication and the rates of HBs seroconversion (translating a “functional 
cure”) remain very low (Zeisel et al., 2015). With increasing evidence of success of HCV 
new therapeutic approaches and the development of new and exciting study models, 
the prospect of developing curative treatment strategies for HBV infection is now 
being vigorously approached (Block et al., 2015). 
The main focus is on the inhibition of cccDNA, either by preventing its formation, 
promoting its degradation or silencing its transcription. However, molecules targeting 
other steps of the viral cycle and new polymerase inhibitors are also in development. 
Drugs undergoing clinical and preclinical development are summarized in Table IV. 
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Table IV. Drugs undergoing clinical and preclinical development for the treatment of HBV 
infection. Reproduced from (Zeisel et al., 2015). 
 
 
 
Entry inhibition 
Myrcludex® B has been developed as a myristoylated peptide that competitively 
blocks the interaction between HBV and HDV envelope and hNTCP. As it has a 
mechanism of action targeting both HBV and HDV, it will be further discussed in the 
HDV chapter. 
 
cccDNA destabilization 
Molecules targeting cccDNA formation or mediating its degradation have been 
identified in preclinical studies and it is tempting to think that they may evolve into 
clinical applications. Examples are: 
 Disubstituted sulfonamide compounds were shown to specifically inhibit 
cccDNA formation in vitro (Cai et al., 2012); 
 Enzymes and cytokines capable of inducing non-cytolytic cccDNA degradation 
have been identified. Examples include zinc-finger nucleases and the CRISP/ 
Thesis Dulce Alfaiate 
63 
 
Cas9 system, and agonists of the lymphotoxin beta receptor, all still in 
preclinical evaluation (Lucifora et al., 2014; Weber et al., 2014). 
 
Transcriptional repression 
As evidence accumulates that cccDNA transcription is subject to epigenetic regulation, 
the hypothesis of using small molecules targeting chromatin modifying enzymes is 
tempting, even more as some compounds, like valproate, are already used in the 
clinics for other indications. Strategies can include induction of histone 
hypoacetylation and induction of DNA and specific histone methylation (Levrero et al., 
2009). 
Another possible strategy involves the use of siRNAs targeting HBV transcripts that 
would be delivered to hepatocytes in polymer formulations (Wooddell et al., 2013). 
 
Encapsidation inhibition 
The HBV nucleocapsid plays a central role in HBV replication. Besides being essential 
for HBV genome packaging, is also necessary for effective reverse transcription and 
intracellular trafficking of viral pgRNA and rcDNA and consequently the maintenance 
of chronic infection from the cccDNA pool (resulting from genome recirculation).  Its 
use as a therapeutic target has been explored for more than one decade, and two 
classes of molecules have been developed so far: 
 
 Heteroaryldhydropyrimidines (HAP) – HAPs have been described to have a 
complex mechanism of action that varies depending on the used dose. At low 
doses these molecules accelerate assembly and induce the formation of 
aberrant particles, whereas at higher doses they accelerate capsid degradation 
by the proteasome (Bourne et al., 2008). Efficacy of these compounds has 
been demonstrated in the humanized mouse model and the first developed 
molecule has entered clinical evaluation (Brezillon et al., 2011). No cross 
resistance with currently available NAs has been demonstrated; 
Thesis Dulce Alfaiate 
64 
 
 Phenylpropenamide derivatives – these molecules specifically target pgRNA 
encapsidation, by promoting capsid formation in the absence of 
pgRNA/polymerase complexes. Despite having no effect on the overall levels 
of core protein function, an effect is noticed in the amount of cccDNA. 
Furthermore, a synergistic effect with 3TC has been suggested (Feld et al., 
2007; King et al., 1998).  
 
Viral assembly inhibition 
Several molecules are in preclinical evaluation regarding their effect on the inhibition 
of viral assembly and release (Block et al., 2015). A particular attention should be 
drawn to the clinical development of nucleic-acid-polymers (NAPs) that, in preclinical 
models were shown to inhibit HBsAg secretion and hence viral particle formation 
(Noordeen et al., 2013a, 2013b). Further details are discussed in the 3. Hepatitis delta 
chapter. 
 
 Immunomodulation 
Several immunomodulatory strategies are undergoing clinical evaluation for the 
control of HBV infection and include interferons, cytokines, Pattern Recognition 
Receptors (PRR) agonists and therapeutic vaccines (Isorce et al., 2015). 
Besides IFNα, inhibition of HBV replication can be achieved in vitro and animal models 
with both interferon  gamma and lambda (Pagliaccetti et al., 2010; Shi et al., 2012). 
Several cytokines have been considered for HBV treatment and are at diverse phases 
of preclinical and clinical evaluation. IL-1β has been shown to have a potent anti-viral 
effect against HBV (Isorce et al., 2014; Watashi et al., 2013). IL-12, in combination with 
3TC, was shown to increase HBV-specific T cell activity and to induce HBeAg 
seroconversion (Rigopoulou et al., 2005). 
Tymosin-alpha-1 is a synthetic polypeptide that has immunomodulating activity and 
has been shown to promote T cell activity, IFN gamma and IL12 production, as well as 
NK-induced cytotoxicity. Preclinical and clinical studies have been conducted on anti-
HBV effects and addition of thymosin- 1 seems to improve the response to 3TC 
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therapy, but adds no benefit to IFN  monotherapy (Kim et al., 2012; Zhang et al., 
2009). 
Active clinical and preclinical research is currently underway to explore the role of PRR 
stimulation in the inhibition of HBV infection. This strategy may be associated with a 
double effect, as it will not only lead to the establishment of an antiviral state in the 
infected hepatocytes, but also to the activation of the innate immune cells, like NK 
and dendritic cells. A first report of efficacy was made for the activation of Toll-like 
Receptor (TLR) 3 by poly (I:C) in the transgenic mouse model (Uprichard et al., 2003) 
and followed by the identification of an antiviral effect of the activation of other TLRs 
(notably TLR2, TLR4, 5, 7 and 9) (Isogawa et al., 2005; Zhang et al., 2012). In parallel to 
TLR activation, stimulation of intracellular RIG-I like receptors (RLRs) was also seen to 
have an inhibitory effect on HBV replication.  
Very promising results are currently being obtained with TLR7 agonizing strategies. 
GS-9620 has been shown to induce a significant decrease of HBV replicative 
intermediates (including cccDNA and HBsAg) and to have a good safety and tolerability 
(Fosdick et al., 2014; Lanford et al., 2013; Menne et al., 2015; Roethle et al., 2013). 
Recruitment for a phase II clinical trial is now underway (NCT02166047). 
Finally, several strategies are being developed to modulate acquired immune 
response, namely PD-1 blockage by the administration of monoclonal antibodies, 
aiming for restoration of T-cell function and therapeutic vaccines, either antigen- or 
DNA-based are undergoing clinical development (Koumbi, 2015; Zeisel et al., 2015). 
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3. Hepatitis delta 
The text and the original illustrations contained in this chapter constitute a review 
article that has been published in Antiviral Research – see pdf in Appendix 1. 
 
3.1. Introduction 
3.1.1. Discovery of Hepatitis D virus 
Hepatitis D virus (HDV), the virus causing hepatitis delta, was first identified in 1977 
by Mario Rizzetto and colleagues, in a cohort of HBV infected patients who 
experienced a severe hepatitis (Rizzetto et al., 1977). Some of these patients’ liver 
biopsies were found positive after staining by anti-sera from some HBsAg positive 
patients, in the absence of HBV Core protein (HBcAg), as evidenced by electron 
microscopy and negative staining with monoclonal specific antibodies. This novel 
‘antigen-antibody system’ (called  antigen/anti-  antibodies), although associated 
with HBV infection, was immunologically different from HBsAg, HBeAg, and HBcAg. 
The δ antigen (HDAg) isolated from these initial patients was then instrumental to 
screen the sera of other patients of diverse geographic origins and associate the 
presence of circulating anti-δ antibodies to chronic liver disease (Rizzetto et al., 1979, 
1980a). The  antigen was later confirmed to be associated with a transmissible 
pathogenic ‘delta agent’, now called HDV. Indeed, the serum from patients with -
positive hepatitis could infect chimpanzees in the presence of its helper HBV both in 
co- or superinfection conditions (Rizzetto et al., 1980b). In these chimpanzees, 
antigen was shown to circulate as particles, containing HBsAg and a low molecular 
weight RNA molecule, raising for the first time the hypothesis of HDV being an RNA 
satellite virus of HBV (Rizzetto et al., 1980c).  
 
3.1.2. Clinical and virological relevance  
Almost 40 years after discovery, HDV and hepatitis D remain challenging entities to 
both clinicians and researchers. The impact of the disease, mostly present in low-
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income countries, is largely neglected. Despite being considered as the most severe 
form of chronic hepatitis, HDV infection is still under diagnosed, either by lack of 
awareness or appropriate diagnostic tools, and available treatments are still largely 
ineffective. Although significant advances have been made in understanding the 
cellular and molecular virology of HDV, they have failed to translate into the 
development of effective therapeutic strategies. Explanations stem from the 
peculiarity of HDV life cycle, which features no virally-encoded enzymatic activity and 
completely relies, not only on cell machinery as other viruses, but also on HBV for 
spreading. 
 
3.2. The virus 
3.2.1. Origin of HDV 
HDV is a 35-37 nm diameter virus featuring a small single-stranded, circular RNA 
genome of 1672-1697 nucleotides, the smallest among mammalian viruses. Its 
particular characteristics still pose unanswered questions regarding its origin. 
Currently, two main theories are considered: HDV may have evolved from plant viroids 
or/and host cell pre-mRNA via the splicing machinery (Taylor, 2014). 
Plant viroids are considered the lowest entities in the biological scale in terms of 
genome complexity. More than 30 species have been described so far, that have in 
common being constituted of a small single stranded, often circular, RNA molecule 
(250-400 nucleotides), having no coding capacity, and being replicated by host cell 
enzymes. Two families of viroids are considered: Pospiviroidae (represented by the 
potato spindle tuber viroid) and Avsunviroidae (represented by the avocado sunblotch 
viroid). HDV has RNA structural and replicative features in common with both families: 
its rod-like RNA structure and nuclear replication relate to Pospiviroidae, whereas the 
existence of a ribozyme and the symmetrical rolling circle mechanism remind 
Avsunviroidae. These common features, added to the fact that RNAs from HDV and 
plant viroids interact with homologous cellular proteins, and the experimental 
preliminary, yet not clearly confirmed by others, evidence that HDV might replicate 
and spread after inoculation of tomato seedlings’ leaves, suggest an analogy between 
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HDV and plant viroids. This hypothesis, however, leaves unanswered questions such 
as the origin of the delta antigen and the relation between HDV and HBV, its helper 
virus (Flores et al., 2012).  
A second theory, which can be complementary to the first one, suggests that HDV may 
have evolved from the host cell transcriptome. This vision was supported by studies 
showing that ribozyme RNA with similar secondary structure and biochemical 
properties to the HDV ribozyme can be found in human cells (e.g. within an intron of 
the CPEB3 gene). However, pseudoknot ribozymes were later found in all life 
kingdoms (except Archaea) and in insect viruses (Salehi-Ashtiani et al., 2006; Webb et 
al., 2009).  A host cell origin has also been proposed to the delta antigen. Indeed a 
protein, named DIPA (as delta interacting protein A), was initially described as a 
potential candidate. Although the actual relevance of its homology has later been 
dismissed, DIPA might still be a cellular HDAg partner (Brazas and Ganem, 1996; Long 
et al., 1997; Taylor and Pelchat, 2010).  
An integrated model suggests that HDV might have arisen from a re-combination 
event between a viroid like element and a cellular pre-mRNA/mRNA (Robertson, 
1996).  
 
3.2.2. Viral structure 
Role of HBV envelope proteins in HDV assembly  
Firstly characterized from sera of chimpanzees experimentally infected with the 
serum from an Italian chronic carrier, HDV was shown to be a HBsAg enveloped 
particle of 35 to 37 nm (Figure 17), with a buoyant density of 1,25g/cm3 in cesium 
chloride gradient and a sedimentation coefficient value intermediate between the 
one from the HBsAg empty SVPs (22 nm) and the HBV virion (Dane particle, 42 nm) 
(Rizzetto et al., 1980c).   
HDV is indeed a defective virus-like particle that uses an envelope composed of the 
three forms of HBV glycoproteins (small (S or S-HBsAg), medium (M or M-HBsAg) and 
large (L or L-HBsAg) HBV surface proteins) to egress from and re-enter into 
hepatocytes, thus conferring the same tropism to both viruses.  
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Figure 17. Electron microscopy of δ-associated particles. Both a predominant 35- to 37-nm 
particle and a few 22-nm forms of HBsAg were observed (magnification 70500X). Reproduced 
from (Rizzetto et al., 1980c). 
 
The three forms of HBsAg share a common C-terminus, as discussed in the HBV Viral 
proteins section, and represented in Figure 18.  
 
 
 
Figure 18. HBV envelope proteins. The three forms of HBsAg share the same C-terminus (S) 
containing four putative transmembrane domains (filled grey rectangles I-IV), a cytosolic loop 
(CL) and an antigenic loop (AL). As translation initiates in different in-frame sites, besides S 
(the only domain of S-HBsAg), M-HBsAg contains PreS2 and L-HBsAg further contains the 108 
aa of PreS1. HDV assembly is dependent on the contact of the CL with HDV RNP, whereas 
HBV’s capsid’s contact with HBsAg is established with the PreS region.  
 
In addition to the S domain, M-HBsAg contains an N-terminal hydrophilic domain 
named PreS2, and, relative to M-HBsAg, L-HBsAg has an additional domain named 
PreS1 (Urban et al., 2014). L-HBsAg is essential for the assembly and infectivity of HBV, 
although not sufficient, and S-HBsAg is needed for the release of particles from cells 
(Gudima et al., 2007). In contrast, HDV can be assembled by S-HBsAg alone, but 
without L-HBAgs, the particle is not infectious (Sureau et al., 1993). These distinct 
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budding requirements are explained by different binding domains of the cytosolic 
loops of the envelope proteins to HBV nucleocapsid and HDV ribonucleoprotein 
(Sureau et al., 1994). A recent study has shown that the assembly (and infectivity) of 
HDV genotype 1 (HDV1) is not restricted to a particular HBV genotype (Freitas et al., 
2014). It can also occur with woodchuck, bat and woolly monkey hepadnavirus 
envelopes (Barrera et al., 2004; Drexler et al., 2013; Ryu et al., 1992).  
 
Viral RNAs  
The HDV virion contains a circular single-stranded negative RNA genome, with a strong 
secondary flexible-quasi double-stranded RNA conformation. During replication in 
infected cells, two other main viral RNAs can be detected: the genomic 
complementary molecule, called antigenome, and the HDV mRNA (Figure 19). 
Constituted of only 1672-1697 nt, the HDV genome is the smallest of all known 
mammalian viruses and presents some similarities with plant viroid counterparts. It 
has a high C+G content (60%) and about 74% intra base pairing allowing it to fold into 
a rod-like structure (Kuo et al., 1988a; Wang et al., 1986). Infected cells may contain 
about 300,000 molecules of HDV genome, divided between nucleus and cytoplasm, 
thus indicating a high level of replication (Chen et al., 1986; Macnaughton and Lai, 
2002). 
The HDV antigenomic RNA is a replicative intermediate of positive polarity, 
complementary to the genome sequence and contains the coding sequence for HDAg. 
It is 5-22 times less abundant than the genome, found exclusively in the nucleus of 
infected cells and therefore not packaged into virions (Chen et al., 1986; Macnaughton 
and Lai, 2002). HDV proteins are translated from a specific 800nt length HDV mRNA 
(Lo et al., 1998), which is transcribed by host DNA-dependent/RNA-polymerase II and 
matured (i.e. capped and polyA-tailed), as cellular mRNAs (Gudima et al., 2000; Hsieh 
et al., 1990). 
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Figure 19. Structure of HDV RNAs. Both genome and antigenome form an unbranched rod-
like structure of ~1700 bp, due to extensive intramolecular base-pairing, and contain a self-
cleaving ribozyme (R). Although antigenomic RNA contains the open-reading frame (ORF) for 
HDAg, the antigen is translated from the ~800bp mRNA. HDV mRNA is transcribed form 
genome by RNA-Pol II and matured as a host cell mRNA (with a 5’ cap and a 3’ polyA tail). S-
HDAg is translated from un-edited mRNAs whereas antigenome editing of the Amber/ W site 
by ADAR1 leads to the emergence of L-HDAg. 
 
Ribozyme  
Small self-cleaving RNA sequences (of about 85 contiguous nucleotides) were 
identified in both HDV genome and antigenome (Kuo et al., 1988b; Wu et al., 1989). 
These ribozymes, whose sequences are very well conserved among HDV genotypes, 
are responsible for the cleavage of multimeric RNA molecules that arise during 
transcription into unit-long genome or antigenome sequences.  
The HDV ribozyme has unique structural and functional characteristics (Figure 20) and 
is distinct from viroid ones (Serganov and Patel, 2007). Several crystal structures of 
HDV ribozyme have been obtained and allowed to uncover a pseudoknot-like 
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mechanism of cleavage (Riccitelli and Lupták, 2013). As previously mentioned, recent 
studies have identified HDV-like ribozyme sequences in host-cell genomes.  
 
 
 
Figure 20. Secondary structures of (A) genomic and (B) antigenomic HDV ribozymes. The 
single-stranded portion containing the catalytic cytosine is pink. Black nucleotides denote 
unconserved, single-stranded joining regions. Arrows connecting nucleotides indicate the 
direction of the strands, and the 5' OH marks the 5' end of the ribozyme following self-scission. 
Reproduced from (Riccitelli and Lupták, 2013). 
 
Viral proteins and editing 
Early cloning and sequencing suggested the existence of 9 putative ORFs in HDV RNA 
(4 in the HDV genome and 5 in the antigenome). Although a small polypeptide 
resulting from an alternative ORF (i.e. ORF-K) has been described (Bichko et al., 
1996a), the virus produces one main viral protein - HDAg (Wang et al., 1986). The 
coding region for HDAg is contained in the antigenome molecule, but translation 
occurs from a linear HDV mRNA. While originating from the same ORF, two isoforms 
of HDAg are translated, i.e. S-HDAg (for ‘small’, 24 kDa) and L-HDAg (for ‘large’, 27 
kDA). S-HDAg can be directly translated from the first round of HDV genome 
transcription and is the earlier form to arise in infected cells. During replication, as 
depicted in Figure 23, the ‘Adenosine Deaminase Acting on RNA’ protein (ADAR1) 
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catalyses adenosine-to-inosine editing on the antigenomic HDV RNA (adenosine 1012; 
the amber/W site is changed from UAG to UIG) (Polson et al., 1996). This gives rise to 
a genome that has a complementary ACC instead of the AUC and ultimately leads to 
the appearance of mRNA forms where the UAG (amber) stop codon is replaced by a 
UGG (tryptophan) codon. This modification allows translation to continue until the 
next stop codon, leading to the appearance of a protein 19-20 amino-acids longer, i.e. 
L-HDAg (Casey, 2012). 
Based on relative levels of expression and knock-down experiments, ADAR1 has been 
shown to be the specific cellular enzyme acting on antigenomic HDV RNA (Wong and 
Lazinski, 2002). ADAR1 has two isoforms – small (ADAR1-S) and large (ADAR1-L) - with 
a common C-terminus. ADAR1-S is the most abundant form, constitutively expressed, 
and has a nuclear localization, whereas ADAR1-L is found mainly in the cytoplasm and 
its expression is stimulated by interferon. Preliminary works indicated that ADAR1-L 
was very efficient in editing transcripts in the cytoplasm, but it was later shown that 
HDV RNA editing occurs in the nucleus and is mediated by ADAR1-S (Wong and 
Lazinski, 2002). However, recent works suggested an increased in HDV RNA editing 
following interferon treatment that could be attributed to ADAR1-L (Hartwig et al., 
2004, 2006).  
The two forms of HDAg share the 195 amino acids of N-terminus and present several 
common functional domains, including RNA binding motifs, a coiled-coil domain, a 
nuclear localization signal and a helix-loop-helix motif (Figure 21). The 19 extra amino 
acids of L-HDAg are proline rich, feature a viral assembly signal, a nuclear export signal 
(NES), and a prenylation site (Lee et al., 2001).  
HDAg undergoes post-translational modifications that can impact HDV replication, 
namely serine phosphorylation, lysine acetylation, arginine methylation and lysine 
sumoylation (Lai, 2005). Prenylation of the Cys211 residue of L-HDAg, by a cellular 
farnesyl transferase  is involved in particle assembly (Glenn et al., 1992). S-HDAg and 
L-HDAg have different roles during the viral life cycle and may contribute to different 
pathogenic mechanisms. S-HDAg, while having no polymerase activity, is necessary for 
the initiation of HDV replication, RNA Pol II elongation and for the accumulation of 
HDV RNAs during the cycle (Kuo et al., 1989; Yamaguchi et al., 2001). L-HDAg acts as 
a dominant negative inhibitor of HDV replication, by specifically inhibiting genome, 
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but not antigenome, synthesis and is essential for virion assembly (Chang et al., 1991; 
Chao et al., 1990; Modahl and Lai, 2000).  
 
 
 
Figure 21. Functional domains and post-translational modifications of HDAg. Both forms of 
HDAg contain and oligomerization domain (OD), a nuclear localization signal (NLS) and an 
arginine-rich motif (ARM). L-HDAg is 19 aa longer the S-HDAg and further contains a nuclear 
export signal (NES). Post-translational modifications that have been described for both forms 
of HDAg are represented by circles (P, phosphorylation; M, methylation; A, acetylation; F, 
farnesylation). 
 
Ribonucleoprotein  
The genomic HDV RNA associates with HDAg to form a ribonucleoprotein (RNP) 
present both in viral particles and infected cells. This RNP is essential, not only for 
virion assembly, but also for the nucleus/cytoplasm trafficking of HDV RNA (Tavanez 
et al., 2002). The exact structure and stoichiometry of this RNP have been debated. 
Early studies suggested that, in the virion, the genome molecule was associated to 70 
HDAg molecules, whereas in the nucleus of infected cells, both genome and 
antigenome formed RNP structures featuring an average of 30 HDAg molecules (Ryu 
et al., 1993). A more recent study suggested a molar ratio of 200 molecules of HDAg 
per genome molecule both in virions and infected cells (Gudima et al., 2002). However 
these numbers have been questioned by studies suggesting the oligomerization of 
delta antigen to attach to the HDV RNA molecule, which would be compatible with 
the smaller proportions previously proposed (Alves et al., 2010; Lin et al., 2010). 
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Importantly, the binding specificity of HDAg to the genome seems to be dictated by 
its secondary structure rather than its primary sequence (Griffin et al., 2014).   
 
3.2.3. Viral life cycle 
An overall representation of HDV life cycle in a hepatocyte co-infected by HBV is 
depicted in Figure 22. 
 
 
 
Figure 22. HDV life cycle. For a productive HDV viral cycle, HBV infection of the same cell is 
necessary. For both viruses, entry is mediated by NTCP binding of the preS1 domain of HBsAg, 
preceded by virion attachment to HSPGs. Apart from entry, replication of HBV and HDV seems 
to be completely independent. HBV nucleocapsid (NC) is transported to the nucleus where 
viral relaxed circular DNA (rcDNA) is converted to covalently- closed circular DNA (cccDNA), a 
mini chromosome-like structure that is permanently kept in the infected cell. Fragments of 
HBV DNA are integrated in the host cell genome. HBV RNA transcription from cccDNA is 
mediated by the cell RNA Pol II and gives rise to mRNA transcripts that can either be included 
in immature nucleocapsids and undergo retro-transcription by the viral retro-transcriptase 
(RT) to form new genomes; or translated into viral structural proteins. Virions are assembled 
and released through the multivesicular body (MVB) pathway (whereas subviral particles – 
SVPs – are thought to be released via Golgi secretory pathway). Replication of HDV genome 
(HDV G RNA) is exclusively nuclear, occurs through a double rolling circle mechanism, involving 
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the formation of antigenome (HDV AG RNA) and multimeric RNA intermediates and the 
recruitement of host cell RNA polymerases. HDV ribonucleoprotein (RNP) is enveloped in the 
Golgi by HBsAg. HDV secretion is thought to occur via Golgi. ER, endoplasmic reticulum; HSPG, 
heparan sulfate proteoglycans; NTCP, sodium taurocholate cotransporting polyeptide. 
 
3.2.3.1. Attachment and entry 
Hepatotropism. The hepatotropism of HDV and its capacity to ensure a productive 
cycle are related to the entry process and HBV coinfection of cells. While a productive 
cycle requires the expression of HBV surface glycoproteins in the same cell to allow 
assembly of HDV virions, other aspects of the two virus replication cycles seem 
completely independent, as no other component of HBV seems to contribute to HDV 
replication and vice versa (Bichko et al., 1996b). In contrast to HBV, which requires 
liver-specific transcription factors, HDV genome replication may occur in various 
mammalian cell types provided that its genome is experimentally delivered to cells 
(Taylor, 2009). Given the shared envelope structure of both virus, attachment and 
entry mechanisms are thought to be similar between HBV and HDV, and most of the 
current knowledge on HBV entry mechanisms has been obtained in HDV infection 
models (Sureau, 2010).  
Viral factors. For both viruses, the presence of the L-HBsAg envelope protein is 
essential for infectivity. Specific mutations in the N-terminal 75 amino acids of the Pre-
S1 domain or inhibition of myristoylation can block infectivity (Blanchet and Sureau, 
2007; Gripon et al., 1995). S-HBsAg antigenic loop domain and pattern of glycosylation 
also seem to play an role, as specific mutations in this domain may inhibit infection, 
independently of the PreS1 domain (Le Duff et al., 2009; Julithe et al., 2014). 
Host factors. Viral attachment on the cell surface precedes receptor-specific entry for 
HBV and is mediated by cellular heparan sulphate proteoglycans (HSPGs) (Leistner et 
al., 2008; Schulze et al., 2007). This was recently confirmed for HDV (Lamas Longarela 
et al., 2013; Sureau and Salisse, 2013). The exact HSPGs involved in HBV/ HDV viral 
attachment are still to be identified, even though Glypican-5 was recently reported to 
be preponderant in this process (Verrier et al., 2015). This step, although necessary, is 
not sufficient for infection, as the entry of HSPG-attached viruses can still be inhibited 
(Han et al., 2011b). A potential role for purinergic receptors (i.e. P2YRs, P2XRs) in the 
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attachment process of both HDV and HBV has also been suggested from the reported 
inhibitory effect of suramin (Lamas Longarela et al., 2013; Taylor and Han, 2010).  
Recently, a ground-breaking study from Yan and colleagues led to the identification of 
hNTCP, encoded by SLC10A1, as a functional receptor for HBV and HDV (Yan et al., 
2012). NTCP is located in the basolateral membrane of hepatocytes and participates 
in the enterohepatic circulation of bile salts. Viral infection seems to be supported by 
amino acids involved in bile acid binding (and not those involved in sodium binding) 
(Yan et al., 2014). The interaction between NTCP and HBV/HDV seems to be mediated 
by the viral PreS1 N-terminal 75 amino acids and a NTCP binding region located on 
helix 5 in the outer leaflet of the cell membrane (Urban et al., 2014). Backing up the 
fact that HDV can replicate into many cell types (i.e. not only human hepatocytes), if 
its genome is correctly delivered, an hNTCP-trangenic mice was recently shown to be 
infectable by HDV (He et al., 2015). Interestingly, a polymorphism of the SLC10A1 gene 
(S267F), affecting NTCP’s bile acid transport function is thought to be present in 9% of 
the East Asian population was shown to impair HBV and HDV uptake by hepatocytes 
(Yan et al., 2014). 
 
3.2.3.2. Uncoating and nuclear transport  
HBV is thought to be internalized through clathrin-dependent endocytosis, via early 
and late endosomal compartments, independently of acidification and protease 
activity (Huang et al., 2012; Macovei et al., 2013). Such evidence is unavailable for 
HDV, although it may be supported by the identification of L-HDAg as a clathrin-
adaptor-like protein (Huang et al., 2007). The steps that mediate post-fusion nuclear 
transport of HDV RNP and virus genome uncoating are not fully understood. 
Trafficking of HDV RNP between cytoplasm and nucleus would involve HDAg and its 
interaction with importins (Chou et al., 1998; Tavanez et al., 2002). Further 
understanding of this phase of the viral cycle would be crucial to understand in 
particular the innate immune response against the virus. 
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3.2.3.3. Replication  
Throughout replication, antigenome RNA is limited to the nucleus, whereas genomic 
RNA molecules can either enter another nuclear replicative cycle or be exported to 
the cytoplasm for assembly into new infectious particles (Macnaughton and Lai, 
2002). A summary of the currently accepted steps involved in HDV replication is 
represented in Figure 23. 
 
 
 
Figure 23. Model of HDV RNA replication. HDV replication is limited to the nucleus and 
involves antigenome and multimeric RNA molecules as replicative intermediates. Genome is 
transcribed in the nucleolus by cellular polymerase(s). The generation of multimeric RNAs is 
necessary for the self-cleavage and ligation activities of HDV ribozyme. The cycle is completed 
by transcription of antigenome by RNA Pol II in order to form a new genome molecule. 
Genome can either enter a new replicative cycle, initiate transcription of HDV mRNA or be 
exported to the cytoplasm as HDV RNA for virion production. In parallel, antigenome 
molecules can enter a novel replicative cycle after editing of the Amber/ W site by ADAR1, 
ultimately leading to the appearance of mRNA coding for L-HDAg (see text for details). ADAR, 
adenosine deaminase acting on RNA. 
 
Double Rolling circle model of replication. It is now accepted that HDV has an RNA-
dependent RNA replication in a “double rolling-circle mechanism”, which involves the 
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recruitment of host-cell DNA-dependant RNA polymerases and likely their switch in 
template specificity (Lai, 2005; Taylor, 2009). The double rolling-circle replication 
(similar to plant viroids symmetrical rolling-circle replication, but modified to include 
mRNA synthesis step) relies on two circular RNA templates of inverse polarity, genome 
and antigenome, and the generation of intermediate multimeric linear transcripts. 
For the replication of HDV RNA, three enzymatic activities are needed: a polymerase 
to synthetize oligomeric strands from circular templates, a ribozyme-dependant 
RNAse activity to cleave them into unit-length strands, and a ligase to circularize 
monomers.  
Transcription. Unlike some RNA viruses with larger genomes, HDV does not possess 
its own RNA-dependent RNA-polymerase. Moreover, in contrast to other satellite 
viruses (e.g.  satellite tobacco necrosis virus), it does not use the polymerase of its 
helper virus, and therefore fully relies on host-cell properties (Lai, 2005). Several lines 
of evidence support the fact that RNA polymerase II (Pol II) would be involved in HDV 
replication: firstly, the HDV mRNA displays a 5’ cap and 3’ poly-A tail as cellular mRNAs 
(Gudima et al., 2000; Hsieh et al., 1990); secondly, HDV RNA transcription has been 
shown to be inhibited by low doses of -amanitin (Chang et al., 2008); and finally, RNA 
pol II has been shown to be able to bind to HDV RNA of both genomic and anti-
genomic polarity (Chang et al., 2008; Greco-Stewart et al., 2007). In other reports, 
antigenome synthesis seemed to be somehow resistant to -amanitin, suggesting that 
Pol I could be also involved (Modahl et al., 2000). This possibility is supported by two 
other studies suggesting that both Pol I and Pol III could interact with HDV RNA (Greco-
Stewart et al., 2009), and that genome and antigenome synthesis could take place in 
distinct nuclear areas (Li et al., 2006). Although several hypotheses prevail and the 
exact role of the various polymerases is still to be clarified, all studies agree that HDV 
is able to redirect an otherwise DNA-dependent RNA-polymerase to its RNA template. 
The underlying molecular mechanism is however largely unknown.  
 
The role ofS-HDAg. S-HDAg is an important candidate to explain this hijacking of RNA 
pol II. It is a nuclear protein known to bind to HDV RNA, which presents structural 
similarities to transcription factors (e.g. NELF-A), and can undergo acetylation and 
methylation as other transcription regulatory proteins (Lai, 2005). S-HDAg can bind to 
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RNA Pol II and enhance transcription either by direct stimulation of elongation or by 
reversion of inhibitory effects (Yamaguchi et al., 2001). Furthermore, S-HDAg has been 
shown to biochemically interact with 9 out of 12 subunits of the RNA pol II in a 
combined proteomic-RNA interference screening (Cao et al., 2009). This interaction 
may not be restricted to Pol II, as S-HDAg has been shown to interact and/ or co-
localize with nucleolar proteins (e.g. B23 and nucleolin), which could further support 
a Pol I involvement (Huang et al., 2001). 
 
Motifs for transcription and replication. The presence of transcription initiation sites 
or promoters on HDV RNA is also debated. It seems to be the case for HDV mRNA 
(Gudima et al., 2000), and a recent study has suggested that the 5’-end region of the 
HDAg mRNA, which coincides with one extremity of the rod-like genomic RNA and 
displays a complex secondary structure, may play an important role in HDV replication 
(Beeharry et al., 2014). 
Cleavage. Genome and antigenome molecules are processed from more than unit-
length linear precursors, needing a cleaving catalytic activity. This activity is exerted 
by the ribozyme auto-cleaving sequences present in both genome and antigenome 
that have to be transcribed at least twice from the circular templates to give rise to 
one unit length, justifying the presence of multimers. 
Ligation. A ligase activity would be needed to circularize the linear monomers into 
genome and antigenome molecules. While a study has suggested the recruitment of 
a host-cell ligase, as ligation of HDV RNA occurred only in mammalian cells (Reid and 
Lazinski, 2000), another has shown self-ligating properties of HDV ribozyme sequences 
(Sharmeen et al., 1989). 
 
3.2.3.4. Viral assembly and release 
To form HDV virions, the HDV ribonucleoprotein is enveloped by at least S- and L-
HBsAg, meaning that, in a natural infection, HDV can only be released from cells co-
infected with HBV. Many questions remain unanswered regarding HDV assembly and 
release. The newly developed infection models should help uncovering this step of 
HDV life cycle in parallel with a better understanding of HBV assembly.  
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In contrast to HBV, the cytoplasmic domain of HBsAg, spanning the junction between 
PreS1 and PreS2, does not seem crucial for HDV release; hence it has been suggested 
that HDV would mostly use the subviral particle release pathway (through the Golgi) 
rather than the multivesicular body pathway, involved in assembly of infectious HBV 
virions (Taylor, 2012; Watanabe et al., 2007; Zeisel et al., 2015). As for post-entry 
trafficking of HDV RNP, clathrin could also be involved in viral particle export (Huang 
et al., 2009). Regarding viral components, the farnesylation of the C-terminal 
sequence of L-HDAg is necessary for HDV envelopment, as it mediates the interaction 
with the S region of HBsAg (Hwang and Lai, 1993). Farnesylation involves the fixation 
of a 15 carbon chain to the C211XXQ box peptide motif that is present at the carboxy-
terminal end of the L-HDAg and conserved among all HDV genotypes. 
 
3.2.4. Experimental models for the study of HDV  
Since the discovery of HDV, both in vitro and in vivo models have been established to 
perform molecular and cellular studies. 
 
In vitro models  
Unlike HBV, HDV replication is not restricted to hepatocytes, and the virus can 
replicate to high levels in a wide range of mammalian cells upon delivery of viral RNA 
(and antigen) or cDNA. In vitro models of transfection of hepatic cancer cell lines (e.g. 
Huh7, HepG2) have allowed major contributions to the study of viral replication. 
However, as viral assembly depends on the presence of HBV envelope proteins, viral 
particle production can only be achieved in the presence of concomitant HBV 
transcription or by the co-transfection of a plasmid encoding HBV envelope proteins 
(Gudima et al., 2007; Sureau, 2010).  
Until recently only differentiated primary human (PHH), chimpanzee (not often used), 
or tupaia (PTH) hepatocytes, as well as the non-transformed, bipotent progenitor 
differentiated-HepaRG cell line were susceptible to HDV (and HBV) infection (Urban 
et al., 2014). These cells are difficult to obtain, to work with, and can be confronted 
(with the exception of HepaRG) to batch-to-batch variability (both genetically and 
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physiologically), thus impairing reproducibility of experiments. The recent 
identification of hNTCP as an essential receptor for HDV and HBV has changed this 
scenario, as its constitutive or inducible overexpression in clonal transformed hepatic 
cell lines (e.g. HepG2 and Huh7) renders them susceptible to high level of infection in 
a more reproducible manner (Urban et al., 2014). 
 
In vivo models  
Although natural HDV infection seems to occur only in humans, a limited number of 
susceptible mammalian hosts has been identified and used for research purposes. 
HDV infection has hence been extensively studied in chimpanzees (with HBV as a 
helper virus) and woodchucks (in the presence of WHB) (Ponzetto et al., 1984; Rizzetto 
et al., 1980b). Tree shrew species Tupaia bengaleri (susceptible to HBV), woolly 
monkeys (with WMHBV as helper virus), and more recently bats have also been used 
for the study of HDV infection, although their use is limited by lack of tools. 
Interestingly, Peking ducks’ hepatocytes, although a useful model for the study of 
avihepadnavirus (DHBV), do not sustain HDV replication (Liu et al., 2001). 
Many mice models, which are more or less relevant, have been developed to date. 
First of all, it is worth noting that a straight HDV injection of wild type mice does not 
lead to an efficient infection, with < 1% of infected hepatocytes; this finding is 
compatible with the current knowledge on species specificity of HDV infection 
mediated by hNTCP (Netter et al., 1993; Yan et al., 2013). Gene delivery strategies 
based on hydrodynamic transfection of plasmids (with trimeric or dimeric constructs) 
led to measurable intrahepatic HDV replication in mice and to the establishment of 
HDV viremia, when HBV-transgenic mice are used (Bordier et al., 2003; Chang et al., 
2001). This approach is interesting to study potential antiviral targeting HDV in an 
immune competent model. In a less flexible approach, a transgenic mouse expressing 
a replication competent HDV genome dimer has also been generated.  Interestingly, 
as the transgene was not only expressed in hepatocytes, it was found that HDV could 
replicate in other tissues than liver, supporting the fact that HDV hepatotropism is 
mediated by an entry restriction (Polo et al., 1995). More recently a transgenic mouse 
model expressing hNTCP was developed and shown to support acute HDV infections 
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(He et al., 2015). But in this model coinfection or superinfection with HBV cannot be 
studied. It is worth noting that transgenic mice expressing either L-HDAg or S-HDAg 
have been developed and have proven useful to exclude a direct 
pathogenic/carcinogenic role in this setting (Guilhot et al., 1994).  
All mice models described so far do not allow co- or superinfection with HBV in a 
context in which cccDNA is present. To overcome this problem, humanized liver mice 
models (initially used for the study of HCV and HBV infections) have been validated 
for HDV (Dandri and Lütgehetmann, 2014). Several models have been developed 
(notably uPA SCID, FRG and TK-NOG mice), having in common a human reconstituted 
liver (from the engraftment of PHH) in the absence of an immune system (Bissig et al., 
2010; Dandri et al., 2001; Kosaka et al., 2013). Notably, the uPA SCID mouse model 
has been used for the preclinical validation of Myrcludex B®, an entry inhibitor for 
both HBV and HDV (Lütgehetmann et al., 2012). More recently, mouse models 
displaying not only a humanized liver but also a human immune system, have been 
developed and reported to be susceptible to HBV infection. Although a promising tool 
for the study of virus-host interactions, their potential contribution for the study of 
HDV infection is yet to be established (Bility et al., 2014; Gutti et al., 2014; Washburn 
et al., 2011).  
 
3.3. The disease 
3.3.1. Epidemiology 
3.3.1.1. Prevalence and geographic distribution  
HDV has a worldwide distribution (Figure 24), with variable prevalence rates, which 
surprisingly do not exactly match the distribution of chronically HBV-infected (CHB) 
patients (Ponzetto et al., 1985; Rizzetto et al., 1980a). HDV prevalence may be 
underestimated by non-standardized and heterogeneous screening practices and the 
inaccessibility to testing in many highly endemic areas. In the 80’s, the number of HDV 
infected patients was estimated at 15 to 20 million worldwide, with an overall 
prevalence rate of 5% of all HBsAg carriers (Ciancio and Rizzetto, 2014). Areas with 
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high endemicity were at that time identified in Africa and South America, with 
prevalence as high as 85% of HBsAg positive patients in the Amazon basin. Countries 
of the Mediterranean basin were considered of intermediate endemicity (with a 
prevalence of 25% in Italy and Turkey), whereas in low endemic countries (Northern 
Europe and USA), the disease seemed to be restricted to intravenous drug users 
(IVDU) (Ponzetto et al., 1985; Rizzetto and Ciancio, 2012). 
 
 
 
Figure 24. Prevalence of Hepatitis delta virus infection among HBV carriers. The scale 
indicates the suspected proportion of HDV co- or superinfection of HBV-infected patients. 
Yellow colour: insufficient data. The black circles indicate preferential area diffusion of HDV 
genotypes, HDV-1 being ubiquitous. Due to globalization, human migration or travel during 
chronic carriage, some strains geographically defined, can extend outside their initial 
spreading area. Therefore, diagnosis has to be adapted for all different HDV genotypes. Note 
that some prevalence remained from the nineties, while others correspond to more recent 
works. 
 
The case of low endemicity regions 
In the 90’s, the decrease in prevalence of HBV infection (due to improvements in 
sanitation, behavioural changes and, mostly, to the introduction of an HBV vaccine) 
was accompanied by a decrease in HDV prevalence in Europe (Rizzetto and Ciancio, 
2012). But for the last 15 years, no further decline has been observed. In Italy, where 
an HDV epidemic spreading occurred during the 80’s, there was a steady decrease 
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during the two following decades, but recent data suggest that no further decrease 
was achieved, with steady prevalence rates of 8,1% of HBsAg carriers in 2008 (Sagnelli 
et al., 2014; Stroffolini et al., 2009). In France, the latest data suggest that the 
prevalence of HDV infection among HBsAg carriers is also stable, if not increasing 
(Servant-Delmas et al., 2014). This trend seems to be associated with the increasing 
number of migrants, originating mainly in Africa and Eastern Europe (Le Gal et al., 
2007). Similar data were reported in Germany, with a current prevalence of 7,4 -11,3% 
of HBsAg carriers, with a significant proportion of patients originating in Turkey and 
Eastern Europe. (Reinheimer et al., 2012; Wedemeyer et al., 2007). 
A recent re-assessment of HDV prevalence in London (UK) reported a decrease in the 
prevalence rate (2.1% of all the HBsAg carriers, while the previous reported 
prevalence was 8,5% in 2008) and attributed a significant proportion of the positive 
cases to IVDUs (22,7%) and to patients of African origin (28-50%) (Cross et al., 2008; 
William Tong et al., 2013). In the USA, the diagnosis of HDV infection has for long been 
neglected. Recent studies indicate that the number of affected patients is comparable 
to the European reality (8% of the HBsAg positive patients) and not restricted to IVDUs 
(26% of the patients).(Gish et al., 2013) 
In summary, three subgroups of patients can be described nowadays in Western 
countries: a) older patients infected during the eighties epidemic (namely in the 
Mediterranean basin), currently suffering from advanced liver disease; b) younger 
IVDUs, often co-infected with HCV and/or HIV; and c) patients migrating from highly 
endemic countries (Ciancio and Rizzetto, 2014). 
 
The case of high endemicity regions 
In the early 90’s, an outbreak of severe acute hepatitis delta (mostly due to 
coinfection) was reported in the IVDUs of the Russian region of Samara. During the 
outbreak, 39% of acute hepatitis B patients had a positive HDV IgG (48% among the 
fulminant hepatitis cases) (Flodgren et al., 2000). High prevalence of chronic hepatitis 
delta (CHD) is still reported in central Europe: 47.6% of HBsAg positive patients in 
Romania and 13,9% in Hungary (Pár et al., 1992). 
Although Brazil as a whole does not have a high prevalence of HDV infection, the 
Amazonian basin was soon recognized as an endemic region (Galizzi F et al., 2010; 
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Ponzetto et al., 1985). In this region, HDV-3 has been associated with “Labrea fever”, 
a form of fulminant hepatitis that affected indigenous populations (Bensabath et al., 
1987). Recent evaluations of HDV prevalence are consistent with high endemicity, 
with HDV seropositivity rates ranging from 8,5% of HBsAg-positive asymptomatic 
blood donors to 65% in HBsAg-positive hospital outpatients (Crispim et al., 2014). High 
HDV prevalence rates are also reported in the Amazonian areas of Venezuela and 
Colombia, where the infection is, as in Brazil, caused by HDV-3 and associated with 
fulminant hepatitis outbreaks (Alvarado-Mora and Pinho, 2013). 
In Africa, HDV infection affects mainly countries in the western and central areas. In 
Mauritania a prevalence rate of 33.1% among HBsAg positive patients was recently 
reported, and HDV was associated with more aggressive disease than HBV infection 
alone (Lunel-Fabiani et al., 2013). Other studies show wide differences in sero-
prevalence in HBsAg positive liver patients, ranging from 1.3% in a Nigerian centre, to 
50% in Central African Republic and 66% in Gabon (Andernach et al., 2014; Makuwa 
et al., 2009). However, it should be kept in mind that data on anti-HDV seroprevalence 
are lacking from several African areas. In Egypt, a seroprevalence of HDV of 20% was 
described among the HBsAg positive individuals (mostly patients with liver disease) 
(Saudy et al., 2003). 
The situation is Asia is particularly interesting: in some places, the distribution of HDV 
infection does not match the high endemicity of HBV in the region. In Taiwan, a classic 
case of high HBV prevalence and an example of HBV vaccination success, HDV 
infection is frequent in the IVDU population (66,7% prevalence) and frequently 
associated with HIV infection, but remains rare in non-IVDUs (6%) (Chang et al., 2011). 
In Mongolia a prevalence of HDV antibodies as high as 82% has been reported in HBV 
infected patients with advanced liver disease (Oyunsuren et al., 2006). Finally, a recent 
report from the Pacific region also suggests high prevalence rates (37% among HBsAg 
positive patients) in isolated Micronesian islands (Han et al., 2014). 
In summary, HDV infections are far from being on the way to eradication, and remain 
a major health problem in developing and low-resource countries where the diagnosis 
is sub-optimal. There is an urgent need to standardize RNA testing procedures 
(Detection of the virus section) and implement them in countries of high endemicity 
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and surrounding ones to better monitor evolution of prevalence, while remaining 
vigilant in the rest of the word, due to increasing travel habits. 
3.3.1.2. Molecular epidemiology and genotypes 
HDV evolution seems to result from 3 main mechanisms: mutation, editing and, as 
recently described, recombination (Chao, 2007). The substitution rate for HDV, 
determined in vivo by the longitudinal evaluation of patient samples was estimated to 
be of 5.9 × 10−4 to 3.0 × 10−2 substitutions per site per year, varying with the phase of 
the infection (higher in the acute phase), the genome location (higher in the less 
conserved regions than in the conserved regions such as ribozyme) (Chao et al., 1994), 
and increasing under therapeutic pressure (Dény, 2006; Lee et al., 1992). These values 
seem to be higher than for the majority of the RNA virus that have estimated rates 
between 1 x 10-5 and 3. 4 x 10-3; as an example, HCV is estimated to have a substitution 
rate of 7.9 x 10-4 and HIV 2.5 x 10-3 (Jenkins et al., 2002). A long term in vitro study 
identified a substitution rate of 2 x 10-2 and suggested that 70% of this substitutions 
may be linked to editing events (Chang et al., 2005a). These evidences of genetic 
diversity led to the proposition that, in the same patient, HDV, as also described for 
other RNA virus, circulates as a quasi-species (Lee et al., 1992).  
Recombination was firstly suggested from a patient sample analysis in 1999, then 
confirmed to occur in mixed genotype infections, both in vivo and in vitro, and recently 
re-visited in a patient suffering from acute hepatitis in Vietnam (Sy et al., 2015; Wang 
and Chao, 2005; Wu et al., 1999). Template-switching driven by the host RNA 
polymerase has been proposed as the most likely mechanism of HDV RNA 
recombination (Chang and Taylor, 2002; Gudima et al., 2005).  
From the phylogenetic analysis of worldwide HDV sequences, eight genotypes have 
been proposed, associated with distinct geographic distribution (represented in Figure 
24) and clinical features (Le Gal et al., 2006; Radjef et al., 2004). Sequence differences 
within a genotype are smaller than 20% but can be as high as 35% between different 
genotypes (Dény, 2006). Interestingly, among HDV isolates, South American HDV-3 
sequences are the most divergent ones, matching the tree topology of the local helper 
HBV genotype F among HBV genetic variability, suggesting common cause of viral 
evolution in South American natives. 
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3.3.2. Transmission 
3.3.2.1. Transmission pathways 
HDV transmission is considered to occur mainly through a parenteral route. The main 
transmission route however may vary between low and high prevalence zones. In 
Europe and in the USA transmission occurs mainly through contact with infected 
blood, particularly in IVDUs, frequently in association with HIV and HCV. There is 
evidence that both homosexual and heterosexual transmission of HDV can occur and 
may be particularly relevant in highly endemic areas (Braga et al., 2012; Brook, 1998). 
Intra-familial transmission, presumably involving unapparent exchange of body fluids, 
occurs in low-income communities and has been proven by sequence analysis in an 
Italian population in the nineties (Niro et al., 1999). Vertical transmission of HDV has 
not been described and is possibly disfavoured by HDV’s repression of HBV replication 
lowering HBV mother-to-infant transmission at birth. 
 
3.3.3. Clinical features 
3.3.3.1. Forms of acquisition 
Being a satellite virus, HDV can establish a productive infection and spread only in cells 
concomitantly infected by its helper virus, HBV. Clinically, this translates into two 
possible forms of HDV acquisition: (i) simultaneously with HBV, corresponding to 
coinfection or (ii) by infection of a patient already chronically infected by HBV, 
corresponding to superinfection. In the transplantation setting a third form of 
acquisition has been suggested as “helper-independent hepatitis delta”. 
Coinfection translates into acute hepatitis, ranging from mild to severe, or even 
fulminant, and usually leads in 90-95% of cases to resolution of both HBV and HDV 
infections; this means that the rate of progression to chronicity is as low as for HBV, 
in immune-competent adults. The proportion of fulminant hepatitis in this setting can 
be as high as 17%, which is far higher than that observed in acute HBV infection  
(Yurdaydın et al., 2010). Superinfection, on CHB setting, may also translate into an 
acute hepatitis episode and may lead to fulminant hepatitis (Farci and Niro, 2012). 
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Although some patients experience an HBsAg sero-conversion upon HDV 
superinfection, the vast majority progresses to chronic infection by both viruses 
(Caredda et al., 1985). A summary of the available data on infection progression is 
proposed in Figure 25. 
 
 
 
Figure 25. Progression of HDV infection depending on the acquisition pattern. 
 
In liver-transplanted HBV/HDV patients a “helper independent HDV infection” or 
“latent” HDV infection has been suggested with markers of HDV replication identified 
in the liver and serum in the absence of HBV markers (Ottobrelli et al., 1991). Re-
evaluation of some of these cases, using more sensitive PCR techniques, has shown 
that HDV infection was maintained in parallel with a very low-level HBV replication, 
ruling out the possibility of an isolated HDV infection (Smedile et al., 1998). 
 
3.3.3.2. Clinical course and serologic patterns 
Acute HBV/HDV coinfection is in most cases clinically indistinguishable from acute 
HBV infection. However, a subset of patients (15% in some cohorts) can present a 
severe clinical course with a pattern of biphasic hepatitis, associated with a re-
increase of transaminase levels after a first period of improvement and that is thought 
to be caused by sequential spreading of HBV followed by HDV (Moestrup et al., 1983). 
HDV acute superinfection of a CHB patient is clinically characterized by an auto-limited 
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flare of hepatitis (clinically evident in half of the patients), that can be mistakenly 
considered to be an hepatitis B reactivation, and is usually followed by progression to 
chronicity of both infections. During acute hepatitis delta, HDV markers do not allow 
a reliable distinction between co- and superinfection. Diagnosis is established based 
on the presence of anti-HBc IgM antibodies (directed against the capsid of HBV) that 
will be positive in the setting of an acute HBV infection (as is the case in coinfection) 
and remain negative or at a very low titre in super-infected patients. Fulminant 
hepatitis (acute liver failure in a patient with no prior liver disease) is more frequent 
in HDV infected patients than in HBV mono-infected patients and, without liver 
transplantation, is associated with a mortality of 80%. Chronic hepatitis D (CHD) is 
clinically indistinguishable from chronic HBV infection, although with a faster 
progression to cirrhosis and hepatocellular carcinoma (HCC) (Farci and Niro, 2012). 
 
3.3.4. Diagnosis 
Detection of the virus  
Given the high prevalence of HDV infection in some parts of the world and the absence 
of decrease in Europe and North America, there is an increasing consensus to suggest 
that all HBV infected patients (including inactive carriers) should be screened, at least 
at the diagnostic of CHB, for HDV infection (Hughes et al., 2011; Noureddin and Gish, 
2014). This is already argued in European HBV treatment guidelines (EASL), but not in 
the North American counterpart; indeed AASLD’s recommendations still restrict HDV 
screening to HBV infected patients originating from endemic countries or with a 
history of IV drug use (European Association For The Study Of The Liver, 2012; Lok and 
McMahon, 2009). 
Anti-HDV ‘total’ antibody (i.e. anti HDV-IgM plus anti-HDV IgG) testing should be used 
as a first approach to hepatitis delta diagnosis, given its early appearance after HDV 
infection and its persistence throughout the course of the disease (Olivero and 
Smedile, 2012). There are two limitations to this approach: first, in the first days after 
infection, anti-HDV antibodies may be undetectable, and patients presenting with 
acute HBsAg positive hepatitis must be re-evaluated for the appearance of anti-HDV 
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antibodies; secondly, anti-HDV IgG may persist after HDV infection resolution. A 
positive anti-HDV serology should be confirmed, ideally by the detection of serum 
HDV RNA. In the settings where HDV PCR is unavailable, anti-HDV IgM may be 
considered as a surrogate marker of HDV active infection and its clearance is 
correlated with therapeutic response (Wranke et al., 2014). Serum HDAg 
measurement is of limited utility, as in immunocompetent patients it is only 
transiently detected just before the acute phase of HDV infection, preceding the rising 
of anti-HDV antibodies. In the chronic phase of disease it can only be occasionally 
detected in immunocompromised patients (Grippon et al., 1987). 
As for other viral infections, nucleic acid quantification plays a crescent role in the 
diagnosis and most importantly therapeutic monitoring of HDV infected patients. 
However, unlike HBV, HCV or HIV, there is no fully standardized PCR technique. HDV 
molecular diagnosis mostly relies on in house techniques developed in academic 
centres. Given the wide genetic variability of the viral RNA, quantification of non-
genotype 1 or African-specific genotype 1 samples has yet to be optimized (Brichler et 
al., 2013). The number of published qRT-PCR techniques has increased over the last 
years, based on both two-steps and one-step protocols (Ferns et al., 2012; Le Gal et 
al., 2005; Homs et al., 2014; Mederacke et al., 2010; Scholtes et al., 2012; Yamashiro 
et al., 2004). Significant technical challenges associated with HDV amplification arise 
from the high CG content and complementarity of viral RNA (that may limit the RT 
efficiency) and the high genetic variability of HDV that requires a careful design of 
primers (and probes) (Le Gal et al., 2005). Utilization of a robust PCR standard and 
internal control are also essential for a reliable HDV RNA quantification. Given the 
need for international quality assessment and control, an international PCR standard 
has now been validated by the World Health Organization to allow result comparison 
between the available PCR techniques (Chudy et al., 2013).  
It is worth noting that the correlation between viral load and disease severity is not 
clear, being suggested in some cohorts, but not in others, possibly as a result of 
distinct patient characteristics, viral genotypes and errors in quantification (Braga et 
al., 2014; Brichler et al., 2013; Romeo et al., 2014; Wedemeyer and Manns, 2010).  
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Evaluation of liver disease  
Liver disease grading and staging must be performed in all patients with HDV infection, 
in order to weight risks and benefits of interferon therapy. Liver biopsy, although not 
needed to establish the diagnosis of HDV infection, remains the gold standard for the 
staging of liver disease and delta antigen detection and is performed in most centres 
before treatment consideration (Wedemeyer and Manns, 2010). While non-invasive 
methods for fibrosis evaluation are increasingly used for other types of hepatitis 
(mostly HCV infection), their use in hepatitis delta still awaits validation. Liver 
elastography has been used by different groups for non-invasive fibrosis evaluation of 
HBV/ HDV/ HIV infected patients, although validation studies in HDV infected patients 
need to be performed (Castellares et al., 2008; Soriano et al., 2014). Furthermore, 
clinical scores currently used as indirect markers of fibrosis and predictors of outcome, 
are not validated in hepatitis delta patients. Part of these scores has shown poor 
performance in one hepatitis delta cohort, and a new Baseline Event Anticipation 
score (BEA) has been proposed, based on age, gender, geographical origin, 
International Normalized Ratio, platelet count and bilirubin (Calle Serrano et al., 
2014). 
 
3.3.5. Natural history and pathogenesis 
Natural history 
CHD is often considered as the most severe form of chronic viral hepatitis. HDV 
infected patients have a more aggressive clinical course than HBV mono-infected 
patients, with a three times higher risk of developing cirrhosis and a faster progression 
(Fattovich et al., 1987). The risk of cirrhosis increases overtime and has been reported 
to be of 23%, 41% and 77% after respectively 10, 20 and 30 years of infection 
(Yurdaydın et al., 2010). Clinical decompensation has been described as the major 
complication in cirrhotic CHD patients, with a more than 2 fold increased risk when 
compared to HBV mono-infection (Fattovich et al., 2000). The course of disease may 
be influenced by HDV genotype, with predominant genotype 1 being associated with 
more severe disease than genotypes 2 and 4 (Su et al., 2006). Genotype 3 has been 
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associated with a particularly aggressive evolution (Casey et al., 1996). A role of HBV 
genotypes in the course of disease has also been suggested. 
The association between CHD and HCC is still a matter of debate. Three major studies 
identified liver decompensation and death, and not HCC, as the major complication of 
CHD, and associated the development of HCC with persistent HBV replication (Buti et 
al., 2011; Niro et al., 2010; Romeo et al., 2009). However, in the Eurohep cohort, an 
increased risk of 3,2 fold was shown in CHD patients in comparison to CHB ones, with 
a 5-year risk of 13% (Fattovich et al., 2000). A more recent Swedish study also 
suggested a 6-fold increase in the risk of HCC in CHD patients (Ji et al., 2012). More 
studies are yet needed to further evidence the link between CHD and HCC. 
 
Insights into fibrosis and carcinogenesis mechanisms  
The pathogenesis of liver damage during HDV infection is still incompletely 
understood, and the relative contribution of direct pathogenic effect of HDV or 
immune-mediated injury is a matter of debate. A direct cytopathic effect of HDV 
antigens seems unlikely given the absence of liver damage upon its expression in 
transgenic mice (Guilhot et al., 1994). However, cell death in the presence of high 
levels of replication (replication-associated cytopathogenicity) has been observed in 
vitro and has been suggested to contribute to cases of acute/fulminant hepatitis, 
where cell death induced by high levels of replication might precede synthesis of L-
HDAg (Chang et al., 2005b). A direct implication of HDV proteins in liver pathogenesis 
can however be supported by studies that showed an interaction with cellular 
proteins and/or a modulation of cell signalling pathways. For a comprehensive review 
of HDV cell interactants refer to Greco-Stewart and colleagues (Greco-Stewart and 
Pelchat, 2010). Large transcriptomic and proteomic studies highlighted several 
possibilities. A combined proteomic RNAi screening identified 100 putative cell 
partners of S-HDAg, mostly involved in transcription and HDV replication, but 
consequences of such interactions for the host cell cannot be ruled out (Cao et al., 
2009). A direct role of L-HDAg in fibrogenesis has been proposed, as L-HDAg was 
shown to activate TGF-  pathway. Moreover, this activation was dependent on 
isoprenylation and synergistic with HBx-mediated TGF-  and AP1 signal transduction 
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(Choi et al., 2007). A similar synergism between HBx protein and L-HDAg has been 
described in the activation of the serum responsive element- dependent pathway 
(Goto et al., 2003). 
The direct effect of HDV on cell proliferation and cancer has been long debated. 
Analysis of cell proteome changes in the presence of delta antigen or viral genome 
replication led to the identification of differentially expressed proteins mostly 
associated to cell cycle regulation and pyruvate metabolism and the suggestion of 
direct involvement of HDV in carcinogenesis promotion (Mendes et al., 2013; Mota et 
al., 2008, 2009). Using another screening approach, clusterin expression was shown 
to be up-regulated upon S-HDAg expression and HDV replication, possibly through 
histone hyper-acetylation, and to be associated with increased cell survival. These 
findings support an oncogenic potential of HDV, given that clusterin is not only 
involved in oncogenic pathways, but was also shown to be overexpressed in HCC 
tissues (Liao et al., 2009). NF- B activity has also been shown to be modulated by HDV. 
Several mechanisms have been proposed, including L-HDAg direct interaction with 
TRAF-2 and potentiation of TNF-  induced NF- B transcriptional activation (Park et 
al., 2009), induction of endoplasmic reticulum stress (Huang et al., 2006), and 
production of reactive oxygen species upon expression of L-HDAg (Williams et al., 
2012).  
 
Immune response and its modulation  
As for other aspects of hepatitis delta, much remains to be explored regarding the 
immune response to HDV infection. Indeed, immune responses, both innate and 
adaptive, are believed to play an important role in liver damage and disease 
progression. 
Regarding the innate immune response, results are conflicting between studies and 
the details of the interaction between HDV and hepatocyte innate immune response 
are only partially explored. Several studies support an activation of interferon 
signalling pathways by HDV: in vitro, HDV replication was first shown to be associated 
with increased expression of IFN  (McNair et al., 1994); later the expression of HDAg 
was associated with an induction of MxA (an Interferon Stimulated Gene – ISG) 
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(Williams et al., 2009) and recently misfolded HDV RNA was shown to directly activate 
PKR (Heinicke and Bevilacqua, 2012). In vivo HDV was also associated with an 
increased expression of ISGs, both in the hNTCP transgenic mouse and in the 
humanized mice model (Giersch et al., 2015; He et al., 2015). Paradoxically, in a study 
by Negro and colleagues, HDV replication was not associated with the expression of 
ISGs, but with an inhibition of the cell response to interferon, by interference with an 
early step of the JAK-STAT signalling pathway (Pugnale et al., 2009). Interestingly, this 
inhibition of interferon pathway was also suggested (although not thoroughly 
explored) in the aforementioned study in the humanized mouse model (Giersch et al., 
2015). 
The role of NK cells during HDV infection and treatment has recently been addressed. 
The number of NK cells was found to be increased in CHD patients in comparison to 
healthy controls, however, as for HBV and HCV, they presented a less activated 
phenotype and were less prone to stimulation (Lunemann et al., 2014). Little is also 
known about T-cell responses in HDV infection. HDV infected patients have a higher 
frequency of perforin-positive TCD4+ cells than patients with HBV or HCV, 
independently of the level of liver inflammatory activity, which may be a possible 
explanation for the faster progression of liver disease in CHD (Aslan et al., 2006). 
Specific HDAg epitopes were shown to induce TCD4+ cells expansion, but only in 
patients with inactive disease (Nisini et al., 1997). Interestingly, HDV CD8+ cytotoxic T 
lymphocyte responses were also only identified in patients with inactive disease 
(Huang et al., 2004). In the HIDIT-1 trial patients, a specific pattern of cytokines was 
shown to decrease during interferon treatment, being related to treatment response. 
Specific T cell response restoration was only observed in treatment responders 
(Grabowski et al., 2011). 
 
Interplay between HDV and HBV  
In the early characterization of HDV infection, it became evident that, despite its 
dependency on HBV for its envelope, HDV suppressed HBV replication in both humans 
and chimpanzees (Hadziyannis et al., 1985; Rizzetto et al., 1980b). The same effect 
was observed in WHV infected woodchucks and more recently in the HBV-infected 
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humanized mouse model (Lütgehetmann et al., 2012; Negro et al., 1989). A study of 
HBV replication in the liver of HDV infected patients, indicated a significant decrease 
in the levels of HBV replicative intermediates, but not in the synthesis of envelope 
proteins, in comparison to HBV mono-infected patients (Pollicino et al., 2011). 
Interestingly, longitudinal follow-up of patients by qPCR, suggests that this pattern of 
interference is more complex, as viruses may alternate patterns of dominance over 
time (Schaper et al., 2010). As HBV viremia is an important predictor of disease 
progression in these patients, a close monitoring of both viral replication markers is 
warranted.  
The mechanisms of viral interference in HBV/HDV infection are still incompletely 
known. This phenotype was confirmed in vitro, indicating its independence from the 
acquired immune system, and HBV suppression could be reproduced upon the 
isolated expression of HDAg (Wu et al., 1991). Indeed, one study proposes that both 
forms of delta antigen might inhibit HBV replication by decreasing HBV enhancer 
effect (L-HDAg could decrease Enh1 activation by 60-80%). Furthermore, the induction 
of MxA expression, whose product is known to be a repressor of HBV replication, that 
has been shown both in vitro and in the humanized mouse,  could contribute to this 
phenotype  (Giersch et al., 2015; Williams et al., 2009).  
 
3.4. Prevention 
Transmission of HDV can be greatly reduced by measures targeting the main exposure 
risks. As for other blood-borne virus, public health measures focused on a strict 
screening of blood and its fractionated products for HBV, practices aiming at reducing 
transmission among IVDUs and hygiene measures in limited resources settings, play 
an important role in limiting HDV transmission. 
HBV vaccine is highly effective in preventing HDV transmission in naïve patients and 
should be proposed to all the close contacts of HDV infected patients. But no 
immunoprophylactic strategy exists for the prevention of HDV superinfection in HBV 
carriers; HBV vaccine does not elicit anti-HBs antibody production in these patients. 
Unfortunately, antibodies directed to HDAg have no strong neutralizing capacity in 
HDV infection, thus precluding any use of HDAg based vaccine. However, it has been 
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shown for other viruses that, even though not providing sterilizing protective 
immunity, immunization with internal viral proteins can produce a T-cell response and 
prevent virus spreading. In vitro results were promising as stimulation of CD8 T cells 
with HDV peptides led to an increase on IFNγ production and cytotoxic activity 
(Roggendorf, 2012). However, in woodchucks, vaccination (either by HDV proteins, 
DNA or recombinant viruses) was only effective in preventing HDV infection of naïve 
animals but not in WHV chronic carriers and, although the course of infection was 
modified, its utility is still to be proven (Fiedler et al., 2001, 2013). 
 
3.5. Treatment 
3.5.1. Current available therapeutic strategies 
There are currently no specific antiviral treatments for HDV. This is mainly due to the 
fact that the virus does not encode enzymatic activities, and fully relies, even more 
than other viruses, on host-cell machinery for its replication. A better understanding 
of the molecular and cellular biology HDV is yet required to identify viro-modified host 
cell functions that could be targeted. 
In the setting of acute hepatitis delta, no specific treatment has proven useful and 
patient management relies on monitoring and general support measures, or referral 
for liver transplantation in patients who progress to fulminant hepatitis (Niro et al., 
2005).  
Interferon alpha (IFN ) remains the only drug recommended by international 
guidelines for the treatment of CHD (European Association For The Study Of The Liver, 
2012; Lok and McMahon, 2009). Both conventional and pegylated interferon (Peg-
IFN ) have been shown to suppress HDV viremia in a subset of patients. Sustained 
virologic response (SVR) rates vary between 14 to 50% for conventional IFN  and 17 
to 44% for Peg-IFN  (Yurdaydin, 2012). However, comparison between studies is 
difficult as methods, treatment schedules, doses and duration used were highly 
variable and the number of patients included is very small. Several questions relative 
to interferon treatment remain unanswered. Firstly, the mechanism of action of IFN  
on the control of HDV infection is not completely understood. In vitro studies have 
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failed to demonstrate an potent effect of IFN  on HDV replication (McNair et al., 
1994), whereas in the hNTCP transgenic mouse model a suppression of IFN 
endogenous IFNα/β stimulation was associated with an increased viral replication, 
suggesting an antiviral effect of the molecule (He et al., 2015). Indeed, IFNα could play 
an indirect role in the regulation of HDV replication through ADAR-mediated editing 
(Hartwig et al., 2004). More recent evaluations have suggested that IFNα may also 
mediate its action via inhibition of viral entry. This was also inferred from 
mathematical modelling based on the kinetics of the IFN  effect (Goyal and Murray, 
2014; Han et al., 2011b). Secondly, unlike what has been described for HCV infection, 
no impact of IL-28b polymorphisms in treatment response has been demonstrated 
(Visco-Comandini et al., 2014; Yilmaz et al., 2014). Thirdly, the optimal duration of 
treatment has not been defined. It is currently advised to treat HDV infected patients 
for at least one year. Although cases have been reported of patients under interferon 
treatment for up to 12 years, the benefit of prolonged IFN therapy is still debated. The 
only study that compared 1 versus 2 years treatment duration found no advantage on 
treatment prolongation but was limited by the small size of the study population 
(Ormeci et al., 2011). Recently, two large clinical trials addressed the question of late 
relapses after interferon treatment of CHD patients. In the first study (HIDIT-1), 
patients were treated for 48 weeks with Peg-IFNα plus adefovir or either drug alone. 
At 24 weeks post-treatment, 28% of interferon treated patients had undetectable 
HDV viremia (Wedemeyer et al., 2011). However, long term follow-up of these 
patients showed that late HDV RNA relapses occurred in 56% of the patients, 
compromising the use of the 24 weeks SVR end-point in CHD patients (Heidrich et al., 
2014). A second study (HIDIT-2) aimed to evaluate a possible benefit of prolonging 
therapy in order to avoid relapses. Patients were treated for 96 weeks with Peg-IFN  
(associated or not with tenofovir). Although at the end of treatment 33 versus 47% of 
the patients receiving Peg-IFN  (without and with tenofovir respectively; non-
significant difference) had undetectable viremia, at 24 weeks post treatment, this 
proportion significantly decreased to 23-30%. The fact that this values are comparable 
to the ones obtained for HIDIT-1 (48 weeks treatment) and that adverse events 
occurred in more than 30% of patients, suggests that extending IFN therapy for more 
than 1 year does not have a clear benefit (Wedemeyer et al., 2014).  
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Another unresolved issue refers to the utility of anti-HBV direct-acting antivirals (DAA) 
in the management of chronic hepatitis delta patients. Although anti-HBV DAAs do 
not seem to affect HDV replication (Alfaiate et al., 2014), an impact on HDV infection 
can be expected from the continuous suppression of HBsAg production, leading to a 
blockage of HDV spreading. However, the persistence of HDV infection in the absence 
of its helper virus is still debated. Data from different experimental models suggest 
that HDV monoinfection is self-limiting, in the absence of spreading. Such a profile has 
been described both in vitro, in PHH, and in vivo, either following hydrodynamic 
injection of HDV cDNA into wild type mice or, more recently, following HDV infection 
of transgenic mice expressing hNTCP (Chang et al., 2001; Gudima et al., 2007; He et 
al., 2015). It is tempting to postulate that, in the absence of viral particle egress, 
accumulation of L-HDAg throughout time ultimately leads to replication inhibition 
(Modahl and Lai, 2000). Furthermore, it has been suggested that, in the absence of 
particle budding, continuous genome editing, associated with the accumulation of 
mutations, may also contribute to such abrogation of replication over time (Chang et 
al., 2005a). Such scenario, combined with the lack of evidence supporting latent HDV 
infection in transplanted patients (Smedile et al., 1998), supports an essential role for 
HBV in the maintenance of a chronic HDV infection and would support the utility of 
HBV DAAs in patients with CHD. However, data exist suggesting that HDV can indeed 
establish a latent infection in the absence of HBV. Following in vitro HDV infection of 
both primary human and chimpanzee hepatocytes, in particular culture conditions, 
HDV replication was kept at stable levels for more than one month (Barrera et al., 
2004; Sureau et al., 1991). More recently, in the humanized liver mouse model, HDV 
infection was shown to be kept latent for at least 6 weeks, in the absence of HBV 
(Giersch et al., 2014). In this scenario, the utility of HBV DAAs in the control of HDV 
infection would be more limited, as in the presence of continuous HDV replication, 
the virus would only be eliminated by the turnover of infected hepatocytes overtime. 
Patient data confirm a limited utility of HBV DAAs in the control of HDV infection, in 
association with modest HBsAg decrease rates. Lamivudine, adefovir and entecavir 
did not prove effective against HDV (Yurdaydin, 2012). However, studies from 
HIV/HBV/HDV co-infected patients suggested that long-treatment with tenofovir not 
only suppressed HBV but also led to a decrease of HDV replication parameters and 
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improvement of liver disease (Boyd et al., 2013; Soriano et al., 2014). The 
aforementioned HIDIT-1 and 2 trials failed to show a significant increase in Peg-IFN  
treatment effectiveness upon association with adefovir or tenofovir, respectively. A 
beneficial effect of the addition of adefovir on the levels of HBsAg levels was observed 
in HIDIT-1 but not confirmed with tenofovir in HIDIT-2. Furthermore, no significant 
decrease in the levels of transaminases was observed during DAA treatment, 
suggesting that, HDV replication needs to be specifically tackled in order to prevent 
liver damage (Wedemeyer et al., 2011, 2014). Other antiviral molecules like ribavirin 
and clevudine also failed to prove effective in human clinical studies, despite 
promising results in experimental models (Yurdaydin, 2012).  
Management of chronic hepatitis delta hence remains mostly empiric and should be 
decided for each individual patient. As for HBV, only HBsAg sero-conversion (and not 
undetectable HDV viremia, even if persistent) is synonymous of hepatitis delta cure, 
making close monitoring of HDV and HBV infection markers mandatory during and 
after treatment. 
 
3.5.2. Investigational drugs in preclinical/ clinical development 
Given the particular characteristics of HDV, replication remains difficult to target. 
Ongoing development of anti-HDV drugs is hence focusing on other steps of the viral 
cycle, namely entry and assembly. Novel strategies based on immune-stimulation with 
cytokines or PRR agonists may also play a role in the future management of HDV 
infection. 
 
Entry inhibition 
As for other viruses, several therapeutic strategies can be used to target HDV 
attachment and cell entry and hence prevent the infection of new cells. After 
identification of myristoylation of the PreS1 region as essential for viral entry, peptides 
mimicking the myristoylated N-terminal 47 aminoacids of L-HBsAg were synthetized 
and shown to potently and specifically, inhibit HBV entry in vitro (Gripon et al., 2005). 
Later on, a lead substance consisting of the consensus sequence of all known primate 
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HBV genotypes (later named Myrcludex-B®) showed a very potent inhibition of HBV 
infection (IC50 80pM) in vitro (Schulze et al., 2010). Studies in the humanized mouse 
model confirmed the inhibitory effect of Myrcludex-B® both in the establishment of 
de novo HBV and HDV infections and in the spreading of previously established 
infections (Lütgehetmann et al., 2012; Volz et al., 2013). Besides blocking viral entry, 
Myrcludex-B® also blocks bile acid transport (NTCP’s physiological function). Although 
the clinical repercussions of this side effect remain to be identified, they may not be 
significant as the EC50 of the drug for viral entry inhibition is almost 1000 times lower 
than the EC50 for inhibition of bile salt uptake (Nkongolo et al., 2014). After safety and 
tolerability testing first in chimpanzees and then in a phase I clinical trial, Myrcludex-
B® is currently undergoing a phase IIa trial. Preliminary results showed a decrease in 
both HBV and HDV viremia at week 24 of treatment (Bogomolov et al., 2014). 
Other molecules have been shown to inhibit HBV/HDV NTCP-mediated entry in vitro. 
Cyclosporin A has recently been identified by two different teams as an inhibitor of 
HBV/HDV  entry through binding to NTCP, in a cyclophilin-independent manner  
(Nkongolo et al., 2014; Watashi et al., 2014). As cyclosporine A is often a part of the 
immunosuppressor combination used in the post-liver transplantation setting, it is 
tempting to consider its potential role to prevent the graft re-infection. Other NTCP 
inhibitors already approved for other indications, as ezetimibe, irbesartan and 
ritonavir, have been shown to inhibit early stages of HDV infection, although the 
mediation through NTCP for this effect is still to be demonstrated (Blanchet et al., 
2014). 
Anti-viral strategies also explore the interaction between HBsAg and HSPGs.  Suramin 
would be a candidate but its use is limited by toxicity (Urban et al., 2014). A new class 
of agents has recently been shown to be effective, not only against HBV, but also HCV, 
HSV 1 and 2 and HIV (Krepstakies et al., 2012). 
 
Assembly inhibition 
As previously described, HDV assembly depends on the prenylation (more specifically 
farnesylation) of the last four amino acids of L-HDAg (CXXQ motif) (Glenn et al., 1992). 
Prenylation inhibitors have been used as anticancer drugs, as oncogenic forms of Ras 
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are dependent on farnesylation. These molecules were shown to inhibit HDV assembly 
and secretion both in vitro and in a mouse model capable of producing HDV viremia 
(Bordier et al., 2002, 2003). Results from a phase 2a clinical trial conducted in adult 
patients with CHD have recently been reported. The patients received the drug for 28 
days and were then followed for 6 months. During treatment, lonafarnib was 
associated with a dose-dependent, albeit modest (-1,54 log IU/ml for the higher dose), 
decrease in HDV viremia. However, treatment had no effect on transaminases and, 
once stopped, a rebound of HDV viremia was observed in all patients, underscoring 
the need for further optimization and development of anti-HDV therapeutic strategies 
(Koh et al., 2015)  
As for entry inhibition strategies, progress can arise from HBV research.  Promising 
results have been reported for the inhibition of DHBV infection by nucleic-acid-
polymers (NAPs). These oligonucleotides interact with structurally conserved 
amphipathic alpha-helical protein domains found in a variety of virus and other 
infectious agents and are known to concentrate in the liver. These molecules have 
been shown to inhibit DHBV infection in vitro and in vivo (Noordeen et al., 2013a, 
2013b). Preliminary works suggest an effect on HBV infection. The mechanism of 
action, although not fully elucidated, seems to be associated with both the inhibition 
HBsAg-mediated entry and release, and opens a perspective for their use in hepatitis 
delta (Noureddin and Gish, 2014). 
 
Immunomodulation  
New immune-modulatory agents, such as interferon lambda and PRR agonists (Zeisel 
et al., 2015), are proving effective against HBV infection. TLR7 agonist GS9620 is 
particularly promising as it has been shown to have a potent antiviral response against 
HBV (with HBsAg loss and reduced amounts of cccDNA), both in the chimpanzee and 
in the woodchuck model (with WHV) (Lanford et al., 2013; Menne et al., 2015). A 
phase II clinical trial is currently underway (clinicaltrials.gov NCT2430181). Although 
its action on HDV infection is for the moment unknown, it is tempting to speculate 
that these drugs may have a role in the future treatment of hepatitis delta.   
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3.6. Conclusion 
In spite of its severity, the overall high number of infected patients, and the viral 
characteristics that make HDV a unique model of study, HDV infection can 
unfortunately be considered as a neglected tropical and non-tropical disease. Many 
questions are still unanswered regarding clinical issues, as well as more basic 
knowledge regarding the virus life cycle and its interactions with the host. Novel 
interest on HDV seems to be arising, as new antiviral strategies are being developed 
against HBV infection. Hopefully the newly developed animal and cell culture models 
will boost research on the mechanisms of HDV infection and pathogenesis, and will 
contribute to the development of novel HDV-specific antiviral strategies. 
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4. Viral coinfections and virus-virus 
interactions 
4.1. Introduction 
In order to approach the possible mechanisms of interaction between HDV and HBV, 
a broader evaluation of the known mechanisms of virus-virus interactions (VVIs) is 
essential. Viral coinfections are found in every branch of life, from unicellular 
organisms (bacteria in particular) to animals, including humans, passing through 
plants. In human pathology, coinfections may modulate disease expression, regulate 
pathogenicity, and lead to greater cumulative immunosuppression in the host (Singh, 
2005). 
Many definitions of viral interaction have been proposed ranging from broad and 
vague to restrictive interpretations of the designation. DaPalma and colleagues 
proposed a systematic approach to VVI and define it as “the measurable difference in 
the course of infection of one virus as a result of a concurrent or prior infection by a 
different species or strain of virus. A concurrent infection may include infection of the 
same cell by two or more virus species, or two viruses may infect different cell types 
within one organism and produce measurable VVI. Measurable differences include 
changes in tissue permissiveness or tropism, viral replication, patterns of progeny 
production and release, latency, pathology including immunopathology, and 
immunological responses” (DaPalma et al., 2010). This stringent definition includes 
not only the influence of coinfection on virus life cycle, but also the modulation of the 
host response to infection. 
In order to study the mechanisms of viral interaction, a systematic classification must 
be used, so that similar viral strategies can be grouped together and compared among 
them. A simple classification splits VVIs, according to their outcome, into facilitative 
and antagonistic. Facilitative interactions involve a benefice for both or at least one 
of the viral partners involved. It comprises synergistic interactions that are reflected 
by increased replication and exacerbated disease progression and helper dependent 
interactions, where there is a facilitation of the dependent virus by its helper. In 
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antagonistic interactions only one of the viruses is beneficiary and its presence and 
activity lower the fitness of the other (Syller, 2012). 
A more comprehensive classification has been proposed considering the known 
mechanisms involved in the interaction. It splits VVIs into three main categories: direct 
interactions, environmental interactions and immune mediated interactions. Table V 
presents common examples of the main groups of interactions. 
 
Table V. Classification of viral interactions according to the mechanism involved. Examples 
include only viruses known to be associated with human disease. Adapted from (DaPalma et 
al., 2010) 
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To contextualize the research work discussed in this thesis manuscript, we will 
proceed with a brief and non-exhaustive discussion of relevant examples of virus-virus 
interference in human disease. Although a number of human viral coinfections has 
been described, as seen previously in Table V, we decided to explore the most 
frequent ones and/ or those associated with a clear modification of the natural history 
of the infection. As such, the discussion will be focused on hepatotropic viruses and 
HIV. 
 
4.2. Coinfections between hepatotropic viruses 
4.2.1. HBV/ HCV 
HBV and HCV infect a considerable number of patients worldwide (around 240 and 
150 million people, respectively), have common transmission modes and share the 
capacity to induce a chronic infection. It is hence not surprising that their combined 
infection is fairly frequent, particularly in highly endemic areas and among subjects 
with a high risk of parenteral infections (e.g. drug users). The estimated prevalence of 
HBV/HCV dual infection is approximately 5%-20% in HBsAg positive patients and 2%-
10% in HCV positive patients, although variable rates are reported depending on the 
geographic region. In these patients, acute infection is frequently asymptomatic. 
Three main patterns of acquisition can occur: i) HBV/HCV coinfection that, as 
previously described for HDV, often has a self-limiting, benign course with complete 
recovery from one or both infections; ii) acute HCV superinfection of an HBV chronic 
carrier or, finally, iii) acute HBV superinfection of a chronic hepatitis C (CHC) patient. 
In all the settings, patterns of viral dominance have been described, mostly related to 
the chronology of infection, with a repression of the chronic infection by the acutely 
acquired virus. In cases of HCV superinfection, suppression of HBV replication is 
commonly reported, although often transient.  In cases of HBV superinfection, HCV 
has been described to be definitively cleared. (Liaw et al., 2000, 2004; Sagnelli et al., 
2002, 2006). Longitudinal studies have shown that, in chronic coinfection, the patterns 
of viral dominance are not stable and may vary over time in the same patient. It should 
be noted that cases of occult hepatitis B are particularly common in the HBV/HCV 
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coinfection setting and, despite absent or low HBV replicative activity, these patients 
still have a more aggressive progression than mono-infected CHC patients (Squadrito 
et al., 2013). Moreover, in patients with an HCV replicative dominance, completion of 
IFNα treatment may be associated to ulterior HBV relapse (Konstantinou and Deutsch, 
2015).  
Clinically, chronic HBV/HCV coinfection is indistinguishable from either chronic mono-
infection. However the prognosis of these patients is more severe: coinfection is 
associated with a higher prevalence of liver cirrhosis and hepatic decompensation as 
compared with HBV or HCV mono-infection and was it demonstrated to be an 
independent predictor of HCC development (several studies report an increased risk 
of HCC in these patients, yet meta-analysis have not been conclusive) (Caccamo et al., 
2014; Cho et al., 2011).  
For long, the study of interactions between the two viruses has been limited by the 
absence of adequate experimental models (both in vivo and in vitro). In vitro studies 
were at first based on heterologous overexpression of viral proteins and have yielded 
conflicting results. Two independent studies based on Huh7 cells (that allow the full 
life cycle of HCV [JFH1 strain] and HBV replication [after transfection]), have excluded 
direct viral interference, as neither virus had its replication affected by the other 
(Bellecave et al., 2009; Eyre et al., 2009). The same results have been recently 
replicated in a new cell line supporting the complete life cycles of both HBV and HCV 
(Yang et al., 2014). However, an immunological interaction between the two viruses 
cannot be excluded in vivo and has recently been supported by evidence of HBV 
superinfection restriction in chimpanzees chronically infected by HCV (Wieland et al., 
2014). 
 
4.2.2. HBV/ HCV/ HDV 
Triple infections by HBV, HCV and HDV are common in populations at risk of parenteral 
transmission, as IVDUs, frequently in association with HIV infection. Although the 
epidemiology, natural history, viral kinetics, and treatment strategies for each single 
infection have been extensively studied, less is known about the specific features of 
multiple hepatitis virus coinfections. Moreover, clinical trials conducted in patients 
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with viral hepatitis commonly exclude triple infections. Consequently, most of the 
data available derive from retrospective studies conducted on a limited number of 
patients or from epidemiologic surveys. It is known that multiple infections aggravate 
liver injury, particularly fibrosis, and increase the risk of HCC, although the long-term 
clinical outcome in these patients is still largely undefined (Farci and Niro, 2012).  
Most reports on patterns of viral dominance are based on cross-sectional studies and 
results seem to depend on geographical location: whereas western studies 
documented a suppressive effect of HDV on both HBV and HCV, studies from Taiwan 
have demonstrated a suppressive role of HCV on HBV and HDV (Jardi et al., 2001; Liaw, 
1995; Lu et al., 2003; Mathurin et al., 2000). Similarly to the other multiple infections, 
longitudinal studies indicate that viremia levels of each virus fluctuate over time 
(Raimondo et al., 2006). The mechanisms underlying such interactions are widely 
unknown.  
 
4.2.3. Interactions between hepatitis viruses and other viral 
agents 
HBV 
Important data has emerged from the Chisari’s laboratory concerning the regulation 
of HBV replication and gene expression in the presence of other viruses, notably 
adenovirus, lymphocytic choriomeningitis virus (LCMV) and mouse cytomegalovirus 
(CMV). Taken together, these successive studies in the HBV-transgenic mouse model, 
evidenced a suppression of HBV replication upon infections with other viral agents. 
Notably, it was shown that: i) adenovirus infection was associated with a decrease in 
HBV DNA but not RNA levels; ii) LCMV and mouse CMV infections lead to a decrease 
in both DNA and RNA; iii) while LCMV post-transcriptionally decreases the levels of 
HBV RNA, MCMV is associated with transcriptional inhibition. Furthermore, it was 
demonstrated that interference was immune mediated, being dependent on TNF  
and/or IFN /  signalling pathways and therefore NF-kB and ISGF3 transcriptions 
factors. A role for IFNγ in post-transcriptional regulation of HBV replication was also 
suggested (Cavanaugh et al., 1998; Guidotti et al., 1996; Uprichard et al., 2003). An in 
Thesis Dulce Alfaiate 
110 
 
vitro study alternatively suggested a direct inhibitory effect of adenoviral EIA protein 
in the inhibition of HBV Enh I activity (Chen et al., 1992).  
In spite of the clear interest of such findings to understand HBV transcriptional 
regulation, the impact of such coinfections in humans is not clear. It was only possible 
to identify an isolated case-report on the consequences of coinfection by HBV and 
CMV. The clinical course was particularly serious with development of 
hemophagocytic syndrome (a hyperinflammatory condition), but the patient 
ultimately progressed to resolution of both infections (Halfon et al., 2009).  
The viral interaction can also be positive. HBx protein was recently reported to 
increase the expression of a transgene delivered to cells by Adeno-associated virus 
(AAV) vectors (Hösel et al., 2014). Indeed, HBx is a transactivating protein particularly 
efficient at up-regulating genes bore by extra-chromosomal  DNA (van Breugel et al., 
2012). This applies to AAV genome and opens interesting opportunities to better 
deliver anti-HBV effector genes into HBV infected cells.   
 
HCV 
In the setting of organ transplantation, significant interactions have been found 
between HCV and herpes viruses, leading to the exacerbation of liver pathology. A 
number of independent studies have shown that CMV infection significantly increased 
the risk of fibrosis and allograft cirrhosis in patients undergoing liver transplantation 
because of HCV. Additionally, this effect seems to be abolished in patients receiving 
anti-CMV pre-emptive therapy. The mechanism of such aggravation is unknown 
(Singh, 2005). 
Interactions between HCV and EBV have been postulated to be reciprocal: on the one 
hand, HCV, by its association with mixed cryoglobulinemia, seems to be associated 
with an increased risk of B cell non-Hodgkin’s lymphoma in EBV infected patients; in 
the other hand, EBV has been found in 37% of analysed CHC tissues from patients with 
HCV. Results from studies evaluating the interactions between the two viruses are 
contradictory, as interactions are not always found. A role for EBV EBNA protein in 
enhancing HCV replication in vitro has been proposed (Challine et al., 2002; Sugawara 
et al., 1999). 
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4.3. Coinfections in the setting of HIV infection 
4.3.1. HIV/ hepatitis coinfections 
Due to similar routes of transmission, coinfection of HIV with other sexual and blood-
borne viruses such as HBV, HCV and/or HDV is relatively common. The average 
estimated risk of transmission for HBV and HCV and HIV based on mode of 
transmission is depicted in Table VI. 
 
Table VI. Average estimated risk of transmission for parenteral agents. The risk of HBV 
vertical transmission varies depending of the mother’s HBeAg serostatus (higher for HBeAg 
positive mothers with HBV viremia > 106 IU/ml). HBV risk of transmission by sexual contact 
also depends on viremia levels. Adapted from (Lacombe and Rockstroh, 2012) 
 
 
 
Of the 35 million people living with HIV worldwide, around 20% ( 7 million) are 
estimated to have chronic hepatitis C (Figure 26). This population is mainly 
represented by individuals with past history of IVDU, haemophiliacs and recipients of 
contaminated blood. With respect to HBV, the situation is slightly different, with rates 
of HBV chronicity in HIV+ patients ranging from 5% in Western countries to 20% in 
some HBV endemic regions of Sub-Saharan Africa and South East Asia. Around 15-50% 
of HBV–HIV co-infected patients worldwide are superinfected by the delta virus 
(Lacombe and Rockstroh, 2012; Soriano et al., 2010).  
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Figure 26. Estimated number of individuals with HIV, HBV and HCV worldwide. Adapted 
from (Soriano et al., 2010). 
 
4.3.1.1. Impact of HIV infection on viral hepatitis progression 
Despite the immune suppression it induces, HIV infection is associated with 
accelerated liver fibrosis progression in patients with chronic viral hepatitis (Farci and 
Niro, 2012). The prevalence of cirrhosis differs among HIV co-infected patients 
depending on the aetiology of hepatitis: HCV, 19.2%; HBV, 6.1%; HBV⁄ HCV, 41.7%; 
and HBV⁄ HCV⁄ HDV, 66.7% (Castellares et al., 2008).  
In these patients, as in mono-infected patients, variable patterns of hepatitis virus 
dominance have been described (Boyd et al., 2010; Maida et al., 2008; Morsica et al., 
2009). 
 
HCV 
HIV infection is associated with an aggravated clinical course of HCV infection, as 
summarised in Table VII. 
Briefly, HCV/HIV coinfected patients have increased levels of HCV viremia, a higher 
probability of progression to chronicity following acute HCV infection (80% versus 
<70% in HIV negative patients), a faster progression of liver fibrosis (development of 
cirrhosis occurs 12–16 years earlier than in patients infected with HCV alone) and a 
worse response to interferon treatment (Joshi et al., 2011; Soriano et al., 2010; 
Thomas, 2002). Interestingly, effective HIV viremia reduction under combined 
antiretroviral therapy (cART) has been shown to be associated with a reversion of 
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progression rates (Bräu et al., 2006). However, an ulterior meta-analysis has shown 
that this reversion was only partial (Thein et al., 2008). 
 
Table VII. Characteristics of HCV infection in HIV infected patients.  
Adapted from (Thomas, 2002) 
 
 
 
The mechanisms underlying the faster progression of hepatitis C in HIV-infected 
patients seem to be multifactorial, both through direct involvement of HIV or via 
modulation of the immune response: 
 
i. in patients with HIV infection, weakened adaptive immune responses to HCV 
infection,  reduced CD8+ cell responses and reduced intrahepatic secretion of 
IFNγ, TNF  and IL-10,  can contribute to HCV persistence (Bruno et al., 2008; 
Joshi et al., 2011); 
ii. HIV can bind hepatic stellate cells and hepatocytes through its coreceptors, 
CXCR4 and CCR5. Although the virus does not enter hepatocytes, binding of 
gp120 to CXCR4 has been shown to increase tumour necrosis factor related 
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apoptosis inducing ligand (TRAIL) production, resulting in cellular apoptosis, 
and to upregulate production of transforming growth factor (TGF)-β1, which 
promotes further stellate cell activation and HCV replication (Babu et al., 2009; 
Lin et al., 2008); 
iii. Direct activation of hepatic stellate cells by HIV triggers a pro-inflammatory 
cascade, leading to myofibroblastic differentiation via enhanced production of 
a-smooth muscle actin, collagen and monocyte chemoattractant protein 1 
(MCP-1) (Tuyama et al., 2010); 
iv. decreased interleukin-10 expression by intrahepatic TCD4+ cells exacerbates 
the profibrotic milieu (Blackard et al., 2006; Joshi et al., 2011); 
v. markers of microbial translocation (lipopolysaccharide, lipopolysaccharide 
binding protein, CD14, and fucose-binding lectin) are raised in individuals 
coinfected with HIV and HCV, and strongly correlate with HIV-related 
depletion of CD4+ cells and progressive HCV-related liver disease (Joshi et al., 
2011); 
vi. Finally, it is important to recognize that there are several additional factors 
that could lead to more severe liver disease in HIV/HCV coinfected patients, 
including drug related hepatotoxicity, concurrent use of drugs and alcohol, and 
steatosis related to metabolic syndrome (Hernandez and Sherman, 2011). It 
will be important to further evaluate the efficacy of new anti-HCV DAAs in HIV 
infected patients and their potential interactions with antiretrovirals drugs. 
 
HBV 
As for HCV, HBV progression also seems to be affected by HIV coinfection. Briefly, HIV 
coinfection is associated with a 5-fold increased progression to chronicity after an 
acute HBV infection in comparison to non-HIV infected adults, a decreased rate of HBe 
and HBs seroconversion (which can be restored with cART initiation), an increased risk 
of liver disease progression and death as well as an increased risk of HCC (in 
association with higher levels of HBV viremia in coinfected patients) (Lacombe and 
Rockstroh, 2012; Soriano et al., 2010). See Table VIII for a summary.  
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Table VIII. Effects of HIV on the natural history of adult-acquired HBV infection. 
Adapted from (Thio, 2009). 
 
 
 
Mechanisms previously mentioned for fibrosis progression in CHC can also apply to 
HBV infection. Additional mechanisms underlying the altered progression of HBV 
infection (extensively reviewed by Iser and Lewin, 2009) could include: 
 
i. Reduced NK cytotoxicity is associated with failure to clear acute HBV infection 
in HIV patients; 
ii. Decreased expression and TLR dysfunction induced by HIV infection may limit 
HBV clearance; 
iii. HBV-specific TCL and TCD4+ responses are decreased in HIV infected patients, 
in comparison to HBV mono-infected patients and an increase is verified in 
patients starting cART; 
 
Finally, HBV infected patients, even with occult HBV infection, are susceptible to 
disease aggravation once HIV mediated immune suppression is reversed, namely by 
cART (the so-called “immune reconstitution syndrome”). This increase in 
inflammatory response, translated by an increase of liver necroinflammatory activity, 
may or may not be associated with a decrease of HBV replication. It is thought to be a 
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consequence of the restoration of anti-HBV adaptive immune response (Iser and 
Lewin, 2009). 
 
HDV 
The prevalence of anti-delta antibodies in HIV infected patients with HBsAg ranges 
from 15% to 50%, depending on geographical region and risk group category. In 
Western countries, HDV is more frequent in IVDU than among persons infected with 
HIV by sexual contact.  
In a sub-analysis of the EuroSIDA cohort, HDV was found to infect 14,5% of the HIV/ 
HBV infected patients (a proportion that is higher than the one observed in non-HIV 
infected patients in Europe), more significantly associated to transmission in IDVUs 
(42%). The majority of patients had detectable HDV viremia. Dominance of HDV over 
HBV was documented and HDV was mainly acquired as a result of superinfections 
rather than coinfections with HBV (Soriano et al., 2010).  Compared to HBV/HDV 
infected patients, HBV/ HDV/ HIV infected patients presented higher level of 
transaminases, frequent presence of circulating HDAg and higher incidence of hepatic 
decompensation (De Pouplana et al., 1995). 
The mechanisms by which HIV facilitates liver disease progression in CHD patients are 
unknown. 
 
4.3.1.2. Impact of viral hepatitis on HIV progression 
HCV 
Clinical studies comparing the evolution of HIV infection in patients with or without 
infection by hepatitis viruses have documented, in some cases, a more serious clinical 
course in coinfected patients. 
Before the introduction of cART, no differences in progression to AIDS, death, or 
decline in CD4+ cell counts were recorded between patients infected with HIV alone 
and those co-infected with HIV and HCV.  Furthermore, progression to AIDS and rate 
of reduction in CD4+ cell counts did not differ between HCV-positive patients acquiring 
HIV and those with HIV infection alone, suggesting that HCV coinfection did not affect 
HIV disease in the absence of cART. However, after the introduction of cART, evidence 
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suggests that HCV coinfection does affect HIV progression. In the Swiss HIV Cohort 
Study, HIV/ HCV coinfection was associated with faster progression to AIDS and slower 
TCD4+ recovery than in patients with HIV infection alone. Posterior studies have 
shown contradictory results, as an impaired response is not always documented in 
HCV infected patients. However, in a review of 8 studies, it was demonstrated that 
HIV/ HCV coinfected patients are more likely to have a worse immunological response 
to antiretroviral therapy than HIV monoinfected patients. Moreover, in a group of HIV 
natural viral suppressors (HIV-1 patients with the ability to suppress HIV viral loads to 
less than 400 copies) chronic HCV infection had statistically significant reduction of 
TCD4+ cell count and TCD4+ percentage, suggesting once more a possible detrimental 
effect of HCV on HIV infection (Hernandez and Sherman, 2011). 
The mechanisms by which chronic HCV replication could have a deleterious effect on 
TCD4+ cell count reconstitution remain unexplored, but may include ongoing T cell 
activation related to HCV infection and direct infection of TCD4+ cells by HCV that has 
been shown to be lymphotropic in the setting of HIV coinfection (Thomas, 2002).  
 
HBV 
Recent data suggest that HBV coinfection might be associated with an increase in 
overall mortality in HIV infected patients. These patients have a 10 times higher risk 
of dying from liver related causes compared with HIV or HBV mono-infected patients 
(Lacombe and Rockstroh, 2012). 
In an African cohort, HBV has been associated with an unfavourable course of HIV 
infection, reflected not only by increased levels of viremia and lower TCD4+ 
lymphocyte counts previous to cART institution, but also by a weaker immunological 
recovery during therapy (Ladep et al., 2013). However, these results have not always 
been reproduced by other long-term outcome studies where HBV did not affect HIV 
response to cART (Joshi et al., 2011). No exact mechanism has been proposed to this 
facilitative effect of HBV on HIV infection. Several possibilities can be evoked for both 
direct and immune-mediated interactions, namely HBx capacity to increase the 
transcription of HIV long terminal repeats (LTR) in vitro and an effect of HBV on the 
function and maturation of dendritic cells (DCs) (Iser and Lewin, 2009). 
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GBV-C  
GB virus type C (GBV-C) was identified in 1995 in the serum of a non-A non-B hepatitis 
patient and variants of the same virus were subsequently discovered in the serum of 
other patients. It was initially considered as a possible cause of hepatitis, however no 
causal association was ever established between GBV-C and viral hepatitis or any 
other human pathology. 
GBV-C is an enveloped positive-sense, single stranded RNA virus of about 9400nt.  It 
belongs to the Flaviviridae family (unassigned genus). It bears sequence similarities 
with HCV. GBV-C tropism is a matter of discussion, with in vivo and in vitro reports of 
both lymphotropism and hepatotropism. 
Shortly after its discovery, screening of HIV patients has shown high prevalence of 
coinfection (GBV-C viremia detected in 17-27% of the patients) in this population. 
Interestingly, a possible modulation of HIV infection in these patients was suggested. 
Most of the subsequent studies confirmed an association of GBV-C coinfection with 
lower HIV viremia, higher TCD4+ cell counts, slower progression to AIDS, improved 
response to cART and reduced mortality. An inverse relationship between GBV-C and 
HIV viral loads was suggested and the possibility of inhibition of HIV replication has 
since been explored (Giret and Kallas, 2012) . 
The exact mechanisms of interference remain obscure, despite the identification of 
several possible pathways, most of them related to immune regulation (Shankar et al., 
2011): 
 
i. GBV-C down-regulates chemokine receptors (CCR5 and CXCR4, which function 
as HIV-1 co-receptors) to interfere with HIV-1 binding to T-cell surface; 
ii. GBV-C effectively prevents the onset of immune activation by preserving the 
Th1 cytokine responses to effectively control viral levels; 
iii. GBV-C infection in HIV-infected patients leads to the activation of ISGs; 
iv. GBV-C replication is associated with lower T-cell activation; 
v. GBV-C could interfere with apoptosis in the T cells of HIV-coinfected patients, 
by modulating Fas expression; 
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Moreover, direct mechanisms of inhibition have also been suggested, namely (Giret 
and Kallas, 2012; Schwarze-Zander et al., 2012): 
 
i. Direct inhibition of HIV entry by binding of GBV-C E2 protein to HIV particles, 
blocks their interaction with the receptor; 
ii. A direct inhibition of HIV replication by GBV-C proteins has also been 
suggested, although details of such interaction remain unexplored. 
 
4.3.2. Others 
HIV infection is associated with increased susceptibility and accelerated progression 
of a number of viral infections, as a consequence of the generalized immune-
depression it induces. As this is not a specifically related to the pathogen, we will focus 
on examples of viruses that have, conversely, been shown to interfere with the course 
of HIV infection. 
 
Herpesviruses 
A number of studies, particularly in the transplantation setting, have shown that HIV 
infection progression could be modulated by herpes virus coinfection. Most of these 
mechanisms are related to transactivation of HDV LTR by herpes viral proteins. 
Clinically, most studies have focused on the interactions between HSV-2 and HIV, 
mainly due to the shared transmission by sexual contact. HSV-2 is thought to infect 
half of HIV infected adults. Support for viral interference arises from two clinical 
observations (Barnabas et al., 2011; Tan et al., 2013): 
 
i. HSV-2 infection is associated with increased HIV plasma viral load. In a meta-
analysis performed in 2011 an overall increase of 0,18 log10 copies/ ml was 
found in HIV viremia in patients with a positive HSV-2 serology. Moreover, an 
increase of 0,4 log10 copies/ ml was evidenced in patients having detectable 
genital HSV-2 DNA. Nonetheless, results on the impact of HSV-2 infection on 
CD4+ cell counts are contradictory and mainly support the absence of an 
effect; 
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ii. Patients under acyclovir suppressive therapy demonstrate a modest 
attenuation of HIV disease progression (-0,28 log10 copies/ ml). This effect is 
not reproduced in patients treated episodically. It must be considered that the 
observed trend may be a result of acyclovir antiviral effect on HIV replication 
and not of HSV-2 control. 
 
It has been shown that herpes viruses can directly influence HIV translation by 
transactivating its LTR sequence, hence supporting the existence of direct interference 
(Singh, 2005). 
An additional form of modulation of HIV infection by HSV-2, concerns the potentiation 
of its transmission. HSV-2 infected patients have a higher susceptibility to HIV 
infection and, when infected, display a higher possibility of transmission to other 
persons. This is associated with the ability of HSV-2 to cause genital mucosal breaks 
and to recruit TCD4+ cells to the lesions (Celum, 2004; Sheffield et al., 2007). 
 
HHV-6 has been proposed to be a cofactor in HIV progression, as it can, not only 
transactivate HIV LTR, but also upregulate CD4 expression (Singh, 2005).  
 
An association between HHV-8 (Kaposi associated Herpes virus, KSHV, itself a 
opportunistic pathogen of HIV-infected patients) and enhanced HIV replication was 
also evidenced both in vivo and in vitro (Mercader et al., 2001). A direct interference 
mechanism has been suggested (Sun et al., 2005). 
 
Interestingly, HHV-7 coinfection has been suggested to inhibit HIV infection 
progression, through competition for CD4 binding, thus interfering with HIV entry 
(Lusso et al., 1994). 
 
Human T-cell lymphotropic virus (HTLV) 
HTLV 1 and 2 are retroviruses that share the same transmission routes as HIV and are 
simultaneously prevalent in several parts of the world, so coinfection is not rare (rates 
vary depending on geographical distribution).  
HTLV-1, which is prevalent in the southern hemisphere, has a tropism for TCD4+ cells.  
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Coinfection with HTLV-1 seems to be detrimental to HIV-1 patients, with accelerated 
disease progression and association with neurologic and haematologic complications. 
HTLV-1 Tax protein has been demonstrated to be involved in the outcome of 
coinfection (Brites et al., 2009; Casoli et al., 2007). 
HTLV-2 predominates in Europe and in the USA and is tropic for TCD8+ cells. 
Interestingly, in HIV-1 infected patients, HTLV-2 coinfection may confer an 
immunologic and survival benefit and is frequently found in long-term non-
progressers. Underlying mechanisms seem to involve regulation of chemokine 
production and TCD8+ cell expansion (Casoli et al., 2007).  
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5. Innate immune sensing of pathogens and 
the antiviral interferon response  
5.1. Introduction 
The role of the immune system is to distinguish between self and non-self, the latter 
designating not only pathogens but also cancer cells, and to eliminate it. Classically, 
three levels of protection against pathogens have been described: i. physical barriers 
to infection (the skin being the most important); ii. innate immune response; iii. 
acquired or adaptive immune response. Viral infection poses a particular problem to 
the host immune responses, as, on the one hand, virus are fast-replicating intracellular 
organisms and therefore more difficult to detect and eliminate, and, in the other, they 
have evolved mechanisms of immune escape and modulation (a characteristic that is 
particularly common in viruses, like hepatitis, that can cause chronic infections).  
Clinical consequences of a viral infection are dictated by the interplay between the 
virus and the immune system. For many infections, the line between immunity and 
immunopathology can be thin, as most of the clinical consequences may result from 
the immune response and not the virus infection itself (Rouse and Sehrawat, 2010). 
Understanding the immune response against viral infection can allow not only the 
identification of new therapeutic strategies but also a clarification of important 
aspects of viral pathogenesis. A deductive approach, may allow the exploitation of 
general mechanisms into particular cases of infection. 
We will focus hereinafter on the innate immune responses to viral infection. 
 
5.2. Pathogen recognition 
Innate immunity is the first barrier of defence against a pathogen and is hence both 
rapid and non-specific. The basic machineries underlying innate immune recognition 
are highly conserved among species (from plants and fruit flies to mammals). It relies 
on the recognition of particular conserved motifs that arise during pathogen life cycle, 
known as pathogen associated molecular patterns (PAMPs) that can be nucleic acids, 
Thesis Dulce Alfaiate 
124 
 
proteins, lipids or carbohydrates. Common examples are double-stranded RNA 
(dsRNA), for some viruses, or lipopolysaccharide (LPS) of gram negative bacteria. 
These molecules are difficult for the microorganism to alter, as they are essential for 
its survival. They are sensed by the host’s pattern recognition receptors (PRRs). It has 
been suggested that, in order to distinguish pathogenic from non-pathogenic (e.g. 
commensal) microorganisms (that will also display PAMPs), a second stimulus is 
needed to activate the innate immune response. This stimulus would be conveyed by 
host molecules resulting from tissue damage, hence called damage associated 
molecular patterns (DAMPs) and may play an essential role in immune-tolerance 
(Seong and Matzinger, 2004). 
PRRs possess two major common characteristics: firstly, they are expressed 
constitutively in the host and detect the pathogens regardless of their life-cycle stage; 
and secondly, they are germline encoded, non-clonal, expressed on all cells of a given 
type, and independent of antigen presentation and immunologic memory. Different 
PRRs react to specific PAMP stimulation, show distinct expression patterns, activate 
specific signalling pathways, and lead to distinct anti-pathogen responses. PRRs are 
commonly expressed on i) bone marrow-derived immune cells such as myeloid 
dendritic cells (DCs), macrophages, and neutrophils, or ii) lymphoid B cells and specific 
types of T cells, but also iii) on liver-resident cells, such as hepatocytes, liver sinusoidal 
endothelial cells (LSECs) and hepatic stellate cells (Akira et al., 2006; Kumar et al., 
2011; Protzer et al., 2012). 
Several classes of PRRs have been described, namely Toll-like receptors (TLRs), RIG-I-
like receptors (RLRs), C-type lectin receptors (CTR), NOD-like receptors (NLRs) and 
DNA receptors (cytosolic sensors for DNA) (Kumar et al., 2011).  
Effective sensing of PAMPs by PRRs results in the rapid (within minutes or hours) 
activation of cascade signalling pathways that culminate in the induction of immune 
responses mediated by various interferons and cytokines/chemokines. IFNs have 
direct and indirect actions: they can induce the expression of ISGs that encode 
proteins bearing antiviral properties within infected cells, as well as contribute to the 
activation/differentiation of other immune cells, both innate and adaptive ones. Other 
cytokines/chemokines will help recruiting immune cells to the site of infection and 
contribute to their activation, proliferation and differentiation. Furthermore, 
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activation of the innate immune system leads to the initiation of more time-
consuming adaptive immunity, which is antigen-specific, long-lasting and has 
immunological memory (Lester and Li, 2014). 
 
5.2.1. Toll-like receptors 
Human TLR identification and characterization was preceded by the discovery of Toll 
receptor, involved in Drosophila melanogaster’s defence against fungal infection 
(Lemaitre et al., 1996). Ten human homologs of Toll (hence called TLRs 1-10) have so 
far been identified and characterized (although the characterization of TLR-10 is still 
very incomplete).  
TLRs are type I transmembrane glycoproteins composed of: i) an N-terminal 
ectodomain containing varying numbers of leucine-rich repeat (LRR) motifs, 
responsible for PAMP recognition; ii) a transmembrane domain; iii) a C-terminal 
cytoplasmic domain, homologous to that of the interleukin-1 receptor (IL-1R), termed 
the Toll/IL-1R homology (TIR) domain, that activates downstream signal transduction 
(Lester and Li, 2014). Their expression is variable according to the cell type. 
Hepatocytes have been shown to express functional TLR1, 2, 3, 4, 5, and 6, whereas 
TLR7, 8, and 9 were not found active in these cells (Luangsay et al., 2015b). 
Several classifications can be proposed for TLRs, based on structural characteristics, 
sub-cellular localization, molecules sensed, etc. TLRs 1, 2, 4, 5 and 6 are primarily 
found on the cell surface and recognize PAMPs (namely lipids) derived from bacteria, 
fungi and protozoa, whereas TLRs 3, 7, 8 and 9 are exclusively found within endocytic 
compartments and primarily recognize nucleic acid PAMPs derived from viruses as 
well as bacteria, as summarized below in Table IX.  
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Table IX. TLR cellular location and known ligands. Adapted from (Kumar et al., 2011) 
 
 
 
TLR downstream signal transduction is mediated by the recruitment of four major 
adaptor/coadaptor molecules: myeloid differentiation factor 88 (MyD88), TIR-
associated protein (TIRAP)/ MyD88-adaptor-like (MAL), TIR-domain-containing 
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adaptor inducing interferon (IFN)-β (TRIF, also known as TICAM1) and TRIF-related 
adaptor molecule (TRAM). The differential responses triggered by distinct TLR ligands 
can be explained in part by the selective usage of these adaptor molecules and their 
activation of distinct signalling pathways. MyD88 and TRIF are commonly associated 
with the production of pro-inflammatory cytokines and type I interferons, 
respectively. The production of proinflammatory cytokines is mediated by IRF-5, AP-1 
and NF-kB transcription factors. IFN  and ISGs expression is stimulated by TLRs either 
via a TRIF-dependent pathway (as is the case for TLR3 and 4), leading to the 
recruitment of IRF3 and IRF7 on ISREs, or, upon stimulation of TLR7 and 9, via a 
MyD88-dependent pathway leading to IRF7 recruitment (Akira et al., 2006; Kumar et 
al., 2011). Figure 27 summarises the main aspects of TLR signalling in mammalian cells 
(comprising both human and murine TLRs). 
 
5.2.2. RIG-I-like-receptors  
The RIG-I-like-receptor family groups several cytoplasmic RNA sensors, namely RIG-I, 
MDA5, DDX3 and LGP2. Small double-stranded RNAs are preferentially recognized by 
RIG-I, while MDA5 is particularly involved in the recognition of longer RNAs, which 
explains their selectivity for the recognition of particular viruses (Kato et al., 2008). 
Their activation is associated with the induction of type I and type III IFNs, but also 
proinflammatory responses. This is mediated by RLRs’ interaction with IPS-1 adaptor 
(also called MAVS, CARDIF or VISA), located in mitochondria (where it will induce the 
recruitment of IRF3) and peroxisomes (where it leads to recruitment of IRF1) (Kumar 
et al., 2011; Reikine et al., 2014). 
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Figure 27. TLR signalling in mammalian cells. TLR5, TLR11, TLR4, and the heterodimers of 
TLR2–TLR1 or TLR2–TLR6 bind to their respective ligands at the cell surface, whereas TLR3, 
TLR7–TLR8, TLR9 and TLR13 localize to the endosomes, where they sense microbial and host-
derived nucleic acids. TLR4 localizes at both the plasma membrane and the endosomes. TLR 
signalling is initiated by ligand-induced dimerization of receptors. Following this, the Toll–IL-1-
resistence (TIR) domains of TLRs engage TIR domain-containing adaptor proteins (either 
myeloid differentiation primary-response protein 88 (MYD88) and MYD88-adaptor-like 
protein (MAL), or TIR domain-containing adaptor protein inducing IFNβ (TRIF) and TRIF-
related adaptor molecule (TRAM)). TLR4 moves from the plasma membrane to the endosomes 
in order to switch signalling from MYD88 to TRIF. Engagement of the signalling adaptor 
molecules stimulates downstream signalling pathways that involve interactions between IL-
1R-associated kinases (IRAKs) and the adaptor molecules TNF receptor-associated factors 
(TRAFs), and that lead to the activation of the mitogen-activated protein kinases (MAPKs) JUN 
N-terminal kinase (JNK) and p38, and to the activation of transcription factors. Two important 
families of transcription factors that are activated downstream of TLR signalling are nuclear 
factor-κB (NF-κB) and the interferon-regulatory factors (IRFs), but other transcription factors, 
such as cyclic AMP-responsive element-binding protein (CREB) and activator protein 1 (AP1), 
are also important. A major consequence of TLR signalling is the induction of pro-inflammatory 
cytokines, and in the case of the endosomal TLRs, the induction of type I interferon (IFN). 
dsRNA, double-stranded RNA; IKK, inhibitor of NF-κB kinase; LPS, lipopolysaccharide; MKK, 
MAP kinase kinase; RIP1, receptor-interacting protein 1; rRNA, ribosomal RNA; ssRNA, single-
stranded RNA; TAB, TAK1-binding protein; TAK, TGFβ-activated kinase; TBK1, TANK-binding 
kinase 1. Reproduced from (O’Neill et al., 2013). 
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5.2.3. Cytoplasmic DNA sensors 
DNA, usually confined to the nucleus and mitochondria of eukaryotic cells, can be a 
potent immune stimulant when recognized as non-self. The presence of cytosolic 
DNA, either through infections (viral or bacterial) or cellular damage, triggers robust 
immune responses, including inflammasome activation and type I IFN induction (Cai 
et al., 2014).  
Several cytoplasmic DNA sensors have been described thus far. The first one to be 
identified was DNA-dependent activator of IFN-regulatory factors (DAI), which has a 
cytoplasmic location and leads to the induction of and IFN type I response (Kumar et 
al., 2011). DAI, however, was shown not to be essential to the IFN production in 
response to DNA, suggesting the existence of other sensors, whose number and 
description have exploded recently (i.e. DDX41, IFI16, DHX9, DHX36, LRRFIP1...). Very 
recently, a new significant pathway has been identified, based on the interaction 
between cytosolic GAMP synthase (cGAS) and stimulator of IFN genes (STING, located 
on the ER membrane). Cytosolic DNA activates cGAS to form a dimeric cGAS-DNA 
complex which synthesizes 2’3’- cyclic di-GMP-AMP (cGAMP) from ATP and GTP. 2’3’-
cGAMP binds and activates STING. Activation of STING ultimately leads to nuclear 
translocation of IRF3 and NF-kB and the subsequent production of type I IFNs and 
other cytokines (Cai et al., 2014).  
 
5.2.4. C-type lectin receptors  
C-type lectin receptors (CLRs) comprise a transmembrane receptor family involved in 
the recognition of carbohydrate structures on microorganisms such as viruses, 
bacteria, and fungi. CLRs are expressed mainly in DCs, macrophages and monocytes. 
Their stimulation leads not only to the production of proinflammatory cytokines 
through the activation of MAP-kinases and NF-kB and regulation of TLR signaling, but 
also to internalization of the pathogen, its degradation and subsequent antigen 
presentation (Geijtenbeek and Gringhuis, 2009; Takeuchi and Akira, 2010). 
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5.2.5. Nod-like receptors and Inflammasomes 
NOD-like receptors (NLRs) are a family of molecules that sense mainly bacterial 
components (peptidoglycans) within the cytoplasm of cells. Upon recognition of 
PAMPs, these sensors either induce production of inflammatory cytokines (through 
NF-κB or MAP-kinases activation) or activate the inflammasome, leading to the 
maturation and production of inflammatory cytokines, such as IL-1β and IL-18 or cell 
death (Kumar et al., 2011; Takeuchi and Akira, 2010). Moreover, recent studies have 
revealed a role for NLRs in type I IFN production as well (Kanneganti, 2010) 
 
Inflammasomes are cytoplasmic protein complexes in which the scaffolding and 
sensing proteins comprise both members of the NLR family (e.g., NALPs) and non-NLR 
proteins, absent in melanoma 2 (AIM2) and apoptosis-associated speck-like protein 
containing a caspase recruitment domain (ASC). Three inflammasomes have been 
described to be involved in the response to viral infection: the NLRP3 inflammasome, 
the RIG I inflammasome and the AIM2 inflammasome. Their activation ultimately 
leads to the proteolytic activation of the proinflammatory cytokines IL-1β and IL-18, 
mediated by caspases (Martinon et al., 2009).  
Caspases are proteases produced in cells as catalytically inactive zymogens and usually 
undergo proteolytic processing during activation. Inflammasomes activate a class of 
caspases known as inflammatory caspases that include caspase 1, 4, 5, 11 and 12 that 
have as main substrate inflammatory cytokines, such as IL-1β, IL-18, and possibly IL-
33 (Martinon et al., 2009). The bipartite, 22-kDa adaptor ASC provides a link between 
NLRP3, RIG I or AIM2 and the pro-form of caspase 1. Activated caspase 1 cleaves pro-
IL 1β and pro-IL 18 into biologically active IL 1β and IL 18. After secretion from the 
cell (through a Golgi-independent mechanism), IL 1β and IL 18 induce various 
biological effects that are associated with infection, inflammation and autoimmune 
processes (Kanneganti, 2010). 
Inflammasomes are involved not only in inflammatory and immune responses to 
pathogens, but also in the so-called danger response (recognition of tissue damage). 
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5.3. Interferon response 
The antiviral potential of interferon molecules has been known for more than 50 years 
(Isaacs and Lindenmann, 1957). Interferon molecules are produced in response to the 
detection of PAMPs by PRRs and constitute a first line of defence against viral infection 
by inducing an antiviral state within infected cells, as well as in non-infected cells by 
auto/paracrine mechanisms. The essential role played by interferon in the antiviral 
response has been well demonstrated by the increased susceptibility of knock-out 
mice models to viral infection and can further be reinforced by the observation that 
patients with specific inborn defects in the IFN signalling pathways have an increased 
risk of viral infection in (Schoggins, 2014). 
 
There are three distinct interferon families: 
 The type I IFN family is a multi-gene cytokine family, whose main 
representatives are IFNα (13 partially homologous subtypes known in 
humans) and IFNβ. Several other gene products have been described but are 
still poorly defined (IFNε, IFNτ, IFNκ, IFNω, IFNδ and IFNζ). IFN  and IFN  can 
be produced by almost every nucleated cell in the human body, mainly in 
response to PRR activation. A broad range of PRRs (cell surface, endosomal 
and cytoplasmic) lead to IFNs’ production, through distinct downstream 
signalling pathways that converge in key molecules such as the IFN-regulatory 
factor (IRF) family. In most cases, IRF3 and IRF7 are the fundamental IRFs 
required, although others, like IRF1, IRF5 and IRF8, can also induce Ifn-  
gene transcription. IFN  and all of the IFN  subtypes bind to and signal 
through a heterodimeric transmembrane receptor (IFNAR), composed of 
subunits IFNAR1 and IFNAR2 that, upon dimerization, can trigger distinct 
downstream signalling pathways, ultimately leading to the selective activation 
of IFN-stimulated genes (ISGs). In the canonical pathway of IFNα/β-mediated 
signalling, activated JAK1 and TYK2 phosphorylate signal transducer and 
activator of transcription 1 (STAT1) and STAT2 in the cytosol, leading to their 
dimerization, nuclear translocation and binding to IRF9 to form the ISG factor 
3 (ISGF3) complex. This complex then binds to IFN-stimulated response 
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elements (ISRE) in ISG promoters and activates ISG transcription, a large 
number of which function to induce an antiviral state within the cell (McNab 
et al., 2015);  
 
 
Figure 28. Pathways of type I interferon induction and receptor signalling. Recognition of 
microbial products by a range of cell-surface and intracellular pattern recognition receptors, 
including Toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG I), can lead to 
induction of the genes encoding type I interferons (IFNs), which is mediated by several distinct 
signalling pathways. On the binding of type I IFNs to their receptor (IFNAR), multiple 
downstream signalling pathways can be induced, leading to a diverse range of biological 
effects. The canonical signal transducer and activator of transcription 1 (STAT1)–STAT2–IFN-
regulatory factor 9 (IRF9) signalling complex (also known as the IFN-stimulated gene factor 3 
(ISGF3) complex) binds to IFN-stimulated response elements (ISREs) in gene promoters, 
leading to induction of a large number of IFN-stimulated genes (ISGs). Type I IFNs can also 
signal through STAT1 homodimers, which are more commonly associated with the IFNγ-
mediated signalling pathway. Other STAT heterodimers and homodimers may also be activated 
downstream, including STAT3, STAT4 and STAT5. Other signalling pathways that do not rely on 
Janus kinase (JAK) and/or STAT activity may also be activated, including mitogen-activated 
protein kinases (MAPKs) and the phosphoinositide 3 kinase (PI3K) pathway, thereby leading 
to diverse effects on the cell. Alt-IRF, IRFs other than IRF3 or IRF7; AP-1, activator protein 1; 
cGAMP, cyclic di-GMP-AMP; cGAS, cytosolic GAMP synthase; DAI, DNA-dependent activator 
of IRFs; ER, endoplasmic reticulum; GAS, γ activated sequence; IKKε, IκB kinase ε; MAVS, 
mitochondrial antiviral signalling protein; MDA5, melanoma differentiation-associated gene 5; 
MYD88, myeloid differentiation primary response protein 88; NF-κB, nuclear factor κB; NOD2, 
NOD-containing protein 2; STING, stimulator of IFN genes; TBK1, TANK-binding kinase 1; TRAF, 
TNF receptor-associated factor; TRAM, TLR adaptor molecule (also known as TICAM2); TRIF, 
TIR domain-containing adaptor protein inducing IFNβ; TYK2, tyrosine kinase 2. Reproduced 
from (McNab et al., 2015) 
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 The type II IFN family consists of a single gene product, IFNγ. Type II IFN is 
predominantly produced by T cells and natural killer (NK) cells, and can act on 
a broad range of cell types that express the IFNγ receptor (IFNγR). It has a 
weak antiviral effect. It is involved in the regulation of innate immune cells 
activity. Unlike type I and III IFNs that lead to the fixation of regulatory factors 
on ISRE sequences, IFNγ leads to regulation of genes possessing GAS elements 
(IFNγ activation site); 
 
 The type III IFN family comprises IFNλ1, IFNλ2 and IFNλ3 (also known as IL 29, 
IL 28A and IL 28B, respectively) and the recently identified IFNλ4. Type III IFNs 
signal through a heterodimeric cell surface receptor composed of two chains: 
IFN- R1, which is specific to IFN-λ, and IL-10RB, which is shared by other IL-
10-related cytokines. IFN- R dimerization, as IFNAR, triggers the JAK-STAT 
transduction pathway and induces the upregulation of ISGs. Type III 
interferons IFNs hence share intracellular signaling functions with cytokines 
of the type I IFN family. Differences in IFNλ activity spectrum may be explained 
by its expression dynamics, as it is only secreted by a subset of immune cells 
such as NK cells and pathogen-specific T cells as well as some epithelial cells 
(including hepatocytes). In addition, the IFN- R is less widely expressed as 
compared to IFNAR, thus conferring a perspectives of better toxicologic 
profile of the therapeutic utilization of IFN . Furthermore, IFN  also 
demonstrates activity at the interface of innate and adaptive immunity (Egli 
et al., 2014; Hermant and Michiels, 2014; Hoffmann et al., 2015). 
 
Details on specific signalling pathways used by the distinct IFN families are conveyed 
by Figure 29.  
As previously described, newly synthesized type I and type III IFNs are secreted from 
the infected cells and upon autocrine or paracrine binding to their respective 
receptors (IFNAR and IFN- R), lead to the development of an antiviral response, via 
activation of the JAK/ STAT pathway. The result is the transcriptional induction of ISGs, 
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which encode direct antiviral effectors or molecules with the potential to positively 
and negatively regulate IFN signalling and other host responses (Schoggins, 2014). 
 
Figure 29. Signalling pathways used by the distinct IFN families. Once type I or III IFNs bind 
their receptors at the cell surface, individual receptor chains are brought into close proximity. 
As a result, intracellular receptor-associated tyrosine kinases of the Janus kinase (JAK) family 
of proteins become activated. Activated JAK proteins subsequently phosphorylate (P) 
members of the STAT family of proteins, ultimately leading to the transcriptional activation of 
ISGs. Inasmuch as is currently known, after receptor engagement, type I and III IFNs signal 
through the same pathway: activation of the two JAK proteins, JAK1 and TYK2, results in the 
phosphorylation of conserved tyrosine residues on STAT1 and STAT2, followed by formation of 
a heterotrimeric complex with IFN-regulatory factor 9 (IRF9). This complex translocates to the 
nucleus and binds to a DNA sequence known as the IFN-stimulated response element (ISRE) 
in the promoters of ISGs. As a result, hundreds of ISGs are transcriptionally regulated. GAF, g-
interferon activation factor; GAS, g-interferon activation site. Reproduced from (Hoffmann et 
al., 2015). 
 
Depending on cell type, IFN dose, and time of treatment, microarray studies have 
identified 50–1000 ISGs, with 200–500 genes typical of many cell types (Schoggins and 
Rice, 2011). However, of the hundreds of known ISGs, relatively few have been 
characterized in vivo for their role in antiviral immune responses. A major contribution 
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was made in 2011, through a comprehensive overexpression screen in which more 
than 380 genes were tested for antiviral activity against six viruses: HCV, HIV-1, yellow 
fever virus (YFV), West Nile Virus (WNV), Venezuelan equine encephalitis virus (VEEV), 
and chikungunya virus (CHIKV). At least 25 genes were shown to have antiviral activity 
against one or several viruses (Schoggins et al., 2011). The antiviral activity of these 
genes is variable and, as more effectors are uncovered, it is becoming clear that a 
gradient of antiviral activity exists, with many gene products acting as only modest 
inhibitors. Although it would be tempting to think that the most highly induced ISGs 
(during infection or IFN treatment) are those that most effectively control viral 
replication, magnitude of ISG induction does not always correlate with the strength of 
antiviral effector function (Schoggins, 2014). 
As for their mechanism of action, most ISGs may have not only a direct effect on virus 
replication, but may also be involved in feedback into antiviral pathways, as molecules 
involved in pathogen recognition and IFN signalling, can themselves be regulated by 
interferon. Such is the case of major IFN signalling components like RIGI-like receptors, 
IRFs, and STAT1. 
 
ISG products play diverse roles in the modulation of viral life cycles, as represented in 
Figure 30. Some of the most common and best characterized examples of ISGs include: 
 
 ‘Classical ISGs’ like interferon-induced, double-stranded RNA-activated protein 
kinase (PKR, encoded by Eif2ak2), the myxovirus (influenza virus) resistance 1, 
interferon-inducible protein p78 (MX1 or MXA, encoded by Mx1) and the 2’,5’-
oligoadenylate synthetase/ RNase L system (OAS1, OAS2, OAS3, encoded by 
Oas1, Oas2, Oas3). PKR is a known inhibitor of cellular and viral mRNA 
translation and is involved in a variety of cellular processes, including 
inflammation and apoptosis. It inhibits translation via the phosphorylation of 
eIF2α. Several members of the OAS enzyme family are activated by double-
stranded RNA to catalyze the formation of 2’,5’-oligoadenylates, which 
activate cellular RNase-L to degrade viral genomes. MX1 is a dynamin-like 
GTPase that appears to target viral nucleocapsids at an early post-entry step, 
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resulting in viral inhibition prior to the establishment of replication (Schneider 
et al., 2014; Schoggins, 2014); 
 
 Interferon stimulated gene 15 (ISG15, encoded by Isg15) is a small, ubiquitin-
like molecule and is one of the most highly induced ISGs. ISG15 has pleiotropic 
antiviral functions including inhibition of virus release, ISGylation of both viral 
and host proteins, and immunomodulatory cytokine-like properties in its 
unconjugated form; 
 
 Viperin (encoded by Rsad2) is a radical SAM domain-containing molecule with 
diverse antiviral activities. It can be induced by at least two different innate 
immune pathways: via JAK-STAT signaling or via direct activation by IRF1/3. It 
normally resides in the ER and in ER-derived lipid droplets. Most of its antiviral 
activities appear are related to lipid biosynthetic or fatty acid metabolic 
pathways. In vitro, viperin has been implicated in controlling a number of 
viruses, including human cytomegalovirus, influenza A virus, Sindbis virus (an 
alphavirus), and flaviviruses such as WNV and DENV. Viperin inhibits HIV-1 and 
influenza A virus budding at the host cell membrane by inhibiting farnesyl 
diphosphate synthase (FPPS), an enzyme involved in isoprenoid biosynthesis; 
viperin inhibits RNA replication of HCV subgenomic replicons (that takes place 
in the membranous web, closely associated with lipid droplets); its effect on 
the inhibition of DENV replication its thought to occur via the same 
mechanism. Interestingly, viperin was shown to be directly induced by HCMV 
and not only was its antiviral role inhibited, but a proviral effect was 
demonstrated as a result of hijacking into the mitochondria mediated by a viral 
protein (Helbig and Beard, 2014; Schneider et al., 2014; Schoggins, 2014); 
 
 IFN-inducible retrovirus restriction factors include APOBEC3, Samhd1, 
Bst2/tetherin and the recently characterized MxB protein (Haller, 2013). 
Humans have seven APOBEC3 genes, with APOBEC3G being the best 
characterized with respect to antiviral function. These are cytidine deaminases 
that introduce deleterious mutations into the viral matrix. APOBEC3A and 3B 
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have recently been shown to have an anti-HBV antiviral activity and to induce 
cccDNA degradation (Lucifora et al., 2014; Schoggins, 2014). 
 
 
Figure 30. ISG products interference with different stages of viral life cycles. 
Particular proteins are represented by stars next to the viral life cycle steps with which 
they have been demonstrated to interfere. Refer to text for details. Reproduced from 
(Schneider et al., 2014) 
 
If the interferon response is effective in controlling viral infection, viruses have in turn 
developed a variety of IFN antagonist proteins to counteract host defence, using 
diverse strategies. Such strategies can be divided into two main categories: inhibition 
of IFN induction (that includes inhibition of the recognition of viral RNAs by RLRs, 
modulation of downstream signalling or inactivation of transcription factors IRF3/7) 
and inhibition of IFN signalling (including dephosphorylation and degradation of STAT 
proteins). Viruses without such abilities to suppress the host type I IFN responses 
generally have low pathogenicity (Hoffmann et al., 2015; Koyama et al., 2008).  
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5.4. Regulation of innate and adaptive cellular immune 
responses 
The effects of IFNs on the host response to viruses are not limited to the acute, cell-
intrinsic antiviral response described above. IFNα/β have effects on both the innate 
and adaptive cellular immune responses that include (McNab et al., 2015): 
 
 Enhanced action of dendritic cells and monocytes. IFNα/β seem to have an 
activating effect on immature committed DCs, enhancing the cell-surface 
expression of Major Hystocompatibility Complex (MHC) molecules and co
stimulatory molecules, such as CD80 and CD86, which is associated with an 
increased ability to stimulate T cells. IFNα/β promote the ability of DCs to 
cross-present antigens during viral infections. IFNα/β may also promote the 
migration of DCs to lymph nodes, through up-regulation of chemokine 
receptor expression, thus promoting T cell activation; 
 
 Enhancement of NK cell responses. NK cells display a wide array of antiviral 
functions that include cytolytic targeting of infected cells (mediated by 
perforins), regulation of DC antigen presenting functions and also secretion of 
IFNγ. IFNα/β promote the function and survival of NK cells, through both direct 
and indirect means. While in some viral infections the direct action of IFNα/β 
on NK cells is required for the activation and expression of cytolytic effector 
functions and the production of IFNγ, in others, signalling through STAT1 is 
required for NK cell accumulation and cytolytic function, but not for IFNγ 
production. The ability of IFNα/β to induce or restrict IFNγ production by NK 
cells is related to differential STAT1 and STAT4 signalling. High levels of STAT1
dependent signalling inhibit IFNγ production by NK cells, whereas high basal 
levels of STAT4 prime NK cells for IFNγ production; 
 
 Promotion of CD4+ and CD8+ T cell responses. IFNα/β have been described to 
have both inhibitory and stimulatory effects on T cell survival and proliferation, 
cytokine (IFNγ) production, cytotoxic function and memory formation. As for 
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NK cells, these diverse outcomes are controlled by differential levels and 
differential activation of STAT molecules downstream of IFNAR; 
 
 Enhancement of B cell responses. As it is the case for viral antigens, IFNα/β 
can promote B cell activation and antibody responses, including class 
switching, during viral infection. 
 
The main cellular types involved in the antiviral response (and the resulting 
immunopathology) are represented in  
Figure 31. 
 
 
 
 
Figure 31. Cell types involved in the immune response to viral infection. Reproduced from 
(Rouse and Sehrawat, 2010) 
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Chapter II. Research project 
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1. Questions, objectives and experimental 
strategy 
Despite the existence of an effective vaccine, hepatitis B remains an important cause 
of cirrhosis and hepatocellular carcinoma worldwide. Current therapies are still 
unable to warrant a cure, as they do not target cccDNA. 
Co- or superinfection by HDV is known to significantly change the progression of 
hepatitis B. Firstly, it is known that a minor subset of CHB patients, when super-
infected by HDV, progress to eradicate both infections; secondly, patients chronically 
infected by both viruses, although presenting dynamic patterns of viral dominance 
often have a suppression of HBV replication evidenced both by decreased levels HBV 
viremia and by a decrease of liver cell replicative intermediates. Finally, HDV 
superinfection of CHB patients has been associated with faster progression of liver 
disease, with a higher incidence of decompensations and hepatocellular carcinoma. 
It is hence clear that, in spite of being a satellite virus, HDV is able to modulate HBV 
infection, both by interfering with its replication and by potentiating the pathogenic 
effect on the infected cell. 
However, little is known about the mechanisms of interaction between the two 
viruses. An important body of research was produced over the years concerning the 
shared processes of viral entry into the hepatocyte and viral assembly. Apart from 
these steps, it is considered that HBV and HDV have fully independent replication 
cycles.  
Two major hypothesis may be considered regarding the interaction between HDV and 
HBV that ultimately leads to an inhibition of HBV replication: HDV replication or viral 
components may exert a direct effect on the HBV replicative cycle or HDV, being an 
RNA virus with a pseudo-double stranded structure, may be associated with an 
intense immune response that counteracts the silencing of interferon response that 
HBV installs in the infected cells and hence ultimately limits its replication. 
As for the first hypothesis, a few arguments have been evoked over the years to 
suggest that a direct effect of HDV and its proteins may at least partially be responsible 
for an inhibition of HBV replication. Very recent data have recently emerged 
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suggesting that HDV induces a strong interferon response. The link between such 
response and the inhibition of HBV replication has not been clearly established, 
although some of the ISGs induced by HDV have been described to inhibit HBV 
replicative cycle. 
Furthermore, HDV research over the years has been hampered by the lack of 
appropriate infection models, with a direct repercussion on the limited number of 
therapeutic options available to these patients. 
 
Our aims hence were: 
i) to study HDV infection, replication and interplay with the host innate immune 
reponse; 
ii) to identify possible innovative therapeutic strategies for the inhibition of HDV 
infection; 
iii) to further explore HDV/ HBV interference and characterize the mechanisms 
involved. 
 
In order to do so, we first adapted the HepaRG cell model, frequentlty used for the 
study of HBV and HDV monoinfections, with the objective of establishing HBV/ HDV 
superinfections. 
 
The first part of the work concerns the optimization of culture and infection conditions 
as well as HDV detection techniques in HepaRG cells and the characterization of HDV 
infection (with or without its helper HBV) in this model. It is presented as a submitted 
paper awaiting for review. 
 
After the characterization of the model and the identification of immune activation 
and interference phenotypes, it was our aim to study the mechanisms underlying such 
observations. The work performed so far is compiled in the form of a chapter of 
additional results, as it is still being validated and further explored. 
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2. Submitted article 
This part is presented as a manuscript and has been submitted to Journal of 
Hepatology – see submission confirmation in Appendix 2. 
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Abstract 
Background & Aims: Hepatitis D virus (HDV) superinfection of Hepatitis B virus (HBV)-
infected patients is the most aggressive form of viral hepatitis. HDV infection is not 
susceptible to direct anti-HBV drugs, and only suboptimal antiviral responses are 
obtained with interferon (IFN)-alpha-based therapy. Our aim was to get insights on 
HDV replication and interplay with HBV in physiologically-relevant hepatocytes and 
evaluate the potential anti-HDV effect of immune-modulators.  
Methods: Differentiated HepaRG (dHepaRG) cells were infected with HDV both in the 
presence and absence of a previous HBV infection and viral markers were extensively 
analyzed. IFN response to HDV was monitored by measuring pro-inflammatory and 
interferon-stimulated gene (ISG) expression. In addition, infected cells were treated 
with various pathogen recognition receptors (PRR) agonists to evaluate their anti-HDV 
activity. 
Results: Both mono- and superinfected dHepaRG cells supported a strong but 
transient HDV replication, accompanied by the secretion of HDV virions only in the 
coinfection setting. Upon HDV superinfection, HBV replication markers including 
HBeAg, total HBV-DNA and pregenomic RNA were significantly decreased, confirming 
viral interference of HDV on HBV. No decrease of circular covalently closed HBV DNA 
(cccDNA) and HBsAg levels occurred. Concomitant to the peak of HDV-RNA 
accumulation and the onset of interference on HBV replication, a strong type-I IFN 
response was observed at day-6 post HDV infection. Importantly, PRR agonists were 
found more efficient than IFN-alpha to impede HDV replication, the best being 
Pam3CSK4 engaging the NF-kappaB pathway via TLR1/2. 
Conclusions: We established a relevant cellular model to further characterize 
HBV/HDV direct and/or indirect interplay and test novel HDV inhibitors, including 
immune-modulators. A suppressive role of HDV on HBV replication could convincingly 
be confirmed, whereas an IFN response to HDV infection was clearly evidenced. This 
model is contributing to assess molecular and immunological mechanisms of this viral 
interference.   
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Introduction 
Chronic hepatitis delta (CHD) is estimated to affect 15-20 million people worldwide 
(5-10% of the Hepatitis B virus (HBV) infected patients) (1). It is considered to be the 
most aggressive form of chronic viral hepatitis, with an accelerated progression 
towards fibrosis and cirrhosis and an increased risk of liver decompensation, 
hepatocellular carcinoma and premature death (2). Pegylated-interferon (Peg-IFN)-
alpha remains the single therapeutic option for these patients, with virological 
response rates of less than 30% at 24 weeks post-treatment and high rates (>50%) of 
relapse (3). HBV reverse transcriptase inhibitors have no effect on Hepatitis D virus 
(HDV) replication. The stretch of investigational drugs against HDV infection remains 
limited due to the fact that i) HDV does not encode enzymatic activities and uses a 
cellular RNA polymerase for its replication, ii) there are remaining gaps in the 
knowledge of the viral life-cycle, and iii) no appropriate in vitro model of super/co-
infection exists for to screening antiviral drugs. 
HDV is a subviral agent, satellite of HBV, and its genome is the smallest known among 
mammalian viruses, having similarities to plant viroids. It is a single-stranded circular 
RNA of ~1680 bp, with a high intramolecular base pairing, allowing a rod-like structure 
folding. Its complementary strand includes the SHD gene that codes for a single 
protein, the hepatitis delta antigen (HDAg), or small, 24 kDa, protein (S-HDAg), which 
is essential for HDV RNA replication. At a later phase of the HDV replication cycle, SHD 
stop codon editing catalysed by Adenosine Deaminase acting on RNA-1 (ADAR-1), 
leads to the synthesis of a 19-20 amino-acid (aa) carboxy-terminal extended isoform 
of HDAg. This large, 27kDa, protein (L-HDAg), thwarts HDV RNA replication and is 
involved in particle assembly. The viral genome encodes no polymerase activity and 
HDV fully relies on the recruitment of host cell DNA-dependent RNA polymerases 
(particularly RNA Pol II) for the nuclear replication of its RNA (4,5). 
To ensure propagation, HDV relies on HBV, as HDV virions are assembled by HBV 
envelope proteins. Furthermore, the entry of HDV in human hepatocytes is mediated 
by the interaction of the large HBV envelope protein (L-HBsAg) with the recently 
discovered cell surface HBV receptor, i.e. the human sodium taurocholate 
cotransporting polypeptide (hNTCP) (6). Both clinical and experimental data support 
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the existence of viral interference between HDV and HBV. In the clinical setting, most 
patients infected with both HBV and HDV feature a pattern of HDV dominance, with a 
significant decrease in HBV-DNA viral load, when compared to monoinfected patients 
(7–9). Moreover, studies on liver biopsies from chronically HDV-infected patients have 
shown a decreased level of HBV replicative intermediates in the liver (10). Finally, this 
negative interference has been confirmed in vivo, in super- or co-infection conditions, 
using HBV-infected chimpanzees, woodchuck hepatitis virus (WHV)-infected 
woodchucks, and more recently HBV-infected humanized mice (11–14).  
To understand the molecular basis of HDV interference on HBV, relevant infection-
based in vitro models are essential. Viral interference has been observed in Huh7 cells 
by transfection of DNA vectors expressing HBV and HDV (or either HDAg isoforms) 
(15). Direct inhibition of HBV enhancer-1 and activation of MxA gene, an interferon 
stimulated gene (ISG) known to suppress HBV replication, have been documented in 
the same model (16). However, transfection models have limitations and protein 
overexpression may lead to inaccurate assumptions. In order to analyse better HBV/ 
HDV interference, a cell culture model featuring both cccDNA formation and a 
competent innate immunity is required. Until recently, the innate immune response 
knowledge to HDV infection remained scarce. After in vitro studies suggesting a 
modulation of the IFN response (17,18), recent data from mouse models (both the 
humanized uPA-SCID mouse and the hNTCP transgenic mouse) revealed a strong 
induction of the intra-hepatocyte ISG expression (19,20). Further knowledge on the 
interactions between HDV and the innate immune system should allow for a better 
understanding of the interplay between HDV and its helper and the identification of 
potential therapeutic pathways. 
The aim of this study was to establish and take benefit of a relevant cellular model of 
HDV superinfection, to characterize HBV/HDV interactions and evaluate the host-cell 
innate immune system in response to infection. This model could furthermore allow 
an evaluation of the effect of immune-modulatory drugs on HDV replication. Using 
the differentiated HepaRG (dHepaRG) cells, which are immune-competent (21), we 
confirmed a suppression of HBV replication and showed that HDV infection is 
associated with induction of ISGs, but not of NF-kappaB regulated genes. We further 
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showed that some pattern recognition receptors (PRR) agonists lead to a more 
significant reduction of HDV replication than IFN-alpha treatment.  
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Material and Methods  
Production of HBV and HDV virions  
Both HBV and HDV virions were produced in vitro as described in supplementary 
material and schematically in Supplementary Fig. 1. 
HepaRG cell culture and infection  
The human liver progenitor HepaRG cells were cultured, differentiated and infected 
overnight with either HBV or HDV as previously described (21–23). For superinfection 
experiments, cells already infected with HBV (100 viral genome equivalents (vge)/cell, 
unless otherwise indicated) for 6 days were exposed to HDV overnight as indicated 
above (100 vge/cell, unless otherwise specified). 
Nucleic acid quantification: qPCR, RT-qPCR and Northern Blot 
Viral and intracellular DNA and RNA extractions are detailed in supplementary 
material. All primers and probes are listed in Supplementary Table 1. HDV 
quantification was performed by one-step RT-qPCR (Express One-Step SYBR Greener, 
Life Technologies) using the primers described by Scholtes et al (24) and the following 
cycling conditions: 50°C for 20 min (retro-transcription - RT), 95°C for 5 min and then 
40 cycles of 95°C for 30 s, 60°C for 20 s, and 72°C for 20 s. PCR was run in the Roche 
LightCycler 480. Further details are described in supplementary materials and Sup. 
Fig. 2.  
HBV DNA/RNA and innate immune gene expression were performed as previously 
described (23). For all intracellular gene expression analysis, the comparative cycle 
threshold (Ct) method was applied and results are displayed as a ratio (2^-DDCt), to a 
control sample (described for each experiment) (25). 
Northern blot for HDV and HBV RNA detection was essentially performed as 
previously described (26,27), with slight modifications, detailed in supplementary 
material. 
Elisa, immunofluorescence and WB 
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These techniques are detailed in supplementary materials. 
Antiviral treatment 
For evaluation of the antiviral effect of PRR agonists, dHepaRG cells were infected with 
HDV (10 vge/cell) and treated at days 3 and 6 post-infection. Supernatants for cytokine 
dosage were collected 24 hours after the beginning of treatment (i.e. day-4 post-
infection). Cells were lysed for RNA extraction at day-9 post-infection. The list and 
concentrations of PRR agonists used for treatment are given in Table 1. All ligands 
were purchased from Invivogen. IFN-alpha (1000 IU/ml; Roche) was used as a positive 
control for anti-HDV activity. 
Cell viability testing  
Cell viability was sequentially evaluated by neutral red uptake and sulforhodamine 
(SRB) assays, as detailed in supplementary material. 
Statistical analysis 
Results were computed with Microsoft Office Excel and Prisma Graph Pad softwares. 
Sample groups were first evaluated for the presence of outliers with Dixon test. 
Statistical analysis was subsequently performed with Mann-Whitney test for single 
comparisons and Kruskal-Wallis test with Dunns correction for multiple comparisons. 
The p-values are represented according to the following convention: p>0.05 (non-
significant, n.s); p<0.05 (*); p<0.01 (**); p<0.001(***).  
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Results  
In a monoinfection setting, dHepaRG cells support a strong but transient HDV 
replication 
To assess the conditions of HDV inoculation, differentiated dHepaRG cells were either 
mock-infected or infected with HDV at multiplicities of infection (MOI) ranging from 1 
to 500 vge/cell. At day-6 post-infection (p.i.), intracellular HDV RNA could be detected 
by RT-qPCR from the lowest MOI tested (i.e. 1 vge/cell), with a linear increase up to 
50 vge/cell, reaching a plateau for a MOI ranging between 50 and 500 vge/cell (Fig. 
1A). Northern blot analysis confirmed RT-qPCR findings and, using a genomic sense 
probe, indicated de novo formation of HDV replicative antigenomic RNA through the 
initiation of a replicative cycle (Fig 1B). Comparing HDV MOI 50 and 100, while an 
increase in amount of both isoforms of HDAg occurred, it did not match an increase in 
the number of infected cells (Fig. 1C and 1D). 
To get insights on infection kinetics, dHepaRG cells were infected 10 vge/cell and total 
RNA and proteins were collected at different time points. As a negative control, cells 
were treated with the entry inhibitor Myrcludex® (100nM) from 2 hours before 
infection to the end of viral inoculation, as shown in Fig. 2A. A steep rise in HDV 
intracellular RNA accumulation was detected from day 2 post-infection (p.i.) by RT-
qPCR, reaching a peak at day 6 and a subsequent decrease (Fig. 2B and 2C). At day 21 
p.i., HDV RNA remained detectable by both RT-qPCR and northern blot, indicating a 
residual amount of replicative intermediates or a low replication persistence. As 
expected, no increase in HDV intracellular RNA occurred in the Myrcludex®-treated 
conditions, confirming the efficacy of the drug and the fact that the detected 
replication was associated with the specific hNTCP receptor-mediated entry. Increase 
in HDV RNA levels was associated with an increase in the expression of HDAg, with 
both forms (S-HDAg and L-HDAg) being clearly detectable from day 3 p.i (Fig. 2D). The 
pattern of expression was slightly delayed as compared to HDV RNA, but followed the 
same bell-shaped curve. At later time points both HDAg isoforms decreased but 
remained detectable at least until day 21 post-infection. By indirect 
immunofluorescence staining, HDAg was detected in a maximum of 3% of cells (Fig. 
2E).  
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In already HBV-infected cells, HDV superinfection is associated with a decreased HBV 
replication. 
To set up the superinfection model, dHepaRG cells were first inoculated with HBV (100 
vge/cell), and, at day 6, at the plateau of HBV replication, (28); cells were inoculated 
with HDV (100 vge/cell) (Fig. 3A). No difference in intracellular HDV RNA accumulation 
was observed between HDV mono- and superinfected conditions over the follow-up 
kinetics (Fig. 3B). HBV replication was monitored by measuring HBeAg and HBsAg 
secreted in the supernatant, intracellular HBV DNA and total and pregenomic RNA 
(pgRNA) levels. Compared to HBV monoinfected cells, HDV superinfected cells 
displayed a significant decrease of both HBeAg secretion and intracellular HBV DNA 
(34 and 39% decrease, p<0.001 and p<0.05, respectively) (Fig. 3C and 3E). Increasing 
HDV MOI (up to 1000 vge/cell) further inhibited HBeAg secretion, indicating the 
relevance of this marker to monitor viral interference (Sup. Fig. 3). In contrast, there 
was no significant difference in HBsAg secretion levels between HBV monoinfected 
and HDV superinfected cells (Fig. 3D and Sup. Fig. 3). Although no significant 
difference was observed in the amount of total HBV RNA (as measured by RTqPCR; 
Fig. 3F), pgRNA level seemed to decrease over time in HDV superinfected cells (24% 
decrease as compared to HBV monoinfection at D15; p<0.05) (Fig. 3G and 3H).  
To further investigate the impact of MOI on viral interference, cells were 
superinfected at variable MOIs for both HBV (0, 100 and 500 vge/cell) and HDV (0, 10 
and 100 vge/cell) (Fig. 4A). Replication parameters were analysed at day-15 post-HBV 
inoculation (9 days post-HDV superinfection). As expected, a significant decrease in 
both HBeAg secretion and intracellular HBV DNA accumulation was observed upon 
HDV superinfection when cells had been infected with HBV at MOIs of 100 or 500, and 
the decrease was more pronounced with increasing HDV MOIs (Fig. 4B and 4E). 
Concomitantly, in the supernatant, HBV-DNA level decreased in the presence of HDV; 
this effect was dominating with low (MOI 100; p<0.05) rather than high HBV infectious 
titer (MOI 500; p=0.08, n.s.) (Fig. 4D). In such conditions, no reduction of HBsAg was 
observed (Fig. 4C), which correlated with the absence of variation on cccDNA levels 
(as measured by qPCR; data not shown). Considering low HBV MOI conditions (100 
vge/cell), the decrease of HBV pgRNA correlated with the HDV MOI (24% reduction - 
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p<0.05) (Fig. 4F and 4G). In contrast, no variation in the amount of total HBV RNA was 
observed even at high HDV MOI. As expected, HDV intracellular RNA levels 
significantly increased by incrementing HDV MOI (Fig. 4H). Surprisingly, total HDV RNA 
levels also paralleled HBV MOI increase, although this tendency was not statistically 
significant (13% increase at HBV MOI 500 versus MOI 100; p=0.39).  
Secretion of HDV particles during superinfection demonstrates HBV/HDV coinfected 
cells. 
In the superinfection setting, three patterns could be identified, upon labelling with 
anti-HBcAg and anti-HDAg antibodies: HBcAg positive/HDAg negative cells, HBcAg 
negative/HDAg positive cells and HBcAg positive/HDAg positive cells (Fig. 5A). This 
suggested that cells were either monoinfected by either HBV or HDV, or co-infected 
cells, respectively. The same observation was obtained when HBsAg immunostaining 
was used instead of HBcAg labelling (data not shown). The proportion of infected cells 
expressing either antigen remained below 3% for either HBV or HDV markers, whereas 
co-labelling occurred in approximately 1% of the total dHepaRG cells (Fig. 5B). 
Interestingly, despite the low number of detectable co-labelled cells, 1.3x107 vge/mL 
of HDV RNA was quantified in the supernatant of HBV-HDV superinfected cells (Fig. 
5C). This result was obtained without detectable cell toxicity (data not shown), 
suggesting a non-cytolytic release of viral particles. Indeed, we could exclude cell lysis 
as the origin of the detection of HDV viral RNA in the supernatant since extracted HDV 
RNA was under the limit of quantification in both HDV monoinfected and mock-
infected cell supernatants. Furthermore, an increase in HDV secretion not only 
significantly matched an increase in HDV MOI (p<0.05); but it also matched an 
increased HBV MOI from 100 to HBV MOI 500 vge/cell, although the difference was 
not significant (6-fold HDV RNA increase: p=0.1). Collectively these results 
demonstrate that some HepaRG cells can be infected by both viruses. Moreover, 
despite the low number of HBcAg/HDAg-positive cells, and likely due to the high 
efficiency of HDV-replication per cell (29), in the HepaRG HBV/ HDV superinfection 
setting, secreted HDV virions could be quantified.  
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HDV induces a strong expression of ISGs both in the mono- and superinfection 
settings 
In contrast to hepatoma cells, differentiated HepaRG cells express functional innate 
immune sensors, namely PRRs, and are therefore relevant to study antiviral response 
in hepatocytes (21). We aimed to decipher IFN response to HDV infection in this 
model. Upon HDV monoinfection, increased expression of several ISGs could be 
detected. Interestingly, ISGs expression peaked at day-6 p.i. and correlated with HDV 
RNA replication kinetics (Fig. 6). Since no ISGs induction occurred during the first 3 
days p.i., nor in the presence of Myrcludex®, it may suggest that the IFN response 
matched HDV RNA replication and neosynthesis rather than the incoming viral RNA 
material. In comparison to non-infected cells, highest expressions were detected for 
RSAD2 (i.e. VIPERIN; mean fold change 469,4) and IFI78 (i.e. MXA; mean fold change 
157,7). Other evaluated genes included ISG15 (mean fold change 44,6), DDX58 (i.e. 
RIGI; mean fold change 26,6), OAS1 (mean fold change 26,3), MDA5 (mean fold change 
11,2) and IFN-beta (mean fold change 6,9). For all studied time points, no significant 
difference was found in IFN-alpha and IL-6 expression levels between HDV infected 
cells and mock or Myrcludex® treated controls.  
The expression of innate immune related genes was also evaluated in superinfection 
setting at day-15 post-HBV infection (day-9 post-HDV infection, corresponding to the 
time point where interference was detected). As previously determined, HBV alone 
did not induce any innate gene expression (Fig. 7). In contrast, HDV infection was 
clearly associated with a strong induction of all studied ISGs, which was HDV MOI 
dependent but HBV independent. Consistent with HDV monoinfection, superinfection 
(HBV MOI 500 + HDV MOI 100), induced preferentially RSAD2 and MXA, with a 
respective 110.3 and a 50.5 fold increased gene expression. Finally, no induction of 
NF- IL-6 (Fig. 7), 
IL-8 and IL-  (data not shown). Collectively, these data indicate that in dHepaRG 
cells, HDV infection induces a strong IFN response at the peak of RNA replication, 
independently of both HBV infection and NF-kappaB pathway.  
Study of the anti-HDV effect of pathogen recognition receptor (PRR) agonists 
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Having found that, in dHepaRG cells, HDV activates IFN response without inducing 
pro-inflammatory response via NF-kappaB, we subsequently sought to examine the 
antiviral effect of some PRR agonists, which are known to induce IFN and/or cytokine 
production via IRFs and/or NF-kappaB transcription factors in this model (21). 
dHepaRG cells were inoculated with HDV (10 vge/cell) and subjected to two 72h 
treatments with PRR agonists, as displayed on Fig. 8A. Doses and treatment schedule 
were selected based on previous toxicity data on dHepaRG cells (30). An array of PRR 
agonists was tested, with the exception of Toll-like receptors (TLR) 8 and 9 ligands, as 
corresponding receptors have been previously shown to be non-functional in 
hepatocytes (21). In addition, we also tested imiquimod, a TLR7 agonist shown to have 
a strong anti-HBV effect irrespective of innate immunity (30). Interferon toxicity in 
dHepaRG cells having been previously described (31), we sequentially evaluated cell 
viability after each PRR agonist treatment by neutral red and sulforhodamine assays 
and found no significant cell toxicity for each drug (Fig. 8B). To measure PRR functional 
response, cytokine secretion was evaluated 24h after the beginning of treatment: IL-
6 relies upon NF-kappaB pathway activation, whereas IP-10 reflects type-1 interferon 
response (Fig. 8C).  
As shown in Fig. 8D, relative to the non-treated condition, a significant decrease (60%) 
of intracellular HDV RNA was obtained using Pam3CSK4 (i.e. Pam3; a TLR1/2 agonist) 
and imiquimod (p<0.01). Treatments with Poly (I:C) and Poly (dA:dT) led also to a 
significant decrease in HDV RNA (40 and 50% respectively; p<0.05). As expected, 
stimulation by Pam3CSK4 was associated with IL-6 secretion, whereas treatment with 
poly (I:C) and led to IP-10 secretion. Despite its significant antiviral effect, no apparent 
cytokine secretion was induced by imiquimod treatment. Under our experimental 
conditions, IFN-alpha treatment (1000 UI/ml) resulted only in a modest decrease in 
HDV RNA (25%); furthermore, this effect was found non-significant in comparison to 
the non-treated condition, thus emphasizing the important anti-HDV effect of some 
PRR agonists/ligands.  
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Discussion 
Despite leading to the most severe form of chronic viral hepatitis and infecting a pool 
of individuals as high as half of human immunodficiency virus (HIV)-infected 
population, HDV remains a neglected pathogen. Understanding the fundamental 
issues associated with the complexity of dual HBV/HDV infections may ultimately 
translate into the development of much needed new therapeutic strategies against 
HDV.  
Since its discovery, the HepaRG cell line has proven to be a very useful in vitro model 
to study HBV biology (21). Indeed, before the era of hNTCP-expressing hepatoma cell 
lines, HepaRG cells were the best alternative to PHH cultures to study HBV infection, 
as a full replication cycle occurred in this model (28). Similarly to primary human 
hepatocytes (PHH) but in contrast to widely-used HepG2 and Huh7 cells, HepaRG cells 
are able to express most of the innate immunity sensors (21) and are functional for 
IFN response (32).  Furthermore, cccDNA can be formed in HBV-infected HepaRG cells, 
and has been shown to be degraded in an APOBEC3A/B-dependent manner by 
activation of either IFN-alpha or LR-beta receptors (29). Therefore, the HepaRG model 
is suitable to study the interplay between HBV and HDV and hepatocyte-specific 
innate immunity, and explore new therapeutics, especially by evaluating the antiviral 
effect of immune modulators. This latter approach was recently implemented for 
exploring anti-HBV effect of PPR agonists (30). With respect to HDV biology, the 
HepaRG model has mostly been used for studying the entry step (26).  
HDV was here confirmed to specifically infect HepaRG cells, as entry was blocked by 
Myrcludex®, a drug competing with hNTCP viral attachment (33). If the proportion of 
HDV infected cells was rather low (3%) and could not be enhanced by increasing HDV 
MOI beyond 50 vge/cell, the level of replication per cell was significant and could be 
detected, without amplification, by northern blot, which has a limit of detection of 106 
vge. This is further sustained by the fact that, in a superinfection setting, despite the 
low proportion of co-infected cells (1%), as determined by IF assays, the HDV virion 
egress titer reached 107 vge/mL. The rather low proportion of infected cells could be 
due, at least in part, to cell polarization and accessibility of hNTCP in the basolateral 
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membrane of hepatocytes (34). Interestingly, HDV replication, in both monoinfection 
and superinfection conditions, seemed to be controlled, while not fully suppressed 
after a peak of replication at day-6 post inoculation. Similar decrease over time has 
also been described in mice injected with a HDV cDNA construct and, more recently, 
in the hNTCP transgenic mouse model (20, 35). At least two hypotheses might explain 
such phenotype: the infection is limited in time either by the decrease of available 
factor needed for replication, such as S-HDAg or some cellular components, or due to 
accumulation of inhibitors, such as L-HDAg or cellular negative factor(s). Alternatively, 
active antiviral innate immune response, temporally related to the peak of RNA 
accumulation, could also contribute to such inhibition.  
Besides mediating virion assembly, L-HDAg inhibits viral replication (36). However, L-
HDAg may not play a major role in the decrease of HDV RNA at day-9 post-inoculation 
in dHepaRG as: i) the ratio of S-HDAg and L-HDAg remained consistent throughout the 
kinetics of HDV RNA replication from day 3, and ii) in the superinfection setting, in 
which HDV virions release is observed, the decline of HDV RNA accumulation after 
day-6 p.i. is still observed. In line with our results, the inhibitory activity of L-HDAg on 
HDV replication has been discussed (37), and may be restricted to trans-expression 
during early steps of viral replication. On the other hand, we showed that the 
induction of some ISGs expression occurs at the peak of HDV RNA accumulation, 
suggesting that neo-synthesised HDV-replicative intermediates, rather than inoculum 
RNA, act as a pathogen-associated molecular pattern (PAMP). Whether the activation 
of IFN response could control HDV replication is still unknown in dHepaRG, but this 
was not confirmed in the transgenic hNTCP mouse model (20).  
In this cellular superinfection model, we were able to confirm that HDV can interfere 
with HBV replication. The observations that HDV superinfection is associated with a 
decreased secretion of HBeAg, HBV virions, intracellular HBV DNA and pgRNA, 
although not HBsAg, total HBV RNA or cccDNA, are in agreement with what has been 
described in HDV-infected patients (10). This is part of the originality of this satellite 
infection that may often overcome its helper replication, while maintaining its 
budding trans-complementation. This might also argue for a modulation of cccDNA 
transcriptional activity (10, 15). In reporter systems and exogenous expression of HD 
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proteins, direct inhibition of both HBV enhancers, especially by L-HDAg has been 
previously suggested (16), however further characterization of the differential 
expression of HBV transcripts is needed. Indeed, this cellular superinfection model 
may contribute to determine at which step (e.g. cccDNA transcription, viral mRNA 
export and/or stability) this inhibition occurs.  
Another explanation may be linked to the HDV-induced IFN response. Our results 
indicate that an increase in HDV MOI was associated with a more significant decrease 
of HBV replicative intermediates and a dose-dependent increase in ISGs expression. 
Previous works on HBV have shown that type-I IFN response modulates transcriptional 
regulation of cccDNA, decreasing pgRNA synthesis through modifications in histone 
acetylation status and recruitment of chromatin modifying enzymes (38). Whether 
HDV superinfection could induce such response remains to be explored. 
During HDV infection we identified a pattern of gene activation suggesting the 
induction of an IFN response, without any effect on NF-kappaB regulated genes. The 
induction of ISG expression by HDV is fully in agreement with results obtained in in 
both the humanized and hNTCP transgenic mice (19, 20) and could be responsible for 
the limited clinical response to IFN-alpha, as described in chronic hepatitis C (39). 
Furthermore, our results suggest that a strong induction of innate immune responses 
by the stimulation of PRRs may induce a decrease of HDV RNA replication. The 
strongest replication reduction (60% inhibition) follows stimulation of TLR 1/2 by 
Pam3CSK4, activating NF-kappaB pathway and secretion of IL-6, suggesting that the 
activation of this pathway, independently of the natural HDV infection, may represent 
an antiviral strategy. The fact that poly (I:C) (i.e. TLR3-L activation) and poly (dA:dT) 
(AIM2-L and indirect RIGI/MDA5-L activation) induce a stronger antiviral response 
than IFN-alpha itself, also opens new perspectives. Finally, the antiviral activity of 
Imiquimod raises a new set of questions: HepaRG treatment with this molecule does 
not lead to cytokine production, which is consistent with the absence of a functional 
TLR7 in these cells (30). Exploration of an alternative mechanism for its antiviral 
activity is needed, especially considering that analogous drugs such as GS9620 are 
entering clinical evaluation with promising results to control HBV infection (40). 
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In summary, we demonstrated here the usefulness of the differentiated HepaRG cell 
line model for the study of HDV infection and could show that a robust HDV replication 
occurs in these cells and is associated with a strong induction of ISG expression. 
Moreover, upon HDV superinfection of HBV-infected cells, viral interference and the 
production of HDV particles could be confirmed. Finally, the screening and study of 
PRR agonists led to the identification of four molecules an antiviral activity against 
HDV, opening promising therapeutic perspectives. 
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Figure legends 
Figure 1. HDV monoinfection in dHepaRG cells: impact of the MOI. dHepaRG were 
infected with HDV at different MOIs (ranging from 1 to 500 vge/cell). At day-6 post-
infection, intracellular HDV RNA was quantified by RT-qPCR (A; representative graph 
out of 3 independent experiments with 3 different viral batches), and Northern Blot, 
using a genomic probe, for antigenome detection (B). HDAg expression was evidenced 
by immunofluorescence (C.i.; magnification 200X); the percentage of labelled cells is 
represented in panel C.ii. (average counting of three 200X fields, normalized to the 
total number of nuclei) and western blot (D).. MOI, multiplicity of infection; AG, 
antigenome; L-HDAg, large hepatitis delta antigen; S-HDAg, small hepatitis delta 
antigen; n.s., non-significant. 
 
Figure 2. Kinetics of HDV monoinfection in dHepaRG cells. dHepaRG cells were 
infected with HDV at 10 vge/cell and infection was followed up to different time 
points. Maximum inoculation time was 24 hours. As controls, cells were either mock-
infected or treated with Myrcludex® at 100nM for 2h pre-infection and during HDV 
inoculation (A). For each point, intracellular HDV RNA was quantified by RT-qPCR (B), 
and Northern Blot, using a genomic probe (C); HDAg expression was evaluated by 
Western Blot (D) and immunofluorescence (E.i.; magnification 200X). The percentage 
of labelled cells is represented in panel E.ii. (average of three 200X fields, normalized 
to the total number of nuclei).  Myr, Myrcludex®; AG, antigenome; L-HDAg, large 
hepatitis delta antigen; S-HDAg, small hepatitis delta antigen. 
 
Figure 3. Kinetics of HDV superinfection of HBV-infected dHepaRG cells. A) Cells were 
either mock or infected with HBV at 100 vge/cell for 6 days, then either mock- or 
superinfected with HDV (100 vge/cell), and viral replication parameters were 
monitored at indicated times p.i. B) HDV total intracellular RNA, all values are 
normalized to HDV infected cells at day 12 post-HBV infection (corresponding to D6 
post-HDV infection); C) HBeAg ELISA and D) HBsAg ELISA (values are normalized to the 
level detected in HBV infected cells at day 6 post-HBV infection); E) HBV total 
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intracellular DNA; F) HBV total intracellular RNA; G) HBV pregenomic RNA (all values 
are normalized to the corresponding HBV monoinfection value); H) HBV Northern 
blot.  
 
Figure 4. HDV superinfection of HBV infected HepaRG cells: impact of variations of 
the MOI of both viruses. A) Cells were infected with HBV at 0, 100 or 500 vge/cell and, 
at day-6, each HBV-infected condition was superinfected by HDV at 0. 10 or 100 
vge/cell. At day-15 post-HBV infection, supernatant was collected and cells were lysed 
for nucleic acid extraction and subsequent analysis of viral replicative parameters. B) 
HBeAg ELISA; C) HBsAg ELISA; D) HBV secreted DNA (supernatant); E) HBV total 
intracellular DNA; F) HBV total intracellular RNA; G) HBV pregenomic RNA. All HBV-
related values are normalized to HBV cells infected at MOI 100. H) HDV intracellular 
RNA (normalized to cells infected at HDV MOI 100). 
 
Figure 5. Characterization of co-infection by IF and RT-qPCR assays. After HBV 
infection (100 vge/cell) and HDV superinfection at day-6 (100 vge/cell), cells were 
labelled with anti-HBcAg or anti-HDAg antibodies at day-10 and -14 post-HBV 
inoculation. A.i) Immunofluorescence at day-14 (upper panels – magnification 200X; 
lower panels – magnification 600X); A.ii) Percentage of labelled cells (average of four 
200X fields, normalized to the total number of nuclei). B) Quantification of HDV RNA 
in the supernatant (normalized to cells infected with HBV MOI 100 plus HDV MOI 100). 
 
Figure 6. Kinetics of IL-6, IFNs, and ISGs expression in cells inoculated with HDV 
alone. dHepaRG cells were inoculated with HDV at 10 vge/cell and cells were 
harvested at different time points post-inoculation. IL-6, type-1 IFNs and ISG 
expressions were evaluated by RT-qPCR. Controls included mock-infected cells, and 
cells treated with Myrcludex® (initiated 2 hours before and kept during HDV 
inoculation, as previously shown on Fig. 2.A). Results are presented as a ratio to the 
mock condition at each day. 
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Figure 7. Expression of IL-6, IFNs and ISGs after HBV and HDV infection. Cells were 
inoculated with HBV at 0. 100 or 500 vge/cell and, and 6 days later, exposed to HDV 
at 0. 10 or 100 vge/cell. IL-6, type-1 IFNs and ISGs expressions were evaluated by RT-
qPCR at day-15 post-HBV infection. Results are presented as a ratio to mock condition. 
 
Figure 8. Evaluation of the effect of PRR agonists on HDV replication. A) dHepaRG 
were infected with HDV at 10 vge/cell and submitted to two 72h-treatments with PRR 
agonists or not. B) Toxicity was evaluated by neutral red assay and SRB assay in 
dHepaRG cells submitted to two 72-hours treatments with PRR agonists. Results 
displayed are normalized to the non-treated condition. Cytokine production was 
evaluated by IP-10 (Ci) and IL-6 (Cii) secretion determined by ELISA evaluation of the 
cell culture supernatant 24 hours after the first treatment. D) HDV replication was 
evaluated by RT-qPCR at the end of the second treatment (day-9 post-infection). 
Results are presented as a ratio to the non-treated condition. SRB, sulforhodamine B. 
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Tables 
Table 1. List of PRR agonists, the respective targets and doses used. 
Molecule Target PRR Dose used 
LTA TLR 2 1 μg/ ml 
Pam3CSK4  TLR 1/2 0.5 μg/ ml 
Poly (I:C) HMW TLR 3 5 μg/ml 
LPS TLR 4 0.5 μg/ ml 
FLA-BS TLR 5 1 μg/ ml 
FSL-1 TLR 2/6 1 μg/ ml 
Imiquimod TLR 7  5 μg/ml 
Poly (I:C) (HMW)/ Lyovec™ RIGI/ MDA5 0.01 μg/ ml 
Poly (dA:dT)/ Lyovec™ RIGI/ MDA5 0.1 μg/ ml 
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Figures 
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Figure 2.  
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Supplementary Methods 
Production of HBV and HDV virions 
High-titer HBV supernatants were produced from HepG2.2.15 cells (1) as previously 
described (2). HDV particles were produced according to Sureau et al. (3), and as 
schematically described in Figure Sup 1. Both HBV and HDV supernatants were 
concentrated with PEG 8000 at 8% final (Sigma-Aldrich). All virus preparations were 
tested for the absence of endotoxin (Lonza). Viral titrations were performed by 
qPCR/qRT-PCR as described below. 
 
Nucleic acid extraction 
For HBV titration, DNA was extracted with the QiAmp Ultrasens Virus kit (Qiagen) and 
submitted to qPCR, as described below. HDV was titrated by qRT-PCR (see below) after 
RNA extraction with the NucleoSpin RNA Virus kit (Macherey-Nagel) and DNAse I (Life 
Technologies) digestion 1h at 37°C followed by 20 min at 70ºC, to eliminate residual 
plasmid DNA. 
Supernatants from infected dHepaRG cells were used for viral RNA and DNA 
quantification. In order to remove free nucleic acid, clarified supernatants were 
submitted to DNAse and RNAse digestion (Roche) followed by overnight precipitation 
with PEG 8000 8% (Sigma-Aldrich). After centrifugation, pellets were re-suspended in 
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PBS 1X and nucleic acids were extracted with the Nucleospin 96 Virus kit (Macherey 
Nagel). The resultant nucleic acids were submitted to qPCR and RT-qPCR for HBV and 
HDV quantification, respectively. All viral titers are expressed in viral genome 
equivalents per mL (vge/mL). 
For HBV intracellular total DNA quantification, DNA extraction was performed using 
the Master Pure Complete DNA and RNA extraction kit (Epicentre) or the Nucleospin 
96 tissue kit (Macherey Nagel). Intracellular total RNA was extracted with the 
NucleoSpin RNA kit (Macherey Nagel), which includes a DNAse digestion step. 
 
RT-qPCR HDV 
Serial dilution of quantified full length HDV-1 RNA (obtained from in vitro transcription 
of a pCDNA-3-derived plasmid containing a monomeric full length HDV-1 cDNA insert) 
was used as a quantification standard.  
For viral titration, extraction was performed in triplicate and 10-fold serial dilution of 
each sample were tested in order to ensure correct RT-qPCR efficiency. Intracellular 
RNA quantification was performed on 10ng RNA/ reaction and GUS was used as a 
housekeeping gene. For each experiment diluted HDV standard RNA (see Fig. Sup. 2) 
and four serial dilutions of one of the samples were used to ensure RT-qPCR linearity. 
RT-qPCR reactions omitting the reverse transcriptase were performed in parallel to 
exclude DNA contamination. 
 
qPCR cccDNA 
For cccDNA quantification, total DNA was submitted to digestion with plasmid-safe 
DNAse (Epicentre) for 4hours at 37ºC, followed by 30 minutes of heat inactivation. 
Quantification was performed by FRET-based qPCR as previously described (4) Beta 
globin was used as a house-keeping gene. 
 
Northern blot 
Purified RNA was denatured at 50°C for one hour with glyoxal reagent (Life 
Technologies) and then subjected to electrophoresis through a phosphate, 1.2% 
agarose gel and transferred to a nylon membrane (Amersham N+, GE). Membrane-
bound RNA was hybridized to 32P-labeled full genome HDV or HBV-specific 
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probes.The membrane was washed twice in low-stringency wash buffer (1× SSC; 0.1% 
SDS) for 30 min at room temperature and twice in high-stringency wash buffer (0.1× 
SSC, 0.1% SDS) for 30 min at 65°C. Quantitative analysis of HDV RNA was achieved by 
phosphorimager scanning (Typhoon Fla 9500, GE) and 18S and 28S rRNA 
quantification was were used as loading control. 
 
ELISA  
Commercial immunoassay kits (Autobio Diagnostics Co., China) were used for HBsAg 
and HBeAg quantification in the cell culture supernatant. Results are presented as a 
ratio to a control sample, described for each experiment. Cut-offs for these ELISA were 
1 NCU/mL (i.e. 1 NCU ≈ 13 ng) for HBeAg and 2.5 ng/mL for HBsAg. 
IL-6 and IP-10 were quantified in the cell culture supernatants by ELISA (R&D Systems), 
according to the manufacturer’s recommendations. 
 
Immunofluorescence 
Cells were fixated with paraformaldehyde 4% and permeabilized by Triton 0.3%. 
Labeling was done using the following antibodies: HBcAg – monoclonal mouse 
antibody from Abcam (8637 – 1/200 dilution); HDAg – polyclonal in-house rabbit 
antibody (1/200 dilution). Secondary labeling was performed with Alexa Flour 
fluorescent antibodies (wavelengths 555 and 488) and cell nuclei were stained with 
4.6-diamidino-2-phenylindole (DAPI). All images were obtained by epifluorescence 
microscopy (Nikon eclipse TE2000-E; Nikon) and processed ImageJ software. Labeling 
were quantified by a combination of automatic nuclei counting provided by the 
software and manual counting of labeled cells. Displayed results correspond to the 
average of at least three fields (200X magnification). 
 
Western Blot 
Cell lysis was performed with M-PER reagent (Pierce) in the presence of protease 
inhibitors. Western blots were performed with standard procedures using in-house 
polyclonal rabbit anti-HDAg antibodies (kind gift from Alan Kay) and anti-tubulin 
mouse monoclonal antibody (Sigma Aldrich). Detection was performed with Gel Doc 
XR+ System (BioRad) and images were analyzed with ImageJ software. 
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Cell viability testing 
Cell viability was sequentially evaluated by neutral red uptake and sulforhodamine B 
(SRB) assays. Neutral red assay was adapted from Repetto et al (5). Briefly, cells were 
first incubated for 2h at 37ºC, 5% CO2 with pre-warmed 40 μg/mL neutral red solution 
diluted in complete culture medium containing DMSO. Then, neutral red medium was 
removed and, after PBS washing, cells were de-stained with 50% absolute ethanol, 
49% deionized water and 1% glacial acetic acid. After homogenization, triplicate 
samples of the destaining solution were collected per condition and optical densities 
were measured at 540 nm. 
After neutral red uptake assay, cells were washed with deionized water, and then 
dried for further staining adapted from Vichai and Kirtikara, 2006 (6). Dried cells were 
incubated with SRB solution for 5 min at room temperature. The solution was then 
removed, and cells were rapidly washed three times with 1% acetic acid solution and 
completely dried at 37 °C. Finally, 10 mM Tris solution (pH 10.5) was added into each 
well and shaken during 5 min. After homogenization, the solution was harvested in 
triplicates for each condition and optical density was measured at 490 nm. All results 
are displayed as a ratio to the non-treated condition. 
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Supplementary figures 
 
 
Figure S1. HDV production. A) HDV was produced in vitro by co-transfection of Huh7 
cells with T7HB2.7 (coding for PreS1-PreS2-S from HBV) and pSVLD3 (containing a 
trimer of HDV genotype 1 genome). Supernatant was collected every other day from 
day-9 to day-15 post-transfection. B) Northern blot analysis (with a full-length anti-
genomic probe, for detection of HDV genome) of HDV RNA in the supernatant of 
transfected cells throughout time. G, genome. 
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Figure S2. RT-qPCR HDV. A) Serial 10-fold dilutions of a full-length HDV-1 RNA 
genomic transcript are used as a quantification standard, confirm PCR linearity within 
a range of 102 to 108 copies/ reaction with a PCR efficiency of ~2,1; B) Electrophoresis 
of PCR products evidences a unique band located between 100 and 200bp, consistent 
with the predicted 129bp amplicon; C) Serial 10-fold dilutions of RNA extracted from 
cell culture supernatant, confirm PCR linearity between 6X101 and 6X105 copies/ 
reaction, with a PCR efficiency of ~2,2; D) Serial 3-fold dilutions of intracellular total 
RNA confirm a linear HDV amplification within a range of 0.4-33,3 ng of total RNA per 
PCR reaction; E) Melting curve plot of HDV infected samples, confirming one single Tm 
peak consistently found at 84ºC. Lad, DNA ladder (100bp, New England Biolabs); NC, 
negative control; Tm, melting temperature. 
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Figure S3. Kinetics of HDV super-infection of HBV-infected dHepaRG cells. Evaluation 
of HBeAg (A) and HBsAg (B) secretion of HBV cells super-infected or not by HDV, as 
described for Fig. 3. at an estimated HDV MOI of 1000. A 70% decrease of HBeAg, but 
not HBsAg, secretion can be observed in HDV super-infected cells. 
 
Supplementary tables 
 
Table S1. List of primers and probes used for qPCR 
Designation   Sequence (5'-3') 
HDV Forward Primer CGGGCCGGCTACTCTTCT 
  Reverse Primer AAGGAAGGCCCTCGAGAACA 
HBV total Forward Primer GCT GAC GCA ACC CCC ACT 
  Reverse Primer AGG AGT TCC GCA GTA TGG 
HBV pgRNA Forward Primer GGA GTG TGG ATT CGC ACT CCT 
  Reverse Primer AGA TTG AGA TCT TCT GCG AC 
HBV cccDNA Forward Primer CTC CCC GTC TGT GCC TTC T 
  Reverse Primer GCC CCA AAG CCA CCC AAG 
  Probe GTT CAC GGT GGT CTC CAT GCA ACG T 
  Probe AGG TGA AGC GAA GTG CAC ACG GAC C 
GUS Forward Primer CGTGGTTGGAGAGCTCATTTGGAA 
  Reverse Primer ATTCCCCAGCACTCTCGTCGG 
RPLP0 Forward Primer CAC CAT TGA AAT CCT GAG TGA TGT 
  Reverse Primer TGA CCA GCC CAA AGG AGA AG 
B-globin Forward Primer ACA CAA CTG TGT TCA CTA GC 
  Reverse Primer CAA CTT CAT CCA CGT TCA CC 
  Probe CAA ACA GAC ACC ATG GTG CAC CTG ACT CCT GAG GA 
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  Probe AAG TCT GCC GTT ACT GCC CTG TGG GGC AA 
IL6  Forward Primer ACCCCTGACCCAACCACAAAT 
  Reverse Primer AGCTGCGCAGAATGAGATGAGTT 
IFNa Forward Primer  GTGAGGAAATACTTCCAAAGAATCAC 
  Reverse Primer  TCTCATGATTTCTGCTCTGACAA 
IFNb Forward Primer GCCGCATTGACCATGTATGAGA 
  Reverse Primer GAGATCTTCAGTTTCGGAGGTAAC 
OAS1 Forward Primer AGGTGGTAAAGGGTGGCTCC 
  Reverse Primer ACAACCAGGTCAGCGTCAGAT 
ISG15 Forward Primer ATGGGCTGGGACCTGACG 
  Reverse Primer GCCAATCTTCTGGGTGATCTG 
MxA Forward Primer GGTGGTCCCCAGTAATGTGG 
  Reverse Primer CGTCAAGATTCCGATGGTCCT 
RSAD2 Forward Primer CTTTGTGCTGCCCCTTGAG 
  Reverse Primer TCCATACCAGCTTCCTTAAGCAA 
RIG-I Forward Primer GCTGATGAAGGCATTGACATTG 
  Reverse Primer CAGCATTACTAGTCAGAAGGAAGCA 
MDA5 Forward Primer CCCATGACACAGAATGAACAAAA 
  Reverse Primer CGAGACCATAACGGATAACAATGT 
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3. Additional results 
The first part of the work, presented above as 2. Submitted article, concerned the set-
up and characterization of a model of HDV infection, either in the absence 
(monoinfection) or presence (superinfection) of its helper virus, HBV. From these 
results, it was possible to identify two main phenotypes:  
 
i) the existence of a robust, HDV replication, although limited in time,  
associated with an IFN response, which was evidenced by the induction 
of the expression of some ISGs; 
ii) the confirmation of an interference phenotype, with an inhibition of 
HBV replication as a consequence of HDV superinfection. 
 
To get further, albeit preliminary, insights into the molecular and immunological 
mechanisms underlying such phenotypes, further experimentations have been 
conducted and are yet being performed. The results obtained so far are presented in 
this chapter. 
 
3.1. Evaluation of HDV infection in other cell models 
3.1.1. Introduction 
Having characterized the phenotype of HDV infection in HepaRG cells, we proceeded 
to evaluate its reproducibility in other models. We hence focused on two additional 
cell models: 
i. Primary Human Hepatocytes (PHH) that are permissive to a complete life cycle 
of both HBV and HDV and are considered to be the most physiological in vitro 
model for the study of these infections; 
ii. HepG2 hNTCP cells that were obtained following stable transduction of 
HepG2 cells (a transformed cell line isolated from hepatoblastoma tissue) with 
a vector coding for the sequence of the putative human HBV/ HDV receptor -
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hNTCP - and were previously shown to support both HBV and HDV infections 
(Ni et al., 2014). 
 
3.1.2. Material and methods 
Primary hepatocyte and HepG2 hNTCP cell culture 
Primary human hepatocytes (PHH) were prepared from surgical liver resections 
(kindly provided by Pr. Michel Rivoire, Centre Léon Bérard and INSERM U1032, Lyon), 
as previously described (Lecluyse and Alexandre, 2010). One day post-seeding, cells 
were thoroughly washed and placed into Williams medium devoid of FCS for 24 hours 
to counter select for endothelial and fibroblastic cells, and afterwards cultivated, and 
infected in medium containing 5% FCS and 2% DMSO.  
HepG2 hNTCP cells were kindly provided by Dr. Stephan Urban (Heidelberg University 
Hospital). Cells were cultured in Dulbecco’s modified Eagle medium (Invitrogen), 
supplemented with 5% FCS and 2.5 μg/mL puromycin (Invivogen), GlutaMAX™, 
sodium pyruvate and penicillin/streptomycin. They were seeded in the same medium 
(without puromycin) at a density 100,000 cells per cm2, and further cultivated and 
infected in medium containing 2.5% DMSO. All cells were maintained at 37 °C and 5% 
CO2. 
 
HBV and HDV infections, ELISAs for HBeAg and HBsAg detection in supernatants, DNA 
and RNA extraction, q(RT)-PCR and Northern Blot were done as previously described 
(Material and Methods section of the 2. Submitted article chapter) 
 
3.1.3. Results 
HDV infection of PHH results in a peak of replication followed by a subsequent 
decline 
In order to validate the main findings obtained in the HepaRG cell line, we proceeded 
to the study of HDV infection (both in the presence and absence of HBV) in PHH. For 
all the experiments shown, cell viability and morphology were monitored by 
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microscopy observation and only experiments where hepatocyte morphology was 
maintained throughout time were considered. 
We first evaluated the kinetics of HDV mono-infection. PHH were either mock or HDV 
infected with MOI of 10 vge/cell and HDV RNA was collected at every third day and 
analysed by qRT-PCR and Northern Blot. As seen in Fig. 1A.i, representative of 2 
independent experiments done with cells from 2 donors, HDV replication was maximal 
between D6 and D9 post-infection and then experienced a five-fold decline. As far as 
we could evaluate while keeping PHHs in good shape, no further decline was 
observed. The qRT-PCR trend was confirmed to be associated with a decrease in the 
anti-genomic RNA by Northern Blot, as shown in Figure 1A.ii. 
 
HDV interference on HBV replication could be confirmed in PHH 
To further characterize HDV infection in PHH, we proceeded to superinfection 
evaluation. Cells were first either mock or HBV infected with a MOI of 100 vge/cell, 
then 6 days after, either mock or super-infected by HDV at MOIs of 10 or 100 vge/cell. 
At day-15 post-HBV infection (9 days after HDV superinfection), HBsAg and HBeAg 
were quantified in the supernatants and cells were lysed for DNA extraction followed 
by quantification of intracellular total HBV DNA by qPCR (Fig. 1B.i). The results 
correspond to one experiment with two biological replicates. As previously described 
for HepaRG, and represented in Fig. 1B.ii, a decrease could be observed in the 
secretion of HBeAg (but not HBsAg) in cells super-infected with HDV. Furthermore, 
this trend was more evident with the increase of the HDV MOI (in comparison to HBV 
mono-infection, cells super-infected with HDV 10 vge/ cell had an 11% decrease in 
HBeAg secretion, while superinfection with HDV 100 vge/ cell was associated with a 
19% decrease; neither difference was statistically significant). Intracellular total HBV 
DNA amounts were not affected by HDV infection at low MOI (10 vge/ cell), but 
decreased by 60% in cells super-infected with HDV 100 vge/ cell (Fig. 1B.iii), thus 
confirming viral interference in this model. 
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Figure 1. Evaluation of HDV infection in primary human hepatocytes. HDV monoinfection of 
PHH was performed at MOI 10 vge /cell and followed for 15 days.  HDV RNA was quantified by 
qRT-PCR HDV (A.i) and Northern blot (A.ii) performed with a full-length genomic probe for 
detection of antigenome. Results correspond to two independent experiments. B.i. HDV 
superinfection (10 or 100 vge/ cell) of HBV infected cells (100 vge/ cell) was performed at day 
6 and followed until day 15. Supernatants were used for HBeAg and HBsAg quantification by 
ELISA (B.ii) and intracellular HBV DNA was analysed by qPCR (B.iii). The results correspond to 
one experiment with two replicates. 
 
HDV interference on HBV replication is not observed in HepG2 hNTCP cells 
A first evaluation of HDV infection in HepG2 hNTCP cells was performed in a 
superinfection setting. Cells were first either mock or infected with HBV at MOIs of 
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100 or 500 vge/cell, then HDV superinfection (MOI 10 or 100 vge/ cell) was performed 
at day-6 post HBV infection and controlled by mock infection, as previously described 
and represented in Fig. 2A. It was possible to keep cells in culture for 12 days post-
infection, as a significant change in cell morphology was observed beyond this time 
point. Supernatants and total intracellular DNA were collected at the end of the 
experiment. The results correspond to two independent experiments, each with 
biological duplicates. As can be observed in Figs. 2B and 2C, no significant variation 
was evidenced in the secreted levels of either HBeAg or HBsAg upon HDV 
superinfection. In cells infected with a high HBV dose (500 vge/ cell), there is a 
decreasing trend of intracellular total HBV DNA levels, upon HDV superinfection (45 
and 60%, for HDV MOIs 10 and 100, respectively). However, due to a high variability 
between the two experiments, this difference was not statistically significant (Fig. 2D). 
 
Figure 2. Evaluation of HDV/ HBV superinfection in HepG2 hNTCP. A. HepG2 hNTCP were 
infected with diferent HBV MOIs (0, 100 and 500 vge/ cell) and superinfected 6 days later with 
HDV (0, 10 or 100 vge/ cell). Experiment was stopped at day 15. Supernatants were analysed 
HBeAg (B) and HBsAg ELISA (C) and total HBV intracellular DNA was quantified by PCR (D). The 
results correspond to two independent experiments, each with two replicates. n.s., non-
significant (p> 0,05). 
Thesis Dulce Alfaiate 
194 
 
3.1.4. Discussion 
Primary hepatocytes, from human, primate or woodchuck donors, have been an 
invaluable model for the study of both HBV and HDV infections. In our study 
conditions, we were able to demonstrate that HDV mono-infection of PHH led to a 
peak of replication between days 6 and 9 post-infection followed by a subsequent 
decline. Although less pronounced, this decline reproduced the observations made in 
HepaRG.  
Previous studies of HDV infection of PHH have demonstrated variable profiles: while 
Gudima and colleagues described a peak of replication followed by a decline, similar 
to that we observed in dHepaRG, studies from the Lanford’s group, both in human 
and primate hepatocytes (primary chimpanzee hepatocytes, PCH), identified a plateau 
of replication. A striking difference can be identified in the culture setting, as in the 
latter case cells were cultivated in particular conditions, with a serum-free, but very 
rich medium, which was associated with long-term cultivation periods (more than 40 
days) and eventually the capability  of PHH/ PCH to sustain or control viral infection 
(Barrera et al., 2004; Gudima et al., 2007; Sureau et al., 1991). It would be interesting 
to use such conditions in the culture of dHepaRG cells to investigate a possible change 
in the kinetic profile of HDV infection and further investigate if the observed decline 
in viral replication is associated with the lack of an essential factor for viral replication 
or an active antiviral response.  
Although further reproduction and characterization is warranted, the replication of an 
interference phenotype in PHH allows us to validate the observations made in the 
HepaRG model, and its usefulness as an alternative and convenient model to further 
study HDV/ HDV superinfection and understand underlying molecular and/ or 
immunological mechanisms at work to explain viral interference. Conversely, the fact 
that such phenomenon was not reproduced in the HepG2 hNTCP cells rises important 
questions, not only relative to their use as a model, but ultimately related to the 
mechanisms of HDV/ HBV interference. In a first approach it will be essential to have 
a more thorough characterization of the kinetics of infection in this model. An 
important technical difference must be noticed: in HepG2 hNTCP, evaluation of 
superinfection was possible 12 days after HBV infection, while in HepaRG the decrease 
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in HBV viral parameters was only significant 3 days later. We cannot exclude the need 
for a longer period of superinfection in order to detect interference. Although HepG2 
hNTCP are known to be susceptible to HDV infection (Ni et al., 2014), and replication 
could be detected in our experiments (data not shown), a thorough characterization 
of the kinetics of HDV RNA and protein accumulation and an assessment of the 
number of infected cells is warranted for further discussion of these results.  
 
3.2. Evaluation of HDV mono-infection 
3.2.1. Introduction 
Results obtained in the first part of this thesis work, and described in the previous 
chapter revealed that, in HepaRG cells, after a peak of replication, HDV infection 
suffered a steep decrease (2. Submitted article, Fig. 2). Coincidently, this kinetic profile 
correlated with a sharp increase in the expression of ISGs. This observation raised the 
question of whether an effective IFN response could be leading to the control of HDV 
replication in this model.  
In order to evaluate such possibility, two strategies were used: 
 
i. Assessment of HDV replication in a context of blockage of the type I interferon 
response. This was performed by reproducing the evaluation of HDV 
replication kinetics in the presence of a neutralizing antibody to human 
Interferon (Alpha, Beta and Omega) Receptor (IFNAR) 2; 
ii. Evaluation of HDV replication in the presence of HBV proteins, previously 
shown to modulate IFN response. Previous works from the laboratory (Gruffaz 
et al., 2013) have demonstrated that HBV core protein is associated with an 
early inhibition of the IFN response in HBV infected cells. Hence, in order to 
evaluate a possible effect of such inhibition on HDV replication, we monitored 
HDV infection in cell lines expressing selected HBV proteins. 
 
Furthermore, beyond the observation that HDV was associated with a strong 
induction of ISG expression, we also evidenced that treatment with exogenous IFN 
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was only modestly effective (2. Submitted article, Fig.8). These observations led to the 
hypothesis, previously approached in a different cell model (Pugnale et al., 2009), that 
HDV infected cells may be resistant to further IFN stimulation. We hence proceeded 
to determine if IFN treatment was effective in further inducing ISG expression in HDV 
infected cells. 
 
3.2.2. Material and methods 
Neutralization of IFN /  signalling 
Differentiated HepaRG cells were subjected to HDV mono-infection as previously 
described. Briefly, as represented in Fig. 3A, cells were inoculated with HDV 10 
vge/cell for 24 hours (as a negative control, cells were treated with the entry inhibitor 
Myrcludex [100 nM] from 2 hours before infection and until the end of viral 
inoculation). At the end of the inoculation cells were thoroughly washed with PBS and 
anti-human IFNAR2 antibody (PBL Assay Science) was added to the culture medium at 
a concentration of 500 ng/ml and kept throughout the experiment. RNA was collected 
at different time points and analysed by RT-qPCR for HDV quantification or subjected 
to RT and subsequent qPCR for ISG expression evaluation as described above (2. 
Submitted article, Material and methods). 
 
Interferon treatment of HDV infected cells 
HDV infection of dHepaRG cells was performed as already described. IFNα (Roche) 
1000 IU/ml was added to the cell culture medium at day-5 post-infection and cells 
were collected for RNA extraction and qRT-PCR analysis after 24 hours of treatment 
(at day-6 post-infection). Mock infected and non-treated cells were used as controls 
(Fig. 4A).  
 
Establishment of HepaRG TR-HBc, TR-HBe, TR-HBs and TR-HBx cell lines 
Recombinant HepaRG cells were previously generated in the laboratory for the 
expression of selected HBV proteins: HBc, HBe, S-HBs and HBx (Gruffaz M, in 
preparation). Briefly, each HepaRG cell line was established using the ViraPower T-Rex 
Lentiviral Expression System from Invitrogen. Stable overexpression of the 
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tetracycline repressor (TR) in HepaRG cells was obtained after transduction with a 
lentivirus (multiplicity of infection of 5) produced upon cotransfection of HEK-293 cells 
with pLenti6-TR plasmid and packaging vectors, according to the manufacturer’s 
indications. Blasticidin-resistant HepaRG-TR cells were then transduced with a second 
lentivirus conferring zeocin resistance and coding for either HBc, HBe, S-HBs and HBx 
(HBV genotype D, serotype ayw, Galibert’s strain), produced upon cotranfection of 
HEK-293 cells with packaging vectors and with corresponding pLenti4/TO plasmids, in 
which transgene are under the control of a tetracycline-regulated promoter. Cells 
were co-selected by blasticidin and zeocin and cultivated as previously described for 
HepaRG. 
HDV infection and qRT-PCR were performed as previously described. 
 
3.2.3. Results 
IFN /  signalling blockage is associated with a decrease, but not abrogation, of ISG 
expression  
In HDV infected cells, the blockage of IFN /  signalling by an anti-IFNAR neutralizing 
antibody was associated with a decline of ISG peak expression (at day-6 post-
infection), as depicted in Fig. 3B. Such decrease was observed for all the tested ISGs 
and it ranged from 32% (for MDA5) to 62% (for RSAD2).  
 
IFN /  signalling blockage does not prevent the decline in HDV replication 
In the presence of anti-IFNAR antibody, the peak of HDV replication is attained later, 
at day-9 and not day-6 post-infection, and is slightly inferior (20%) to that observed in 
the control condition. However, HDV replication still declines after attaining the peak, 
following the same kinetics as the control condition (Fig. 3C), suggesting that other 
factors than IFN α/ β may be involved in such decrease. 
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Figure 3. Evaluation of the effect of IFN /  signalling blockage on HDV replication. A. HDV 
monoinfection was established and after inoculation cells were treated or not with anti-
IFNAR2 neutralizing antibody, that was kept until the end of the experiment, when cells were 
collected for RNA extraction and qRT-PCR. The results represent two replicates (wells) in the 
same experiment. B. RNA quantification of selected ISGs. C. HDV RNA quantification by qRT-
PCR. 
 
Interferon alpha treatment of HDV infected cells does not lead to a further increase 
of ISG expression 
As discussed before, HDV replication in HepaRG cells is associated with a strong 
induction of ISG expression. To evaluate the responsiveness of HDV infected cells to 
IFN  treatment, a 24 hour IFN treatment was done, and HDV replication and ISG 
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expression were assessed at their peaks (previously determined to occur at day-6 
post-infection) – Fig. 4A.  
As seen in Fig. 4B, HDV replication was not affected by the 24-hour IFN treatment.  
As expected, and can be observed in Fig. 4C in mock infected cells, IFN  treatment 
was associated with a strong increase in ISG expression ranging from 20x for RIG-I to 
2298x for RSAD2. A strong induction of ISG expression by HDV infection alone was 
once again confirmed and attained levels were comparable to those induced by 
treatment with IFN  1000 IU/ml. Moreover, treatment of infected cells with IFN  did 
not induce a further increment in ISG expression (maximum increase was observed in 
RIG-I expression: 1,5 fold). Table 1 represents the average fold increase in ISG 
expression after interferon treatment of both mock and HDV-infected cells. 
 
Table 1. Fold change variation of ISG’s RNA in response to IFNa treatment 
 
 
 
HDV replication is increased in cells expressing HBc 
HepaRG cell lineages expressing HBc, HBe, HBs and HBx under the control of a 
tetracycline inducible promoter were constructed and characterized in the laboratory 
beforehand. A summary of their functional evaluation is presented in Fig. 5. 
We first evaluated HDV replication in the HepaRG TR-HBc lineage. Cells were plated 
and differentiated as described for HepaRG cells. Transgene expression was induced 
by addition of tetracyclin (10 μg/ml) to the cell culture medium and 3 days after cells 
were infected by HDV (MOI 1vge/ cell). RNA was collected at days 1, 4, 8, 11 and 14 
post-infection.  
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Figure 4. Assessment of the effect of IFNα treatment of HDV infected cells. A. dHepaRG cells 
were infected with HDV 10 vge/ cell and after 5 days treated with IFNα 1000 IU/ml. Cells were 
harvested at day 6 post-infection (corresponding to 24 hours of IFNα treatment) and RNA was 
analysed by qRT-PCR HDV (B) and RT-qPCR for selected ISGs (C). The displayed results 
correspond to the average of two biologic replicates in one experiment. 
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Figure 5. Characterization of HepaRG TR-HBc, -HBe, -HBs and -HBx cell lines. For each lineage, 
protein expression was evaluated in function of tetracycline dose A. HBc expression was 
evaluated by intracellular and extracellular HBcAg ELISA and by Western Blot. B. HBe 
expression was verified by intracellular and extracellular HBeAg ELISA. C. HBsAg expression 
was also quantified by ELISA. D. HBx expression was assessed by western blot. 
 
As seen in Fig. 6A.i, corresponding to the result of three independent experiments, 
HDV replication is favoured in the cells expressing HBc (labeled Tet+), although a 
statistically significant difference was not attained (maximum 1,7 fold increase). 
Transgene expression was confirmed by RT-qPCR using primers designed for PreC/C 
/pgRNA detection (2. Submitted article, Table 1) as shown in panel Fig. 6A.ii. 
In order to confirm the specificity of the HBc effect on HDV replication and to evaluate 
possible interactions of other HBV proteins, the experiment was repeated with 
HepaRG TR-HBc, TR-HBe, TR-HBs and TR-HBx. Differentiated cells were pre-treated 
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with tetracyclin for 3 days (10μg/ml) and then infected with HDV (MOI 5 vge/ cell). As 
HBe and HBs are secreted in the cell culture supernatant, inoculation was performed 
using the conditioned supernatants. RNA was collected at days 3, 6, 9, 12 and 15 post-
infection. As seen in Fig. 6B (representative of one experiment), a favourable effect of 
core expression on HDV replication was confirmed. Furthermore its specificity could 
be verified as neither HBe nor HBx seem to interfere with HDV replication. A slight 
increase of HDV RNA was detected with HBs expression and must be confirmed. 
 
 
 
Figure 6. Evaluation of HDV mono-infection in HepaRG cell lines expressing HBV proteins. 
A.i. Evaluation of HDV replication (estimated by RT-qPCR) in HepaRG TR-HBc cells treated or 
not with tetracycline. A.ii. Assessment of transgene expression in response to tetracycline 
stimulation, by RT-qPCR using specific PreC/C/ pgRNA primers. B. Evaluation of HDV replication 
in HepaRG TR-HBc, -HBe, -HBs and –HBx. 
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3.2.4. Discussion 
Results obtained regarding HDV monoinfection of HepaRG cells reveal a temporal 
coincidence between the peak of HDV replication (reflected by maximum amounts of 
HDV antigenomic RNA) and the greatest levels of ISG induction. This observation raises 
questions regarding the causal link between the two observations, most importantly, 
concerning the possible influence of the IFN response on the control of HDV 
replication. Such an antiviral effect is only partially comforted by clinical data as, while 
the administration of exogenous IFN  is associated with a decrease in HDV viremia, it 
occurs in a minority of patients and evidence of a direct effect of IFN on HDV 
replication is scarce (other mechanisms as entry inhibition have been suggested) (Han 
et al., 2011b; McNair et al., 1994; Wedemeyer et al., 2011). Furthermore, it has been 
suggested that HDV directly inhibits type I IFN signalling, which would justify the 
absence of response observed in most of the patients (Pugnale et al., 2009). Our data 
are in line with such possibility, as no further increase in ISG expression is observed in 
HDV infected cells treated with IFN. However, in contradiction to our findings, in the 
aforementioned work, the authors did not find a basal ISG induction in the absence of 
IFN stimulation. Hence, whether, in our model, this absence of response is due to an 
active inhibition of IFN signalling or a mere reflection of a state of response saturation 
remains to be elucidated. 
 
To verify the hypothesis that, if an IFN response is responsible for the control of HDV 
replication in HepaRG, the observed decline in RNA amounts should be abrogated or 
at least attenuated in settings where such response in blocked, we set-up two types 
of experiments.  
We first evaluated the possibility that autocrine or paracrine type I IFN stimulation 
may be involved in the control of HDV replication, using an anti-IFNAR neutralizing 
antibody. It has previously been shown that HepaRG cells produce low doses of IFN-  
upon PRR agonisation - less than 10 IU/mL with RIGI/MDA5 agonists (Luangsay et al., 
2015b). Its neutralization is associated with increased HBV replication in the case of 
delivery with baculoviral vectors (Lucifora et al., 2010). In HDV infected cells, IFNAR2 
neutralization was associated with a decrease, but not a complete suppression, of ISG 
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expression. Surprisingly, this was correlated with a slight decrease in the maximum 
levels of HDV RNA and the replication peak was delayed. However, the subsequent 
decline in replication was similar to that observed in the non-treated cells, thus 
suggesting that either ISG protein production is still high enough to lead to anti-HDV 
effect or that a part of the ISG protein production could be independent of auto/ 
paracrine effect (i.e. independent of the activation of ISGF3). The meaning of such 
findings is for the moment difficult to explore, as these experiments have yet to be 
reproduced to become convincing. Moreover, although the decrease in ISG expression 
constitutes an evidence for IFN type I response inhibition (at least partial), the 
neutralization conditions need further optimization. It will be essential to verify a 
dose-response effect of the neutralizing antibody, although the doses used should be 
neutralizing, given the small quantity of IFN produced by HepaRG cells (even after PRR 
stimulation). Interestingly, similar results have recently been reported in the hNTCP 
transgenic mouse model, suggesting that HDV replication control in that model may 
be independent of the type I IFN response (He et al., 2015). 
 
We next evaluated HDV replication in a cell line with an inducible expression of HBV 
core protein (HBc). HDV replication was repeatedly found to be increased upon its 
expression (and not when HBe or HBs were expressed). HBc expression in these cells 
has previously been shown to lead to a blockage of type I IFN response triggered by 
PRR agonists or exposition to viruses (e.g. Sendai), an argument in favour of the 
immune-modulation effect of HBV core protein (Gruffaz et al., 2013). However, the 
fact that the replicative profile of HDV in this cells is distinct from that observed in 
association of IFNAR neutralization, raises the question of whether this apparent 
proviral effect of HBV core protein on HDV replication is indeed mediated through an 
abrogation of the IFN response or another mechanism. 
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3.3. Evaluation of HDV-HBV interference 
3.3.1. Introduction 
In the HepaRG cell model, HDV superinfection of cells persistently infected with HBV 
was associated with a decrease in HBV replicative parameters. 
Previous works have suggested that this interference phenotype could be associated 
with a direct effect of HDAg on the regulation of HBV enhancers and/or mediated by 
the induction of MxA expression, as it is a known restriction factor for HBV RNA 
nuclear export (Williams et al., 2009).  
It was our purpose to evaluate both the possibility of a direct effect of HDV proteins 
in HBV replication repression, namely through epigenetic cccDNA transcriptional 
regulation and to ascertain the importance of the interferon response induced by HDV 
in this interference phenotype. 
 
3.3.2. Material and methods 
Establishment of HepaRG TA-SHDAg and HepaRG TA-LHDAg cell lines 
In order to study the effects of HDV antigens on viral replication, we generated two 
recombinant cell lines, through lentiviral transduction of HepaRG cells, to allow the 
tetracycline/doxycycline-inducible expression of S-HDAg and L-HDAg respectively. 
S-HDAg and L-HDAg coding sequences (derived from cDNA obtained from a patient 
infected with HDV genotype 1, studied in the setting of an outbreak of fulminant 
hepatitis (Dény P, unpublished data) and containing a Strep-tag at their N-terminus 
were cloned into pEN_Tmcs entry vectors (Addgene) and then, through a LR 
recombination, inserted into a pSLIK-Hygro vector (Addgene), which expresses the 
transgene under the control of a tetracycline/doxycycline-activated promoter, and a 
tetracyclin trans-activator (TA). Lentiviruses were generated upon cotransfection of 
HEK 293T cells with the pSLIK plasmid and lentiviral packaging vectors following 
Invitrogen protocols. HepaRG cells were transduced at a multiplicity of infection of at 
least 1. HepaRG TA-SHDAg and HepaRG TA-LHDAg polyclonal cell lineages were 
derived upon hygromycin selection. A similar procedure was followed for the 
generation of a control HepaRG TA-GFP cell line. 
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HepaRG cell culture and induction of transgene expression 
HepaRG cells were cultured as previously described in the Submitted Paper. 
Induction of transgene expression was achieved by addition of doxycycline (Sigma) to 
the cell culture medium in the concentrations and time period specified for each 
experiment. 
 
Subcellular fractionation 
Differentiated HepaRG TA- SHDAg and TA-LHDAg cells were subjected to subcellular 
fractionation using the “subcellular protein fractionation kit” for cultured cell (Thermo 
Scientific). After 48 h of induction of transgene expression by addition of doxycycline 
(80 ng) to the cell culture medium (or not), cells were harvested with trypsin-EDTA 
and centrifuged at 800g for 8 min at 20°C. For extraction of the cytoplasmic proteins 
enriched fraction: ice cold cytoplasmic extraction buffer (CEB) containing protease 
inhibitors (1X) was added to the cell pellet and incubated for 10 min at 4°C with gentle 
mixing. The cytoplasmic lysate was centrifuged at 500g for 5 min and supernatant 
enriched with cytoplasmic proteins was transferred to a pre-chilled microfuge tube. 
The resulting pellet was used for membrane associated proteins extraction by addition 
of Ice cold membrane extraction buffer (MEB) containing protease inhibitors (1X), 
incubation at 4°C for 10 min with gentle mixing and centrifugation at 3000g for 5 min. 
The supernatant enriched with membrane-associated proteins were transferred to a 
pre-chilled microfuge tube. The ice cold nuclear extraction buffer containing protease 
inhibitors was added to the pellet obtained lastly, vortexed vigorously and was 
incubated at 4°C for 30 min with gentle mixing. The nuclear lysate was centrifuged at 
5000g for 5 min and the supernatant, enriched with nuclear associated proteins, was 
transferred to a pre-chilled microfuge tube. Finally, chromatin-associated proteins 
were recovered by addition of room temperature nuclear extraction buffer containing 
protease inhibitors, 5 μl of 100 mM CaCl2 and 3 μl of Micrococcal Nuclease to the 
pellet obtained after the last step. The sample was vortexed vigorously and was 
incubated at 37°C for 5 min. After incubation, the lysates enriched with protein 
extracts were vortexed vigorously and centrifuged at 16,000g for 5 min. The 
supernatant was transferred to a pre-chilled tube.  
10 μg of protein of each compartment was subjected to western blot. 
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Transcomplementation assay 
Proliferative HepaRG TA-S-HDAg and TA-L-HDAg cells were transfected with 
pSVL(D2m), a plasmid that contains a dimer of a mutated HDV-1 cDNA, under the 
control of an SV40 promoter. This mutant has a two-nucleotide deletion within the 
delta antigen sequence, which leads to abortive translation of the S−HDAg protein and 
hence, given the need of S-HDAg for HDV replication, is replication incompetent. As a 
control, cells were alternatively transfected with pSVLD3 that contains a trimer of 
wild-type HDV-1 cDNA (also under the control of an SV40 promoter) and is replication 
competent. Mock transfection was also established. Transfection was made with 
Mirus LT1 reactive, following the manufacturer’s protocol. Transfection medium was 
removed 24h hours of contact with the cells. The next day (D2 post-transfection), 
transgene expression was induced by the addition of doxycycline to the culture 
medium. Cell culture medium was changed every other day, with addition of 
doxycycline, and cells were lysed for RNA extraction at D8 post-transfection. HDV 
replication was evaluated by Northern Blot (using a full length genomic probe for 
detection of anti-genome). 
 
Western blot 
Western blot analysis was carried as previously described using as primary antibodies: 
Anti Strep−Tag® (Qiagen), Anti-Tubuline (Santa Cruz), Anti-Histone H3 (Cell Signalling). 
 
HBV infection, HBeAg and HBsAg ELISA, RNA and DNA extraction qPCR and qRT-PCR 
HBV, Immunofluorescence, Northern Blot and neutral red assay were carried as 
previously described. 
 
cccDNA specific chromatin immunoprecipitation 
ChIP analysis was based on the protocol described by Testoni et al. (Testoni et al., 
2011) with minor modifications. Briefly, cells (2-5X106 per condition) were washed in 
phosphate-buffered saline (PBS) and cross-linked for 10 min with 1% formaldehyde, 
followed by quenching with Glycine 0.125 M. Cells were then submitted to nuclear 
lysis and light sonication. Immunoprecipitations were performed with Dynabeads® 
Protein G (100.03D, Life Technologies) and 5–10 μg of the following antibodies: 
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Monoclonal mouse antibody anti-Strep-Tag (Qiagen) and Polyclonal rabbit antibody 
anti-HDAg (kind gift from Alan Kay). After immunoprecipitation, washes and reverse 
cross-linking, the samples were extracted with phenol/chloroform/isoamyl alcohol 
and ethanol precipitated in the presence of 3 M sodium acetate and 20 μg of glycogen 
(Sigma Aldrich). For cccDNA quantification, total DNA was submitted to digestion with 
plasmid-safe DNAse (Epicentre) for 4hours at 37ºC, followed by 30 min of heat 
inactivation. Quantification was performed by FRET-based qPCR as previously 
described (Werle-Lapostolle et al., 2004). Results are expressed as a ratio of the 
cccDNA copy number of the precipitated samples to the corresponding input. 
 
Neutralization of IFN /  signalling 
Differentiated HepaRG cells were first infected with HBV 100 vge/cell, and  at day-6, 
which corresponds to the plateau of HBV replication with established levels of all viral 
parameters (including cccDNA), cells were super-infected by HDV with 100 vge/cell. 
At the end of HDV inoculation, cells were washed and fresh medium was added 
containing or not anti-human IFNAR2 antibody (PBL Assay Science) at a concentration 
of 500 ng/ml. The neutralizing antibody was kept until the end of the experiment and 
HBV replication was monitored at different time points by HBeAg quantification by 
ELISA and at day-15 by HBV DNA qPCR. 
 
3.3.3. Results  
HepaRG TA-SHDAg and TA-LHDAg have a good expression of the transgene upon 
induction with doxycycline 
 As seen in Fig. 7A, HepaRG TA-SHDAg and TA-LHDAg stimulation with increasing 
doxycycline doses leads to a stepwise increase in protein expression. L-HDAg 
expression is detectable from 8h post-stimulation and reaches a plateau from 48 
hours on, while S-HDAg expression is present after 24h of doxycycline treatment and 
does not increase beyond 72 hours (Fig. 7B). Immunofluorescence does not show a 
significant system leak for any of the lineages, as evidenced by the absence of labelled 
cells without stimulation (Fig. 7C).  
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Figure 7. Characterization of HepaRG TA-LHDAg and TA-SHDAg cell lines. Cells were 
differentiated and treated with rising doxycycline doses for 72 hours (A) of with doxycycline 
80 ng/ ml for different time periods (B). Evaluation was performed by western blot or 
immunofluorescence labelling (C). 
 
As expected SHDAg has a predominant nuclear localization and is competent in 
trans-complementing a replication defective plasmid, whereas LHDAg is distributed 
between nucleus and cytoplasm and may be associated with replication inhibition 
To ensure that the presence of the N-terminal Strep-Tag sequence had no influence 
in the physiologic role of the proteins, verification of their subcellular distribution and 
functionality was warranted for validation of the model. 
As first suggested by immunofluorescence and further evaluated by western blot of 
subcellular protein fractions (Fig. 8A), L-HDAg is distributed between all the protein 
fractions, while S-HDAg has a predominantly nuclear localization and can be found 
mostly in the chromatin-associated fraction. 
For evaluating protein functionality, a trans-complementation assay was set-up based 
on the following principles: i) transfection of a plasmid containing a trimer of wild type 
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HDV-1 cDNA (pSVLD3) starts a replicative cycle, with formation of the replication 
intermediate antigenomic RNA; ii) as S-HDAg has been shown to be essential for HDV 
replication initiation (Kuo et al., 1989), a plasmid containing a dimer of HDV-1 cDNA, 
with a point mutation in the HDAg ORF leading to abortive S-HDAg expression, with 
not be replication competent; iii) this replicative deficit can be overcome by trans 
expression of S-HDAg. Furthermore, L-HDAg expression may be associated with a 
decreased replicative activity of pSVLD3, as this form of the protein has been shown 
to have an inhibitory role during HDV replication (Chao et al., 1990). 
 
 
 
Figure 8. Evaluation of HDAg localization and functionality in HepaRG TA-LHDAg and TA-
SHDAg cells. A. Analysis of S-HDAg and L-HDAg by western blot of subcellular protein fractions 
B. Northern blot analysis of intracellular RNA obtained from a transcomplementation assay. 
HDV AG, HDV antigenome; G, genome; rRNA, ribosomal RNA; MM, millennium marker. 
 
We hence evaluated HDV replication through Northern Blot detection of HDV anti-
genome, following transfection of both cell lines with either pSVLD3 or pSVLD2m, 
followed or not by induction of transgene expression. As shown in Fig. 8B, when 
HepaRG TA-SHDAg cells were treated with doxycycline to induce transgene 
expression, both pSVLD3 and pSVLD2 transfection led to detectable HDV antigenome. 
However, in the absence of doxycycline, no specific band could be observed following 
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pSVLD2m transfection, consistent with the absence of HDV replication, while 
antigenome was still detected for pSVLD3. As expected, no antigenomic RNA was 
detected in HepaRG TA-LHDAg either in the presence or absence of transgene 
induction. Interestingly, pSVLD3 transfection led to no detectable anti-genome in the 
presence of L-HDAg expression, suggesting an inhibition of replication by L-HDAg. 
However, as only a faint band could be seen in the control condition (non-induced 
HepaRG TA-LHDAg cells), due to a loading problem, these results must be interpreted 
with caution. 
 
Transgene expression induces a decrease in HBV infection markers in a dose-
dependent manner 
Once the functionality of the cell lineages was established, we proceeded to the 
evaluation of a possible effect of HDAg expression on HBV replication. To this end, 
both HepaRG TA-LHDAg and TA-SHDAg and the control cell line HepaRG TA-GFP were 
differentiated in the presence of DMSO, as previously described, and then subjected 
to HBV infection (100 vge/ cell). In order to replicate the conditions used for HDV 
superinfection, transgene expression was induced by the addition of doxycycline to 
the cell culture medium at day-6 post-infection and kept throughout the experiment. 
Growing concentrations (from 3,2 to 2000 ng) were used to induce increasing levels 
of protein expression (as already described in Fig. 7A). Supernatants were collected 
for HBeAg and HBsAg quantification by ELISAs, and at endpoint (day-15 post-infection) 
cell viability was evaluated by neutral red assay and cells were lysed for DNA, RNA and 
protein extraction (Fig. 9A). The results presented correspond to a total three 
independent experiments. 
 
We first verified if the prolonged doxycycline treatment had had an impact on cell 
viability, by neutral red assay. As can be seen in Fig. 9B, doxycycline treatment induced 
a moderate decrease in cell viability at the highest doxycycline doses (15% in HepaRG 
TA-LHDAg cells and 22% in HepaRG TA-SHDAg cells). Dose-dependent transgene 
expression was confirmed by western blot, as depicted in Fig. 9C. 
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Figure 9. Evaluation of HBV replication in HepaRG TA-LHDAg and TA-SHDAg cells. A. Cells 
were infected with HBV for 6 days, before induction of transgene expression with rising doses 
of doxycycline. B. cell viability was evaluated by neutral red assay at the end of the experiment 
(results are displayed as a ratio to the non-treated condition). C. the expression of the 
transgene was assessed by western blot. D. Supernatants collected throughout the 
experiment were submitted to HBeAg and HBsAg ELISA (results are displayed as a ratio to the 
non-treated condition). Intracellular nucleic acids were quantified by qPCR for HBV total DNA 
and RT-qPCR for HBV total RNA. Results are normalized to the percentage of cell viability. n.s. 
non-significant; *p< 0,05. 
 
As seen in Fig. 9D, following the addition of doxycycline, HBeAg secretion decreased 
over time in both HepaRG TA-LHDAg and TA-SHDAg cells, but not in the control 
HepaRG TA-GFP cells. For HepaRG TA-LHD, significant differences were observed for 
the two highest doxycycline doses (400 and 2000 ng), when compared to non-induced 
cells (65 and 70% decrease, respectively; p< 0,05). A significant difference was also 
documented in S-HDAg cells treated with 2000 ng doxycycline (90% average decrease; 
p<0,05). A lesser, yet significant, decline was detected in HBsAg secretion when 
HepaRG TA-LHDAg cells (but not TA-SHDAg or TA-GFP cells) were treated with the 
highest doxycycline dose (63% decrease in comparison to non-treated cells; p< 0,05). 
As seen in the lower panels of Fig. 9D, greater doses of doxycycline are associated with 
a more important decline in HBeAg than in HBsAg secretion, both in HepaRG TA-LHD 
and particularly HepaRG TA-SHD, but not in the control lineage. Such a finding allows 
the exclusion of a non-specific reduction of antigen secretion and suggests a 
differential regulation of HBeAg secretion in the presence of HDAg. 
HBV replication in these cells was further characterized by dosing intracellular HBV 
total RNA and DNA (Fig. 9E and 9F). Following normalization, to account for 
differences in cell viability, an important decrease in both parameters was observed 
in the both lineages expressing HDAg, but not in the control cell line. RNA but not DNA 
decreases were significant (at the maximal doxycycline dose: HepaRG TA-LHDAg 45% 
decrease, p< 0,05; HepaRG TA-SHDAg 62% decrease, p< 0,05). 
 
Inhibition of HBV replication may be associated with SHDAg recruitment on cccDNA 
We previously documented that SHDAg, and to a lesser extent LHDAg, has a 
preferential nuclear (chromatin bound) localization and a greater impact on the 
decrease of HBV replication. Furthermore, in superinfection, HDV has been shown to 
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preferentially decrease HBeAg and not HBsAg, with no decrease in the amounts of 
cccDNA. This may suggest an underlying mechanism of differential transcriptional 
regulation of HBV minichromosome, possibly associated with epigenetic 
modifications.  
We hence first focused on a possible interaction between SHDAg and HBV cccDNA. To 
this end, differentiated HepaRG TA-SHDAg cells were infected with HBV, and 
transgene expression was induced at day-6 post-infection as previously described. 
Based on the previously described kinetics of transgene expression in this system 
(with SHDAg being detected as soon as after 8 hours of doxycycline stimulation), 
doxyclycline treatment was performed for 24 hours (as shown in Fig. 10A). At that 
time point, cells were cross-linked and then subjected to ChIP analysis. Mock-infected 
and non-induced cells were used as controls. We performed, for the moment, two 
independent experiments. In the first experiment, chromatin present in the nuclear 
fraction was immune-precipitated with a monoclonal anti-Strep-Tag antibody. As seen 
in Fig. 10B a 20 fold increase in cccDNA precipitation with S-HDAg was observed in the 
doxycycline induced condition in comparison to the non-induced. A second 
experiment, using the same settings, was performed in order to validate the results 
using both strep-tag and HDAg immunoprecipitation (with a polyclonal anti-HDAg 
antibody). Results displayed in Fig. 10C confirm the cccDNA enrichment in the induced 
condition, upon anti-Strep-Tag immunoprecipitation, however with a lower 
magnitude than the verified in the previous experiment (3,2 fold change). 
Furthermore, the same tendency was confirmed with HDAg precipitation (2,6 fold 
change).  
 
Blockage of IFN /  signalling is associated with partial reversion of the HDV/HBV 
interference phenotype in HepaRG cells 
As shown in Fig. 11A, HBV infected HepaRG cells were super-infected by HDV and 
subsequently treated with anti-IFNAR2 antibody or not. Results displayed correspond 
to the average of 3 biological replicates from a single experiment. Viral interference 
was once more translated by a decrease in HBeAg but not HBsAg secretion that could 
be partially reversed by the addition of anti-IFNAR antibody (Fig.11B and 11C), 
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although the observed differences are small, probably as a consequence of a low level 
HBV infection in this experiment. 
 
 
Figure 10. CccDNA specific chromatin immunoprecipitation. A. Cells were infected with HBV 
for 6 days, before doxycycline induction of transgene expression. Cross-link and ChIP analysis 
were performed after 24 hours of induction. Panels (B) and (C) represent two independent 
experiments. CccDNA is represented as a ration between the number of copies precipitated 
and that of the input. No Ab, no antibody (negative control); ST, anti-Strep-Tag antibody; 
HDAg, anti-delta antigen antibody.  
 
 
 
 
Figure 11. Evaluation of the effect of IFNa/b signalling blockage on HDV/HBV superinfection. 
A. HDV superinfection of HBV infected cells was established as described above. At the end of 
HDV inoculation, anti-IFNAR2 neutralizing antibody was added to the cell culture medium and 
kept until the end-point at day 15 post-HBV infection. HBeAg (B) and HBsAg (C) secretion in 
the supernatant were followed by ELISA. The displayed results are an average of three 
replicates of one single experiment. 
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3.3.4. Discussion 
Having confirmed a previously described phenomenon of HDV/HBV interference in 
HepaRG cells (and later in PHH), we focused on the assessment of two different, yet 
not mutually exclusive, possible mechanisms to explain this phenotype. First, we 
evaluated the hypothesis of a down-regulation of HBV cccDNA transcriptional activity 
directly mediated by HDAg. In parallel, we were interested in appraising a possible 
involvement of IFN type I signalling in the restriction of HBV replication. 
In order to approach the first possibility, we first constructed HepaRG cell lines, with 
an inducible expression of either form of HDAg. The strategy used involved insertion 
of an N-terminal Strep-Tag, in order to facilitate protein detection and eventual 
precipitation. To ensure that tagged proteins were biologically and functionally 
relevant, we proceeded to extensive characterization of each cell line. Both proteins 
were found to localize intracellularly as previously described (Bichko and Taylor, 1996; 
Han et al., 2009), with an important enrichment of S-HDAg in the chromatin associated 
fraction. Moreover, strep-tagged S-HDAg was capable of restoring replication of an 
HDAg defective plasmid, confirming its functionality (Kuo et al., 1989). For L-HDAg, 
that assertion was less clear as it is more difficult to verify its functionality in the 
regulation of HDV replication. That could eventually be achieved by demonstrating its 
capability to permit HDV assembly and secretion. Such an experimental setting is not 
straightforward as it would involve the need to have in the same cell (in this case the 
HepaRG TA-LHDAg lineage) an HDV replication-competent construction, with an 
abrogated LHD expression (that could be achieved by a mutation on the amber/w 
editing site), and a replicating HBV genome (or a construction expressing its surface 
proteins). Detection of HDV genome in the supernatant upon transgene expression 
(and not in its absence) would confirm functionality of strep-tagged L-HDAg in the 
interaction with HBsAg and consequent assembly and release of HDV virion. We were 
however able to have an indirect indication of L-HDAg functionality, as HDV replication 
was not detected when L-HDAg expression was induced, implying the conservation of 
its described dominant-negative role in HDV replication (Chao et al., 1990).  
An inhibitory effect of both forms of HDAg on HBV replication was described early in 
the characterization of HDV infection (Wu et al., 1991) and was later suggested to be 
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related to a direct, yet partial, inhibition of HBV replication, through interaction with 
its enhancer sequences (Williams et al., 2009). In our cell lines, we confirmed that both 
forms of HDAg were associated with a decrease in HBV replication, as evidenced by 
diminished HBeAg (and to a lesser extend HBsAg) secretion, HBV total intracellular 
DNA and RNA. A limitation can be pointed out in this study, as, with time, doxycycline 
treatment was associated with a detectable (yet not significant) decline in cell viability, 
potentially underestimating the number of HBV infected cells. However, the verified 
inhibition was more important than the decrease in cell viability, excluding it as the 
underlying cause. Moreover, loss of cell viability would have led to a comparable 
decline of both HBV secreted antigens, which was not the case. The same argument 
can be used to exclude a decrease in the amounts cccDNA (that does not occur in the 
superinfection setting in HepaRG cells). Overall these findings may suggest a 
differential regulation of HBV transcriptional activity. 
Regulation of HBV replication can be achieved through epigenetic control of cccDNA 
transcription, as described in response to interferon treatment (Belloni et al., 2012). 
Furthermore, viral proteins such and HBx (and HBc) have been immune-precipitated 
with cccDNA and shown to play a role in the recruitment of transcription factors and 
histone modifying enzymes (Belloni et al., 2009; Bock et al., 2001). S-HDAg, as a 
nuclear protein, preferentially chromatin associated, is suggested to be a 
transactivator of cellular genes. Moreover, although no DNA binding properties have 
clearly been demonstrated, its RNA binding domain is a homologous of the HMG box 
of SRY (a DNA binding domain) (Veretnik and Gribskov, 1999). Furthermore, S-HDAg 
has been suggested to be involved in the epigenetic modification of clusterin, a cellular 
gene, with a role in carcinogenesis (Liao et al., 2009). We hence hypothesized that, 
like HBx and HBc, S-HDAg could directly o indirectly interact with cccDNA and 
eventually regulate its transcriptional activity. Two independent cccDNA specific 
chromatin immunoprecipitation experiments confirmed, yet with distinct 
magnitudes, co-precipitation of cccDNA with S-HDAg, indicating a possible interaction 
of the HDV protein with HBV minichromosome. The specificity of the cccDNA ChIP 
technique is warranted by: i) a nuclear extraction procedure, to eliminate the major 
pool of rcDNA, located in the cytoplasm; ii) a mild sonication step, optimized to keep 
cccDNA integrity, while promoting chromosomal DNA fractioning; iii) a plasmid safe 
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digestion of the obtained DNA; iv) a specific PCR (Werle-Lapostolle et al., 2004), based 
on FRET technlogie, with primers and probes desiged for hybridation in the ‘gap’ of 
the positive strand of rcDNA. PCR specificity was further validated by the lack of 
amplification of DNA extracted from a high titer viral inoculum. 
These ChIP results, although being suggestive of an interaction between S-HDAg and 
cccDNA, do not allow for the moment to affirm its involvement in epigenetic 
regulation. Further validation is needed, as well as evaluation of possibly associated 
epigenetic modifications (namely histone alterations and recruitement modifying 
enzymes). 
 
A possible dependence of the interference phenotype on type I IFN signalling, cannot 
not be excluded from the analysis of a preliminary experiment with the use of an anti-
IFNAR antibody (Fig. 11). Although the results are difficult to interpret due to a weak 
HBV infection in this single experiment, the decline in HBeAg secretion upon HDV 
superinfection is partially reversed by the blockage of type I IFN signalling, supporting 
the need for confirmation and further exploration of such hypothesis. 
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4. Discussion and perspectives 
In the present study we characterized virological and immunological aspects of HDV 
infection using in vitro models, most particularly HepaRG cells. We first focused on the 
optimization of the infection conditions and the characterization of HDV infection 
parameters and later on the interactions of HDV with its helper HBV and the 
hepatocyte innate immune response. In this cellular model, we were able to 
demonstrate, or confirm, that: 
 
i. HDV mono-infection is associated with a strong, yet transient replication in a 
limited number of cells and is associated with a potent induction of the 
expression of interferon stimulated genes; 
ii. IFN-  treatment of HDV-infected cells does not induce a further increase of 
ISG expression and has a modest antiviral activity. Conversely, some PRR 
agonists, in particular those inducing the NF- B pathway, induce a strong 
decline in HDV replication; 
iii. In a setting of superinfection, despite the low number of coinfected cells, HDV 
as well as its encoded proteins/antigens exert a repressive effect on HBV 
replication.  
 
A number of new questions arises from the identification and characterization of 
these phenotypes. 
 
Characteristics of the experimental model 
HepaRG cells have been demonstrated to be a useful model for studying either HBV 
or HDV infection. The functional characterization of these cells has shown 
physiological properties close to primary human hepatocytes. Notably, i) they display 
a physiologic metabolism, with relevant detoxifying properties (Gómez-Icazbalceta et 
al., 2013); ii) they have the ability to produce VLDL, a characteristic of differentiated 
hepatocyte, not present in hepatoma cell lines (e.g. Huh7 and HepG2 cells) (Jammart 
et al., 2013); iii) they express functional innate immune sensors and display functional 
interferon responses (Luangsay et al., 2015b; Maire et al., 2008; Parent et al., 2004). 
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Since their identification, they have been an invaluable tool for the study of HBV 
infection (Gripon et al., 2002; Hantz et al., 2009) and constituted, until recently, the 
only alternative to PHH for the study of a full HBV life cycle, including NTCP-mediated 
entry (Ni et al., 2014), and the biology of cccDNA synthesis and degradation (Lucifora 
et al., 2014). 
Their utilization for the study of HDV infection has mostly been limited to the 
characterization of viral entry steps, as HDV is an easier to manage surrogate model 
for the study of HBV envelope functions (Sureau, 2010; Urban et al., 2014).  
For the interpretation of results obtained in these cells, two main limitations are to 
keep in in mind: i) likely due to differences in polarization, the pool of cells permissive 
to HBV or HDV infection is limited (Schulze et al., 2012); and  ii) despite the production 
of infectious particles, no propagation is observed, i.e. only one cycle of infection 
occurs (Hantz et al., 2009).  
The aforementioned characteristics of this cell model may partially explain our 
findings, namely the reduced number of infected cells and the saturation profile 
despite the increase in the multiplicity of infection. Moreover, the fact that the pool 
of susceptible, correctly polarized, cells is rather limited, may also explain that, upon 
HDV superinfection, the proportion of coinfected cells is higher that the number 
predicted by probability calculation, being associated with significant levels of HDV 
particle secretion. 
 
Features of HDV monoinfection 
The particular kinetic profile of HDV infection in HepaRG cells has to be interpreted 
based not only on the characteristics of the model, but also on data collected from 
other models. The exploitation of our results can be useful for a more comprehensive 
understanding of the kinetics of HDV replication at a tissue level. It is important to 
acknowledge that HepaRG cells are not the only model where HDV replication is 
limited in time. Indeed, both our results and previous reports from Gudima and 
colleagues seem to suggest that a limitation of HDV replication occurs as well in PHH 
(Gudima et al., 2007). Furthermore, such a profile has been described in vivo, first 
following hydrodynamic injection of HDV cDNA into wild type mice and recently 
following HDV infection of transgenic mice expressing hNTCP (Chang et al., 2001; He 
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et al., 2015). All these models have in common the establishment of an HDV mono-
infection in the absence of an HBV-mediated propagation or an external source of 
transcription (as is the case in cell transfection or transgenic mice expressing HDV 
cDNA). Full data on the kinetics of mono-infection in the uPA SCID model with 
humanized liver are missing, as no evaluation of the early intracellular levels of HDV 
RNA has been reported; therefore, a similar profile cannot be excluded (Giersch et al., 
2014). HDV infection in the presence of its helper virus, to our knowledge, has only 
been studied in vivo. In such models, including chimpanzee, woodchuck and the uPA 
SCID mouse with humanized liver, no decrease in replication overtime has been 
described. Overall, these data may suggest that HDV infection would only be 
maintained overtime in the presence of its helper virus. Two main hypotheses arise 
concerning the contribution of HBV:  i) either the assembly and exit of viral particles 
is crucial to the maintenance of HDV replication at a single cell level; or ii) at the tissue 
level, preservation of a stable HDV infection is dependent on viral propagation and 
infection of new cells, more than on persistently infected cells.  
The first hypothesis can be physiologically sustained by the dominant negative role of 
the L-HDAg during HDV replication (Modahl and Lai, 2000). Indeed, it is tempting to 
postulate that, in the absence of viral particle egress, persistent editing leads to an 
accumulation of L-HDAg throughout time, ultimately leading to replication inhibition. 
This hypothesis can however be disputed based on our data, considering that, in HDV 
monoinfection of HepaRG we have shown that S-HDAg/ L-HDAg ratio remains rather 
consistent throughout the kinetics of infection, with no evidence of L-HDAg over-
accumulation. Moreover, we observe a similar HDV RNA decline in the superinfection 
setting, in which HDV secretion is made possible.  
The second hypothesis would imply that HDV infection is maintained in time, not by 
stable replication at a single cell level, but by viral spreading and infection of new cells. 
It would explain the different phenotype observed between experimental models, but 
not experimental data from the Lanford’s group, showing a persistent replication of 
HDV in PHH for several weeks. Indeed, based on this hypothesis, it is hard to explain 
why HDV mono-infection is effectively kept for a long time, in the absence of HBV, 
suggesting that no or very slow decline in replication is being induced at the single-cell 
level (Barrera et al., 2004). The validity of such a hypothesis will ultimately be verified 
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in the clinical evaluation of entry inhibitors. If propagation is indeed necessary for the 
maintenance of a stable viral infection, Myrcludex B® treatment might be able to lead 
to an effective inhibition of HDV infection over time. In this respect  preliminary results 
of a phase IIb clinical trial seem to confirm this hypothesis (Bogomolov et al., 2014). 
 
The mechanism underlying the control of HDV replication in infected cells is still not 
clear. As a general principle, it could be due either to a lack of a factor needed for 
replication (as is the case in avian cells) or due to the active inhibition of replication. 
As previously mentioned, our data do not support the possibility that HDV replication 
decrease is due to an imbalance of the ratio S-HDAg/L-HDAg, not only by the reasons 
evoked above, but also because HDV replication starts decreasing while the amount 
of S-HDAg is still stable, excluding S-HDAg depletion as the cause of such decline. 
Moreover, unlike HBV, HDV replication is not liver specific, ruling out the role of 
possible hepatocyte dedifferentiation over time in the limitation of replication. It is 
not possible, from the available data to exclude a possible role of the depletion of a 
yet unknown factor in the decline of HDV replication.  
 
Interaction with the innate immune response and its use for the identification of 
novel therapeutic strategies 
The fact that the maximal HDV replicative level is coincident with the peak of ISG 
expression raises the possibility of a role of an IFN response in the control of HDV 
replication. However, our data show that neutralization of type-I IFN signalling, in this 
background, does not prevent the decline of HDV replication indicating that other 
mechanism(s) may be involved. Further possibilities will have to be evaluated, namely 
the hypothesis that replication control may be associated with direct activation of 
intracellular effectors, independently of IFNAR signalling, i.e. bypassing ISGF3 
activation. A possible involvement of type-II and III IFN responses in the control of HDV 
replication must also be ascertained. 
 
Another question that requires further exploration concerns the identification of the 
HDV PAMP sensed by the infected cell. We have shown that for the first 72 hours 
following infection no induction of ISGs could be observed. The expression of these 
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genes arises simultaneously with the peak of antigenome production, supporting the 
possibility that the viral inoculum induces no antiviral response, which seems to be 
elicited by neo-synthesis of viral components during replication. As is the case for 
most viruses, it is tempting to consider viral RNAs to be responsible for the induction 
of the observed innate immune response. Indeed, in spite of being single stranded, 
HDV RNA presents a high degree of base pairing and could hence be sensed as a 
pseudo-double stranded RNA (namely by TLR3 or the cytoplasmic sensors RIG-I or 
MDA5). However, this hypothesis is not clear-cut, as the current knowledge of HDV 
infection suggests that there is no free RNA in the cytoplasm or in the endosomes of 
infected cells in any phase of the viral cycle. Indeed, the replication is exclusively 
nuclear and RNA shuttling between the nucleus and the cytoplasm is mediated by the 
formation of the HDV RNP. Although far less likely, it will be important to exclude the 
role of DNA-sensing PRR (such as IFI16, which has nuclear localization). On the other 
hand, the potential role of HDAg in the eliciting of the innate interferon response or 
directly modulating ISG expression cannot be excluded from our results, as no 
temporal distinction was observed between maximum RNA accumulation and protein 
expression. A previous study has indeed suggested that the MxA promoter could be 
activated by L-HDAg (although no direct interaction was evidenced) (Williams et al., 
2009) 
 
Interestingly, in our conditions, HDV infection is rather resistant to IFN treatment, in 
line with in vivo observations, as previously discussed in point 3.2.4. This resistance 
correlated with a failure of IFN-  to induce ISGs beyond the levels already induced by 
HDV replication itself. A parallel can be drawn here with HCV infection, where a basal 
up-regulation of ISG expression was found to be related, not only with particular 
polymorphisms of the IL28b gene, but most importantly, with a worsened response 
to IFN- -based treatments (Abe et al., 2011; Honda et al., 2010). Very interestingly, a 
recent work in our laboratory has shown that, in HCV infected patients, the antiviral 
contribution of ribavirin is associated with a reversion of the up-regulation of a set of 
ISGs through epigenetic regulation of their expression (Testoni et al., 2015). It would 
hence be tempting to propose a possible role for the addition of ribavirin to IFN in the 
therapy of CHD. Unfortunately, such a strategy has previously been tested in a clinical 
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trials and was not associated with an improved outcome as compared to mono-
treatment with IFN-  (Gunsar et al., 2005; Niro et al., 2006). In order to elucidate the 
clinical relevance of our findings, it will be essential to perform a thorough evaluation 
of the baseline hepatic gene expression profile of HDV infected patients (with a 
particular focus on innate immunity related genes), and to eventually establish a 
correlation between patterns of expression and outcomes of IFN therapy. Such an 
evaluation will only be possible through a multicentre collaborative effort, given the 
restricted number of patient samples available. 
 
The molecular mechanisms of interaction between the virus and IFN signalling 
pathways also need further clarification. It has been suggested that HDV could inhibit 
a crucial step in the Jak/STAT signalling pathway and hence the response to exogenous 
IFN (Pugnale et al., 2009). Furthermore, the pattern of ISGs it induces does not seem 
to be associated with an antiviral effect and may actually favour viral replication (as 
suggested by the finding of a reduced replication peak following IFNAR neutralization). 
Such a mechanism of viral adaptation and even hijacking of host-antiviral effectors to 
its own profit, has previously been described in the virologic world. An example is the 
induction of expression of viperin (coincidentally, the most up-regulated ISG in our 
study) by cytomegalovirus and the diversion of its mechanism of action in favour of 
viral infectivity (Seo et al., 2011). The existence of such mechanisms in the case of HDV 
infection needs further characterization, as, by adding to the current understanding 
of IFN-resistance, it may allow the design of complementary therapeutic strategies 
involving IFN sensitizing.  
 
In contrast to IFN, we observed a strong antiviral activity of poly (I:C) (i.e. TLR3-L) and 
poly (dA:dT) (associated with AIM2-L and indirectly RIGI/MDA5-L stimulation) to HDV 
monoinfected cells. This antiviral response, being stronger than the one elicited by 
IFN  itself, raises interesting questions regarding the possibility of further stimulating 
endogenous IFN production. Clarification of the role of ISGs and autocrine/ paracrine 
IFN  /IFN  signalling in this antiviral response would be a first step towards the 
understanding of its mechanism. 
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Nonetheless, the strongest antiviral effect was obtained with the stimulation of TLR-
1/2 by Pam3CSK4 (an analog of the acylated amino-terminus of bacterial 
lipopeptides), which is associated with the activation of the NF- B pathway and 
secretion of pro-inflammatory cytokines, such as IL-6. This is an interesting finding as 
this pathway does not seem to be modulated by the virus itself. Moreover, two recent 
contributions highlight the role of the inflammatory response in the control of HBV 
infection through the strong antiviral effect of both IL-1  and a lymphotoxin-receptor-
 agonist (Isorce et al., 2014; Lucifora et al., 2014; Watashi et al., 2013). A screening 
of the antiviral effect of pro-inflammatory cytokines is hence warranted to further 
explore the potential role of NF- B signalling in the control of HDV replication.  
A strong antiviral effect was also documented for imiquimod, opening a new set of 
interesting questions with respect to a mechanism of action possibly independent of 
TLR7 signalling. This is particularly exciting, as analogous drugs, such as GS9620, are 
entering clinical evaluation with very promising results in the control of HBV infection 
(Menne et al., 2015). The mechanisms of its potential activity against HDV must be 
evaluated. Validation of the imiquimod antiviral effect by the use of the analogous 
molecule GS-9620 could represent a major contribution to a therapeutic field with 
rather limited efficient options.     
 
HDV/ HBV interaction 
Besides providing new data on aspects of HDV infection and therapy, by confirming 
and exploring its interactions with the helper virus, our results open new perspectives 
on the regulation of HBV replication itself. This interference phenomenon has 
previously been well characterized in liver samples from CHD patients (Pollicino et al., 
2011) and the pattern of expression of HBV replication intermediates found is 
compatible with a modulation of HBV transcriptional activity in the presence of HDV. 
Other model systems have been used to reproduce the interference phenomenon, 
both in vivo as in vitro. To the best of our knowledge, our work represents the first 
characterization of an HDV/HBV interplay in a cellular model of infection. As discussed 
in section 3.3.4, we focused on the evaluation of a possible direct mechanism of 
interference involving a role of S-HDAg in the epigenetic regulation of cccDNA 
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transcriptional activity. We have so far been able to demonstrate a co-precipitation of 
cccDNA with S-HDAg, suggesting a possible fixation of this protein on HBV 
minichromosome. However, up until now, it was not possible to identify the possible 
epigenetic changes associated with such an interaction and to correlate them with the 
observed phenotype. It would be expected for HDV infection to be associated with a 
decrease of activation marks (as histone 3 acetylation), an enhancement of repressive 
marks and possibly a recruitment of histone modifying enzymes on the cccDNA (as 
HDAC). Furthermore, it is not possible to exclude the indirect regulation of cccDNA by 
IFN-regulated transcription factors (Belloni et al., 2012). The characterization of such 
epigenetic modifications has been hampered in our model by the the low amounts of 
cccDNA, near to the lower limits of detection of the ChIP procedure. This limitation 
can be circumvented by the use of cell models allowing a more significant 
accumulation of cccDNA. Indeed, an in vitro study based on transfection of HepG2 
cells, whose preliminary results were reported by Raffa et al, was able to the evidence 
a spectrum of cccDNA epigenetic modifications that is compatible with the hypothesis 
of an inhibitory effect of delta proteins, but has not been confirmed in an infectious 
model (Raffa et al., 2011). HepG2-hNTCP cells may constitute a valuable option to 
perform further ChIP assays, as the amounts of cccDNA accumulated during HBV 
infection are significantly increased in comparison to HepaRG. Furthermore, contrary 
to PHH (that also accumulate significant cccDNA amounts), they can be transduced 
and selected in order to achieve an inducible expression of HDV proteins. 
Alternatively, in the eventuality of persistent technical limitations related to the ChIP 
procedure and cccDNA detection, a proof of concept would consist in the evaluation 
of the effect of drugs acting on histone modifying enzymes and study its effect on the 
reversion of the interference phenotype. The definite proof of the validity of this 
mechanism would have invariably to be obtained in vivo, by ChIP analysis of liver 
samples from CHD patients.  
 
In summary, by having adapted and explored an existing model for the study of HDV 
infection and having identified particular phenotypes associated with HDV replication, 
the work here discussed opens an array of new perspectives to a better 
characterization of the pathogenesis of hepatitis delta. 
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2. Research paper submission 
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3. Congress presentations 
1. EASL Monothematic Conference – Translational Research on Chronical Viral 
Hepatitis 
Lyon, 28-30 November 2014 
Poster: FULMINANT HEPATITIS B AND DELTA HEPATITIS OUTBREAK IN THE MID-
EIGHTIES IN CENTRAL AFRICAN REPUBLIC (CAR): FOCUSING ON SHDAG 
Dulce Alfaiate, Natali Abeywickrama-Samarakoon, Sumantra Ghosh, Gina Laghoe, 
Ségolène Brichler, Christian Trépo, Emmanuel Gordien, Fabien Zoulim, Narcisse P. 
Komas, David Durantel, Jean Claude Cortay, & Paul Dény 
 
2. 14ème Réunion du Réseau National Hépatites de l'ANRS  
Paris, 23-24 January 2014 
Poster: STUDYING RECIPROCAL VIRAL INTERPLAY BETWEEN HBV AND HDV IN CO-
INFECTED HEPARG CELLS 
Dulce Alfaiate, Natali Abeywickrama-Samarakoon, Barbara Testoni, Marion Gruffaz, 
Jean Claude Cortay, Fabien Zoulim, David Durantel and Paul Dény 
 
3. EASL 2014 International Liver Congress 
London, 9-13 April 2014 
Poster: STUDYING RECIPROCAL VIRAL INTERPLAY BETWEEN HBV AND HDV IN CO-
INFECTED HEPARG CELLS 
Dulce Alfaiate, Natali Abeywickrama-Samarakoon, Barbara Testoni, Marion Gruffaz, 
Jean Claude Cortay, Fabien Zoulim, David Durantel and Paul Dény 
 
4. 2nd Silibinin Workshop 
Cologne, 23 May 2014  
Oral Communication: SILIBININ AS AN ENTRY INHIBITOR OF HEPATITIS B AND DELTA 
VIRUSES: WHAT DO WE LEARN FROM HEPATITIS C VIRUS INFECTION? 
Julie Blaising, Claire Gondeau, Dulce Alfaiate, Chloé Montès, Emma Reungoat, 
Camille Sureau, Fabien Zoulim, Eve-Isabelle Pécheur 
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5. HBV International Meeting 2014 
Los Angeles, 3-6 September 2014 
Poster: STUDY OF THE VIRAL INTERPLAY BETWEEN HEPATITIS B VIRUS (HBV) AND 
HEPATITIS DELTA VIRUS (HDV) AND EVALUATION OF ANTIVIRAL THERAPIES IN 
HEPARG CELL LINE SUPER-INFECTION MODEL 
Dulce Alfaiate, Natali Abeyvikrama-Samarakoon, Barbara Testoni, Julie Lucifora, 
Fabien Zoulim, Jean Claude Cortay, Paul Dény and David Durantel 
 
Poster: MID-EIGHTIES HEPATITIS B AND DELTA FULMINANT HEPATITIS OUTBREAK IN 
CENTRAL AFRICAN REPUBLIC (CAR): REASSESSMENT OF VIRAL STRAINS FROM A LARGE 
COHORT AND COMPARISON WITH 2010 STRAINS (ANRS 12202) 
Sumantra Ghosh, Dulce Alfaiate, Natali Abeywickrama Samarakoon, Ségolène 
Brichler, Gina Laghoe, Mariama Abdou-Chekaraou, Jean-Omer Ouavene, Jean Louis 
Lesbordes, Christian Trépo, Olivier Hantz, Alan Kay, David Durantel, Fabien Zoulim, 
Emmanuel Gordien, Jean-Claude Cortay,  
Narcisse P. Komas* & Paul Dény* 
 
6. 75èmes Journées Scientifiques de l’AFEF 
Paris, 24-26 September 2014 
Oral communication: MODELE CELLULAIRE DE SUPER-INFECTION HBV/HDV POUR 
L’ETUDE MOLECULAIRE DES MECANISMES D’INTERFERENCE VIRALE ET L’EVALUATION 
D’ANTIVIRAUX 
Dulce Alfaiate, Natali Abeyvikrama-Samarakoon, Barbara Testoni, Julie Lucifora, 
Fabien Zoulim, Jean Claude Cortay, Paul Dény and David Durantel 
 
7. 3rd Antivirals Congress  
Amsterdam, 12-14 October 2014 
Poster: MODEL OF HBV/HDV SUPER-INFECTION TO STUDY MECHANISMS OF VIRAL 
INTERPLAY AND ANTIVIRALS 
Dulce Alfaiate, Natali Abeyvikrama-Samarakoon, Barbara Testoni, Julie Lucifora, 
Fabien Zoulim, Jean Claude Cortay, Paul Dény and David Durantel 
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8. AASLD - The Liver Meeting 2014  
Boston, 7-11 November 2014 
Poster: MODEL OF HBV/HDV SUPER-INFECTION TO STUDY MECHANISMS OF VIRAL 
INTERPLAY AND ANTIVIRALS 
Dulce Alfaiate, Natali Abeyvikrama-Samarakoon, Barbara Testoni, Julie Lucifora, 
Fabien Zoulim, Jean Claude Cortay, Paul Dény and David Durantel 
 
9.  XII Congresso Nacional de Doenças Infecciosas e Microbiologia Clínica 
Lisbon, 1-3 December 2014 
Oral communication: ABORDAGEM EXPERIMETAL DA SUPERINFECÇÃO PELOS VIRUS 
DA HEPATITE B E HEPATITE DELTA 
Dulce Alfaiate, Natali Abeywickrama-Samarakoon, Barbara Testoni, Julie Lucifora, 
Fabien Zoulim, Jean-Claude Cortay, Paul Dény and David Durantel 
 
9.  15th International Symposium on Viral Hepatitis and Liver Diseases 
Berlin, 26-28 July 2015 
Oral Communication: STUDY OF THE SUPERINFECTION BY HBV AND HDV IN THE 
HEPARG CELL MODEL 
Dulce Alfaiate, Natali Abeywickrama-Samarakoon, Barbara Testoni, Julie Lucifora, 
Fabien Zoulim, Jean-Claude Cortay, Paul Dény and David Durantel 
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4. Curriculum vitae 
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